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Abstract 
The thesis entitled, "Isolation, Characterization and Derivatization of Selected 
Fatty Acids" consist of five chapters. The work is based on the isolation and 
characterization of hydroxy fatty acids from natural source and synthesis of various fatty 
acid derivatives. The synthesized compounds have also been investigated for their in 
vitro antibacterial and antifungal activities. The preparation of such derivatives is a 
valuable addition to the fatty acid and medicinal chemistry. 
1. Synthesis, Antibacterial and Antifungal Activity of Some New 2,5-
Disubstituted-l,3,4-oxadiazoles" 
A series of novel 2,5-disubstituted-l,3,4-oxadiazoles (3a-d) (Scheme 1) have 
been synthesized from long chain alkenoic acid hydrazides (la-d) via the formation of 
semicarbazides (2a-d). The reactions occurred under reflux conditions and afforded the 
desired product in good yields. The structures of these compounds have been elucidated 
by elemental and spectral (IR, 'H NMR, '^C NMR, Mass) analyses. 
Further, these compounds were screened for their in vitro antibacterial activity 
against the representative panel of two Gram-positive {Streptococcus pyogenes and 
Staphylococcus aureus (ATCC-25923)) and three Gram-negative {Pseudomonas 
aeruginosa (ATCC-27853), Klebsiella pneumoniae (Clinical isolate) and Escherichia 
coll (ATCC-25922)) bacterial strains. 
* Research paper entitled "Synthesis, characterization, and in vitro antimicrobial 
activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-oxadiazoles and 
thiadiazoles" is published. (Nida N. Farshori, Mudasir R. Banday, Anis Ahmad, Asad 
U. Khan, Abdul Rauf, Bioorg. Med. Chem. Lett., 2010,20,1933-1938). 
Abstract 
All the synthesized compounds were also tested for their inhibitory action against four 
strains of flingus viz. Candida albicans, Aspergillus fumigatus, Pemcillium marneffei and 
Trichophyton mentagrophytes (recultured). The various compounds show potent 
inhibitory action against test organisms. The compounds 3c and 3d were found to be the 
most active antimicrobials whereas the compound 3b was the most potent antifungal 
agent. 
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Scheme 1. Synthesis of 2, 5-disubstituted-l,3,4-oxadiazoles 3a-d 
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2. A Facile One-pot Synthesis of Novel 2,5,-Disubstituted-l,3)4-
oxadiazoles Under Conventional and Microwave Conditions and 
Evaluation of their in vitro Antimicrobial Activities 
Fatty acid derivatives containing hetero atoms are regarded as potential 
antimicrobial agents. Thus a rapid and efficient solvent-free synthesis of 2,5-
disubstituted-l,3,4-oxadiazoles (3a-I) (Scheme 2) from fatty acid hydrazides (la-f) under 
microwave irradiation is described. The procedure constitute a simple, practical and 
green synthetic protocol for the synthesis of pharmaceutically important 2,5-
disubstituted-l,3,4-oxadiazoles (3a-I). The one-pot synthesis on solid inorganic support 
provided the products in good yields. The structural elucidation of these compounds is 
based on their spectral data (IR, 'H NMR, '^C NMR and MS). 
All the compounds (3a-l) were also screened for their antibacterial and antifungal 
activities against various Gram positive and Gram negative bacterial strains and selected 
strains of fungus by disk diffusion method using Ciprofloxacin and Greseofulvin as a 
standard drugs respectively. 
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Scheme 2. Conventional synthesis of2,5-disubstituted-l,3,4-oxadiazoles 3a-l. 
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3. Synthesis, Antibacterial and Antifungal Activity of Some New 2,5-
Disubstituted-l,3,4-thiadiazoles'' 
The long chain alkenoic acid hydrazides (la-d) on reaction with 
phenylthiocyanate gave their corresponding thiosemicarbazides (2a-d) (Scheme 3), 
which on further refluxing with AC2O underwent dehydrative cyclization to give the 
corresponding 2,5-disubstituted-l,3,4-thiadiazoles (3a-d) in good yields. The structure 
elucidation of synthesized compounds is based on the elemental analysis and spectral 
data (IR, 'H NMR, '^C NMR and MS). 
The synthesized 2,5-disubstituted-l,3,4-thiadiazoles have been screened for 
antibacterial and antifungal activities against Escherichia coli (ATCC-25922), 
Staphylococcus aureus (ATCC-25923), Pseudomonas aeruginosa (ATCC-27853), 
Streptococcus pyogenes and Klebsiella pneumoniae (Clinical isolate) bacterial strains and 
Candida albicans, Aspergillus fumigatus, Penicillium marneffei and Trichophyton 
mentagrophytes (recultured) fungal strains by disk diffusion method. The investigation of 
antimicrobial screening revealed that compounds 3c, 3d and 3b showed good 
antibacterial and antifungal activities respectively. 
Research paper entitled "Synthesis, characterization, and in vitro antimicrobial 
activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-oxadiazoles and 
thiadiazoles" is published. (Nida N. Farshori, Mudasir R. Banday, Anis Ahmad, Asad 
U. Khan, Abdul Rauf, Bioorg. Med. Chem. Lett., 2010, 20, 1933-1938). 
Abstract 
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Scheme 3, Synthesis of2,5-dbubstituted-l,3,4-thiadiazoles 3a-d 
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4. Facile One-pot Synthesis and in vitro Antimicrobial Activity of 
Novel 3-Substituted-l,6-dihydro-l,2,4-triazin-5-(2/0-ones. 
A series of 3-substituted-l,6-dihydro-l,2,4-triazin-5(2H)-ones (3a-f) (Scheme 4), 
have been synthesized using the cyclocondensation reaction of fatty acid hydrazides (la-
f) with 2-chloroacetamide (2) in A ,^iV-dimethyIfomiamide medium. The structural 
Abstract 
elucidation of the synthesized compounds is based on IR, 'H NMR, mass spectral data 
and elemental analysis. 
NH-NH, CI—\ O ^ ^ ^ - ' ^ 
/ ^ ^ DMF, Reflux ^ T NH 
R—A . V-NH2 *- I I \ + / N ^ N H 
R 
la-f 2 3a-f 
Scheme 4. Synthesis of3-substituted-l,6-dihydro-l,2,4-triazin-5-(2H)-ones 3a-f 
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The newly synthesized compounds have been tested for their in vitro antibacterial 
and antifungal activities. The MIC, MBC and MFC were also determined. The data 
pertaining to antibacterial studies showed that the compounds 3c, 3d and 3f have a 
significant influence on the antibacterial profile of 5. pyogenes, S. aureus and E. coli 
Abstract 
species at 6.25 i^ g/ml concentrations. The antifungal screening data revealed the 
compounds 3d and 3f to be the most potent antifungal agents. 
5. Fatty acid alkenoates 
A. Synthesis, Characterization and Preliminary Antimicrobial 
Activity of 7-Hydroxy-coumarin Derivatives' 
A new series of 7-0-coumarinyl alkenoates (6-9) (Scheme 5) were synthesized in 
a single step from 7-hydroxy-coumarin (5) and fatty acids (1-4) using DCC and DMAP 
as catalyst. The synthesized compounds were characterized on the basis of their spectral 
data (IR, 'H NMR, '^C NMR, COSY and MS). 
All the target compounds were evaluated for their in vitro antimicrobial activity 
against Bacillus subtilis (ATCC 6501), Staphylococcus aureus (ATCC 25923), 
Streptococcus pyogene (recultured), Pseudomonas aeruginosa (ATCC 27853), 
Salmonella typhimurium (recultured) and Escherichia coli (ATCC 25922) bacterial 
strains and fungal cultures of Candida albicans (ATCC 24433), Candida krusei (ATCC 
6528), Candida parapsilosis (ATCC 22019) and Cryptococcus neoformans (recultured). 
The minimum inhibitory concentration (MIC) was determined for the test compounds as 
well as for reference standards. 
Research paper entitled "7-Hydroxy-coumarin derivatives: synthesis, characterization 
and preliminary antimicrobial activities" is published. (Nida N. Farshori, Mudasir R. 
Banday, Anis Ahmad, Asad U. Khan, Abdul Rauf, Med. Chem. Res., DOI 
10.1007/S00044-010-9347-9). 
Abstract 
Among the tested compounds, 7-0-coumarinyl (9Z,12i?)-12-hydroxyoctadec-9-enoate (8) 
and 7-0-coumarinyl(12Z,9/?)-9-hydroxyoctadec-12-enoate (9) showed the most potent 
antifungal as well as antibacterial activities. 
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Scheme 5. Synthesis of 7-0-coumarinyl alkenoates (6-9). 
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Abstract 
B. Synthesis and in vitro Antimicrobial Activity of p-Sitosterryl Esters 
of Hydroxy and Non-liydroxy Olefinic Fatty Acids'" 
A new series of p-sitosterryl alkenoates (11-14) (Scheme 6) were synthesized in 
quantitative yields using an appropriate synthetic route involving DCC and DMAP as 
catalyst. The reactions were carried out at room temperature. The synthesized compounds 
were characterized by their spectral data (IR, 'H NMR, '•'C N M R and MS). 
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Scheme 6. Synthesis of fatty acid analogs offi-sitosterol (11-14). 
Research paper entitled "DCC/DMAP mediated esterification of hydroxy and non-
hydroxy olefinic fatty acids with p-sitosterol: In vitro antimicrobial activity" is 
published. (Nida N. Farshori, Mudasir R. Banday, Zeeshan Zahoor, Abdul Rauf, Chin. 
Chem. Lett, 2010, 21, 646-650). 
10 
Abstract 
All the synthesized compounds were evaluated for their in vitro antimicrobial 
activity by disk diffiision method. The minimum inhibitory concentration (MIC), 
minimum bacterial concentration (MBC) and minimum fungicidal concentration (MFC) 
was determined for test compounds as well as for reference standards. Among the 
compounds tested, compounds having hydroxy group at the fatty acid chain (13 and 14) 
showed the most potent antibacterial as well as antifungal activities. 
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PUBUCATIONS AND PRESENTATIONS 227 
dHtrodtutloH 
In the next century the availability of fossil organic feedstock-both as energy 
sources and for the production of organic chemical raw materials will gradually decrease. 
Hence it is important to look for alternatives. These can be found in renewable resources 
both for the energy purposes as well as for raw materials for the chemical industry. In the 
later case, much attention has already been given to the use of natural fats and oils of 
vegetable and plant origin in the oleochemical (oils/fats derived chemicals) industry. 
Abundant fatty acids from natural sources are recognized as a versatile group of 
chemicals in the oleochemical industry. About 15% of the world production of fats and 
oils is used in the oleochemical industry as starting materials for a wide range of 
chemical products. The utilization of fatty acids as agrochemicals finds their way into 
industries not only in a simple acid form but also as esters or other derivatives. The 
reactions of fatty acids are readily accepted to lead towards general perfection of the 
development and progress of organic chemistry. 
The recent trends in technology of fats and fatty acids have given importance to 
industrial processes such as polymerization, oxidation and metathesis. Consequently fatty 
acids have interestingly been found usable as specific and characteristic base materials 
for the emerging organic chemical industry. 
For quite sometime now, the attention of chemist has been diverted to synthesize 
oleochemicals. These oleochemicals by virtue of their economic and ecological 
advantages are now competing with petrochemicals. These fat-derived chemicals are 
essential to a variety of industrial uses such as in coatings, surfactants, plasticizers, 
lubricant additives, cosmetics, pharmaceuticals and organic pesticides. In esterified form 
the fatty acids are used as antifogging agents and found very useful for plasticizer in 
biodegradable plastic materials and also known to be good alternative fuel (biodiesel). 
Fatty acid monoesters are widely used in industry due to their lubricating and softening 
applications. Some fatty esters are found very effective for the treatment of dermatis, 
cardiovascular, hepatic and renal diseases. 
Heterocycles form by far the largest of the classical divisions of organic chemistry 
and are of immense importance biologically, industrially, and indeed to the functioning of 
any developed human society. The majority of pharmaceuticals and biologically active 
agrochemicals are heterocyclic, as are countless additives and modifiers used in 
industries as varied as cosmetics, reprography, information storage, and plastics. Many 
natural drugs such as quinine, papaverine, emetine, theophylline, atropine, procaine, 
codeine, morphine and reserpine are heterocycles. Almost all the compounds we know as 
synthetic drugs such as diazepam, chlorpromazine, isoniazid, metronidazole, 
azidothymidine, barbiturates, antipyrine, captopril and methotrexate are also 
heterocycles. Some dyes (e.g. mauveine), luminophores, (e.g. acridine orange), pesticides 
(e.g. diazinon) and herbicides (e.g. paraquat) are also heterocyclic in nature. 
Furthermore, it has been found that the incorporation of a heterocyclic moiety into 
drug molecules can enhance the biological activity of the drug for eg. Red sulfanilamide 
and the less toxic white sulfanilamide (second generation) were the first sulfa drugs, and 
these contained no heterocyclic fragments. However, the intensive research work that 
followed their discovery demonstrated that modification of the p-
aminobenzenesulfonamide structure by the introduction of heterocyclic substituent into 
the amide markedly enhanced their biological activity. 
Fatty acids are a privileged class of organic chemistry having distinctive feature 
of undergoing classical and non-classical reactions. Fatty acids have two dynamic sites 
which can be employed in chemical reactions for the synthesis of derivatives displaying 
diverse activities: (i) double bond (terminal and internal) (ii) carboxylic acid end. Along 
with the classical reactions of organic chemistry, fatty acids also act as a potential 
substrate to undergo microwave assisted reactions. The microwave assisted organic 
synthesis (MAOS) continues to affect synthetic chemistry significantly by enabling rapid, 
reproducible and scalable chemistry development. Microwave heating has attracted the 
attention of investigators as it makes it possible to shorten the reaction time significantly, 
to increase their selectivity, and to increase the product yields, which is particularly 
important in the case of high-temperature processes that takes a long time. 
Further, the development of antimicrobial agents (antibacterials, antifungals, 
antivirals and antiparasitics) to treat infections has been one of the most notable medical 
achievements of the past century. These advances in medical care are threatened, 
however, by a natural phenomenon known as "antimicrobial resistance." The increased 
use of antibacterial and antifungal agents in recent years has resulted in the development 
of resistance to these drugs with important implications for morbidity, mortality and 
health care costs. In spite of a large number of antibiotics and chemotherapeutics 
available for medical use, the antimicrobial resistance created a substantial medical need 
for new classes of antimicrobial agents in the last decades. In view of the above, the 
design and synthesis of newer antimicrobials will always remain an area of immense 
significance 
III 
A variety of new industrially and biologically useful long-alkyl and 
alkenyl/hydroxyalkenyl chain heterocyclic moieties can thus be prepared by taking 
advantage of the inherently present functional groups in the fatty acids. These aspects 
created an active interest to undertake the present work which involves the isolation and 
characterization of the hydroxy fatty acids from natural source and the synthesis and 
antimicrobial activity screening of the various fatty acid derivatives. 
IV 
CHAPTER-1 
oxadiazoics 
2,5-Disubstituted-l,3,4-oxadiazoles 
1.1. Theoretical 
1,3,4-Oxadiazoles are five membered aromatic heterocycles with great utility in 
synthetic, medicinal, polymer and material chemistry. The widespread use of 1,3,4-
oxadiazoles as a scaffold in medicinal chemistry has established this moiety as a member 
of the privileged structural class. In a study of new pharmaceuticals, the application of 
these heterocycles is warranted to improve their biological profile. These molecules are 
used as pharmacophores because of their favorable metabolic profile and ability to 
engage in hydrogen bonding. Presently there are a number of drugs used clinically, which 
comprise oxadiazole moiety in association with various heterocyclic rings. In particular 
marketed antihypertensive agents such as tiodazosin' and nesapidil and antibiotics, such 
as furamizole'' contain oxadiazole nucleus. 
1,3,4-Oxadiazoles is a popular bioisostere for improving the pharmacological 
profile of biologically active amides, esters and ureas'*. They are used as surrogates of 
carboxylic acids, esters and carboxamides. Symmetrical and unsymmetrical 1,3,4-
oxadiazoles are biologically versatile compounds displaying a variety of biological 
effects which include antipheripheral vasmotility^ anti-inflammatory ,^ antimicrobial, 
antiparasitic^, insecticidal^, herbicidal"', hypoglycemic" and anti-tumor activity . A 
number of biologically relevant entities containing 1,3,4-oxadiazole mofif are used as 
HIV integrase (i)'^ and angiogenesis (ii)''* inhibitors. 
2,5-Disubstituted-l,3,4-oxadiazoles 
<r^^ r-^% 
F,C 
Some C-(P-D-glucopyranosyl)-l,3,4-oxadiazoles (iii) were synthesized as 
potential glycogen phosphorylase inhibitors'^ 2-Amino-l,3,4-oxadiazoles were shown to 
possess antidiabetic' , antiarthritic and anti-inflammatory activities'^. 2-Hydroxyphenyi-
1,3,4-oxadiazole acts as a hypnotic and as a sedative'^. Analgesic, anti-inflammatory, 
anticonvulsive, diuretic and antiemetic properties'^ are exhibited by 5-aryl-2-
hydroxymethy 1-1,3,4-oxadiazoles. 
,0H 
OH N—N 
111 
In addition oxadiazoles were used as models for studying intramolecular 
interactions and structural chemical design of new molecules with (improved 
o • 
< 
parameter^". 2-Amino-1,3,4-oxadiazoles are also used as functional tools for chemical 
synthesis, for eg. Ishikawa et al.^^ have exploited them as azadiones in [4+2] 
cycloaddition reactions for the sy|:i^ hesis of vinca alkaloids. Certain oxadiazole 
derivatives also havd interesting photochemical propertiB5t>and are becoming an important 
2,5-Disubstituted-l,3,4-oxadiazoles 
member of heterocyclic family because of their wide usage in dyes and electrical 
materials . 
2,5-Disubstituted-l,3,4-oxadiazoles containing 2-benzothiazolythiomethyl moiety 
(vi) were synthesized by condensation of (2-benzothiazolylthio)acetic acid imino ester 
dihydrochloride (iv) with hydrazides of various carboxylic acids (v) (Scheme 1.1.1). 
NH.HCI 
OMe NH-NH2 
IV VI 
Scheme 1.1.1 
The treatment of a suspension of salicylic hydrazide (X=0)/thiosalicylic 
hydrazide (X=S) (vii) in toluene with acetic anhydride or ^ acid chloride in presence of 
an equimolar amount of methansulfonic acid at room temperature, and then heating to 
reflux temperature gave 1,3,4-oxadiazoles (ix) (Scheme 1.1.2). 
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R= CH3, CH2CI, C2H5COO, C6H5, C6H5NH X= O, S 
Scheme 1.1.2 
A series of substituted 5-[4-(benzyloxy)-phenyl]-3-(2-cyanoethyl)-1,3,4-
oxadiazol-2(3/f)-one (xii) were synthesized from substituted l-[4-(benzyloxy)benzoyl]-2-
2,5-DisubstUuted-l,3,4-oxadiazoIes 
(2-cyanoethyl) hydrazine , (x) by a cyclization reaction using 
bis(trichloromethyl)carbonate(triphosgene) ^^  (Scheme 1.1.3). 
X= H, 2-1, 3-1,4-1 
XI 
Y=H,I 
Scheme 1.1.3 
XII 
5,5-Dimercapto-bis-[l,3,4-oxadiazol-2-yl]octane and 5,5-dibenzylthio-bis-[l,3,4-
oxadiazol-2-yl]-butane were synthesized by the reaction of alkanedioic acid hydrazides 
(xiii) with CS2 in alcoholic KOH solution to give (xiv) which yielded (xv)(Witn)the 
addition of benzyl bromide (Scheme 1.1.4). 
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,NH L-4 ^NH 
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CS, HS^ 
\\ 
N—N > ^ . 
,SH 
n f j_N 
KOH PhHzCS 
2PhCH,Br w rKWJ 
SCH2Ph 
XIll XIV XV 
Scheme 1.1.4 
5-Aryl-3-(4-hydroxyphenyl)-l,3,4-oxadiazole-2(3/f)-thiones (xvii), inhibiting the 
function of P-glycoprotein, were prepared by the cyclocondensation of l-(4-
27 hydroxyphenyl)-2-aroylhydrazines (xvi) with thiophosgene (Scheme 1.1.5) 
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CSCI, 
HO-
np 
XVI 
\ / / 
XVII 
N—N 
Scheme 1.1.5 
2-Chloro-5-(5-aryl-l,3,4-oxadiazole-2-yl-methyl)-pyridine (xix) were synthesized 
from 2-chloropyridine-5-acetic acid hydrazide (xviii) by refluxing with phosphorus oxy 
chloride for 8 hrs^* (Scheme 1.1.6). 
\\ / 
POCl^ CI N 
XVIIl XIX 
R= H, CI, F, CH3, OCH3 
Scheme 1.1.6 
The treatment of 3-chloro-2-(A^-formylacid hydrazide)-benzo[Z?] thiophene (xx) 
under reflux with phosphorus pentoxide in xylene yielded corresponding 2-(3-chloro-l-
benzothien-2-yl)-l,3,4-oxadiazoles (xxi)^' (Scheme 1.1.7). 
CI CI 
•^^ \ J N-} P2O5 
XX XXI 
Scheme 1.1.7 
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The reaction of 2-({[(3-alkyl-5-oxo-4,5-dihydro-l//-l,2,4-trizaol-l-yl)-methyl]-
l,3,4-thiadiazol-2-yl}thio)-acetohydrazide derivatives (xxii) with carbon disulfite in 
presence of KOH afforded 5-alkyl-2-[(5-{[(5-mercapto-l,3,4-oxadiazol-2-yl)-
methyl]thio}-l,3,4-thiadiazoI-2-yl)-methyl]-2,4-dihydro-3//-l,2,4-triazoI-3-ones (xxiii)-'° 
(Scheme 1.1.8). 
N—N N—N 
/ / \V X ~ - ^ CS,/KOH .. ./ \ c / ^ S \ n ^ ^ S H 
N-N S IjH ^ // 
N—N 
H 
xxii xxiii 
R=CH3,CH2C6H5,C6H5 
Scheme 1.1.8 
The synthesis of 5-furan-2-yl-[l,3,4]oxadiazole-2-thiol (xxv) from furan-2-
carboxylic acid hydrazide (xxiv) was reported by Koparir et al. (Scheme 1.1.9). 
N—N 
SH 
CS,/NaOH ^ >J~\V 
Ethanol ° o " " ' ^ 
XXIV xxv 
Scheme 1.1.9 
When terephthalic acid hydrazide (xxvi) was refluxed with phenyl isocyanate 
(xxvii) then bis-semicarbazide (xxviii) was formed. The compound (xxviii) on treatment 
with phosphorus oxy chloride underwent cyclization to corresponding 5,5-(1,4-
phenylene)-bis-(2-phenylamino-l,3,4-oxadiazole) (xxix) (Scheme 1.1.10). The 
compound (xxix) showed p t^AtfW antibacterial activity. 
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NH2 
r f ^ ^ ^ Ph—N (/•) NaH/DMF 
U " \\=o • 
I 
NH, 
XXVI XXVII XXVUl XXIX 
Scheme 1.1.10 
A effective one-pot acylation/cyclization approach for conversion of 
acylhydrazides to 1,3,4-oxadiazoles is described by James et al.^^. Tetrasubstituted 
alkenyl-l,3,4-oxadiazoles (xxxi) were synthesized in excellent yield, under mild 
conditions and in presence of sensitive functional groups, via the cyclization of 
diacylhydrazides (xxx) using triphenyl phosphine and hexachloroethane in presence of 
Hunig's base (Scheme 1.1.11). 
2,5-DisubstUuted-l,3,4-oxadiazoles 
^ = ^ 
HN 
I 
NH 
A, 
BOC 
PPhj/CljCCClj 
fPr^NEt/ChjCN ^ 
BOC^ 
XXX XXXI 
R= c-Pr, CHzBr, OMe, CH2OTBS, COaEt, H 
Scheme 1.1.11 
4-(5-Amino-[l,3,4]oxadiazole-2-yl-methylsulphonyl)chromen-2-ones (xxxiii) 
were prepared by refluxing (2-oxo-2//-chromen-4-methylsulphonyl)acetic acid hydrazide 
(xxxii) with cynogen bromide in methanol for 3 h '^' (Scheme 1.1.12). 
N—N 
-NH2 
0 \ / O 
~NH, 
CNBr 
b^o-^o CH3OH 
XXXIl XXXllI 
R= 6-CH3, 7-CH3, 7,8-Benzo 
Scheme 1.1.12 
The cyclo-condensation of (7-hydroxy-2-oxo-2//-chromen-4-yl) acetic acid 
hydrazide (xxxi) with carbon disulfide afforded 7-hydroxy-4-[(5-mercapto-1,3,4-
oxadiazol-2-yl)methyl]-2//-chromen-2-one (xxxv) (Scheme 1.1.13), which were found to 
possess high antimicrobial activity against Staphyloccous pneumoniae 35 
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CS/KOH 
XXXIV XXXV 
Scheme 1.1.13 
A series of new 2-[(4-aIkylthio/alkylsulfonyl phenoxy)methyl]-5-substituted-
1,3,4-oxadiazoles (xxxvii) exhibiting promising antimicrobial activity, have been 
synthesized from 2-(4-alkylthio/alkylsulfonyl phenoxy)-acetohydrazides (xxxvi) 
(Scheme 1.1.14). 
36 
, / 
ArCOOH/POCl, N—N 
XR 
xxxvi 
XR 
XXXVll 
R - CH3, C2H5 X= S, SO2 Ar= CfiHs, 4-CH3C6H4, 2-CIC6H4, 3-OCH3C6H4 
Scheme 1.1.14 
The reaction of 1 -adamantanecarbonyl chloride (xxxviii) with various carboxylic 
acid hydrazides (xxxix) yielded the corresponding jV-acyl adamantine-1-carbohydrazide 
derivatives (xL), which were cyclized to the corresponding 2-(l-adamantyl)-5-
substituted-1,3,4-oxadiazoles (xLi) via heating with phosphorus oxy chloride (Scheme 
1.1.15). The synthesized compounds showed anti-inflammatory activity. 
2,5-Disubstituted-l,3,4-oxadiazoles 
NH-NH 
XXXVIIl XXXIX xL xLi 
R= C6H5, 4-FC6H4, 4-CIC6H4, 4-BrC6H4, 4-NO2C6H4, 3,5-(N02)2C6H3, 1-Adamantyl 
Scheme 1.1.15 
2,5-Disubstituted-l,3,4-oxadiazoles (xLiv) have been synthesized by the 
condensation of 4-methoxybenzohydrazide (xLii), by refluxing with different aromatic 
acids (xLiii) in presence of phosphorus oxy chloride^* (Scheme 1.1.16). The in vitro 
growth inhibiting activity against different strains of bacteria and fungi was assessed and 
encouraging resuhs were obtained. 
H3C0-
\ // 
OH 
+ Ar 
NH 
POCK 
HoN 
xLii xLiii xLiv 
Ar= C6H5, 4-CH3C6H4, 4-NO2C6H4, 4-NH2C6H4,4-OHC6H4, C5H4N 
Scheme 1.1.16 
New derivatives of 2-aminomethyl-l,3,4-oxadiazoles (xLvi) were synthesized by 
the reaction of jV-protected phenylglycine hydrazide (xLv) and triethyl orthoesters in 
presence of glacial acetic acid^' (Scheme 1.1.17). 
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0 NHR2 
V-NH R3C(OC,H3)3 )L/°\^R3 
\ AcOH, reflux N—N R, 
NHR2 
xLv xLvi 
R,= Ph R2= Ac, BOC R3= H, CH3, C2H5, Ph 
Scheme 1.1.17 
2,5-Disubstituted-l,3,4-oxadiazoles (xLviii) have been conveniently prepared by 
oxidative cyclization of iV-acyl-A'^ -aryliden-hydrazines (xLvii) promoted by an excess of 
Dess-Martin periodinane under mild conditions'**' (Scheme 1.1.18). 
/? J • ,• • N—N 
• /^ P oxidative cyclization // \\ 
NH-N^ Aco 9^ =^ R f ^ O ^ ^ ^ ' ^ z 
xLvii xLviii 
R,= Ph, 4-ClC6H4,4-N02C6H4, 2-Furyl, 4-Pyridyl 
R2= Ph, 4-MeOC6H4,4-BrC6H4, 2-Furyl, 4-Pyridyl, 2-Thienyl, Pr 
Scheme 1.1.18 
A new class of 1,3,4-oxadiazoles were prepared from acid hydrazides on 
treatment with different carboxylic acids in presence of phosphorus oxy^chloride. The 
arylsulfonylacetic acid/arylmethanesulfonylacetic acid hydrazides (xLix) reacted with 
aromatic carboxylic acids to give 2-(arylsulfonylmethyl)-5-aryl-l,3,4-oxadiazoles/2-
(arylmethanesulfonylmethyl)-5-aryl-1,3,4-oxadiazoles (L) in good yields •*' (Scheme 
1.1.19). 
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r ^ ^ RiCgH^COOH 
POCL 
n=l,2 
xLix 
R= H, 4-Cl R,= H, 2-Cl 
Scheme 1.1.19 
The reaction of ethyl 2,6-dimethyl-5-(N-methylsulfanyIthiocarbohydrazino-
carbonyl) nicotinate (Li) with a two fold excess of hydrazine hydrate in 2-propanal leads 
to the formation of 2,6-dimethyl-5-(5-methylsulfanyl [l,3,4]oxadiazol-2-yI)nicotinic acid 
hydrazide (LH)'*^  (Scheme 1.1.20). 
HjC N ^CHs 
N—N 
w 
Nri V ^ "^CH, r 2NH,.NH, 
Li 
2-propanol 
Scheme 1.1.20 
H3C ^ N CH3 
CH, 
Lii 
The various aroylpropionic acid derivatives containing 1,3,4-oxadiazole nucleus 
(Liv) were synthesized by treating 3-aroylpropionic acid (Liii) with various aryl acid 
hydrazides in presence of phosphorus oxy chloride'*'^  (Scheme 1.1.21). 
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0 
0 
OH 
r f ^ 
R-
" - ^ 
Liii 
POCl 
NH, 
HN 
y-
3, reflux 
/ = \ 
^ ^ J ^ ^ ^ 
R= H, Ph, 4-CH3, 2,4-(CH3)2 
^ x ^ 
Liv 
R,= H, 2-Cl, 4-Cl, 4-NO2, 4-(OCH3)2 
Scheme 1.1.21 
A facile, convenient and high yielding synthesis and in vitro anti-cancer activity 
of a series of 5-(3-indolyl)-2-substituted-l,3,4-oxadiazoles (Lvi) has been described by 
Kumar et a//"*. The key step of synthesis involved the cyclization of A^-acylhydrazones 
(Lv) using [bis(trifluoro-acetoxy)iodo]benzene under solvent free condition (Scheme 
1.1.22). 
R 
PhI(OCOCF3)2 
grinding, rt 
SOsPh SOzPh 
Lv Lvi 
R= CfiHs, CH2C6H4,4-Pyridyl, 4-CH3OC6H4, CH3, CF3 
Scheme 1.1.22 
Watanabe et al.'^^ synthesized the biologically important 2,5-diphenyl-l,3,4-
oxadiazole (Lix) derivatives by reacting 4-iodo/bromo benzhydrazide (Lvii) with 4-
dimethyl-aminobenzaldehyde (Lviii) in presence of eerie ammonium nitrate (CAN) 
(Scheme 1.1.23). 
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K / < NH-NH2 r-VJT' 
Lvii Lviii Lix 
R= Br, I 
Scheme 1.1.23 
The reaction of anthranilic acid derivatives (Lx) with (//-isocyanimino) 
triphenylphosphorane (Lxi) at room temperature afforded 2-substituted-l,3,4-oxadiazoles 
(Lxii) via an intramolecular aza-wittig reaction under neutral condition'*^ (Scheme 
1.1.24). 
° 0 N-N 
. . . // 
+ C=N—N 
PPh, 
rt 
Lx Lxi Lxii 
X= H, Me, Ac 
Scheme 1.1.24 
The 3-substituted benzoic acid derivatives (Lxvi) and (JV-
isocyanimino)triphenylphosphorane (Lxvii) in dry solvent reacted together in a 1:1 ratio 
at room temperature to produce 1,3,4-oxadiazoles (Lxviii)''' (Scheme 1.1.25). 
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N—N 
+ C=N—N 
PPh, 
Lxvi 
X= F, OMe, NH2, OPh, OAc 
Lxvii Lxviii 
Scheme 1.1.25 
The cyclization of ;7-toluic acid (Lxiii) and hydrazine hydrate (Lxiv) catalysed by 
polyphosphoric acid (PPA) yielded 2,5-di-/7-tolyl-l,3,4-oxadiazole (Lxv) in good yield'*^  
(Scheme 1.1.26). 
r H,C 
_j. H2N—NH2 PPA 
150X, 15h 
CH, 
Lxiii Lxiv Lxv 
Scheme 1.1.26 
The synthesis of imidazo[5,l-fe][l,3,4]oxadiazole motif (Lxxi) by the double 
cyclodehydration of amino acid-derived acyl hydrazide amides (Lxix) has been described 
by Tran et al.'^^ (Scheme 1.1.27). 
R 
1 ' Ph FOCI, P R 
NH ^ O CH3CN • " P h - ^ N H - ^ ) 
Lxix 
R= H, /-Pr 
Lxx 
Scheme 1.1.27 
0- ^ p/ "N-^"^ 
Lxxi 
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A primary aromatic amine and formaldehyde solution on reaction with 5-(2-
thienyl)-l,3,4-oxadiazoline-2-thione (Lxxii) in ethanol gave 3-arylaminomethyl-5-(2-
thienyl)-l,3,4-oxadiazoIes (Lxxiii)^° (Scheme 1.1.28). 
H 
N—N ArNHJCH^O iryji ^ -^ 
~S EtOH, rt 
Lxxii Lxxiii 
R= 2-F, 4-F, 4-Cl, 2-CF3, 3-CF3 
Scheme 1.1.28 
The environmentally benign electroorganic synthesis of 5-substituted-2-amino-
1,3,4-oxadiazoles (Lxxv) by electrocyclization of semicarbazone (Lxxiv) has been 
described by Sharma et a/.^' (Scheme 1.1.29). 
/ / \ \ Electrocyclization !/ \! 
Lxxiv Lxxv 
R = CftHs, 4-CIC6H4,4-(OCH3)-C6H4,4-(OH)-C6H4, 3-(N02)-C6H4, CH3 
Scheme 1.1.29 
The synthesis of 2-styryl-5-(arylmethanesulfonylmethyl)-l,3,4-oxadiazoles 
(Lxxviii) was achieved by refluxing a mixture of arylmethanesulfonylacetic acid 
hydrazide (Lxxvi) with cinnamic acid (Lxxvii) in presence of phosphorous oxy chloride 
(Scheme 1.1.30). 
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.NH2+ 
NH R 
POCI, 
Lxxvi Lxxvii Lxxviii 
n=0, 1 R= H, Me, CI R,= H, CI 
Scheme 1.1.30 
The reaction of 4-aminoisothiazdcarboxyHc-3-acid hydrazide (Lxxix) with 
isothiocyantes, ArpNCS, followed by in situ cyclization of intermediate 
thiosemicarbazides with DCC afforded 2-(4-aminoisothiazolyl-3)-5-(arylamino)-1,3,4-
oxadiazole (Lxxx) in good yields^'' (Scheme 1.1.31). 
Ar|C6H4NCS,tBuOH 
DCC, reflux 
Lxxix 
-NH 
// W // 'Ar. 
s-ii -^^  
Lxxx 
Ar= 3,4-(OCH20)-C6H4, 3,4-(OCH2 CH20)-C6H4, 4-CI-C6H4 
Scheme 1.1.31 
The synthesis of 2-(4-isopropylthiazol-2-yl)-5-substituted-l,3,4-oxadiazoles 
(Lxxxii) was achieved by the reaction of 4-isopropylthiazole-2-carbahydrazide (Lxxxi) 
with appropriate aromatic acid in phosphorus oxy chloride under reflux condition '^* 
(Scheme 1.1.32). 
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CHo 
CHo 
H,C N RCOOH 
H,C N 
NH POCIj.reflux 
y<r 
N—N 
H2N 
Lxxxi Lxxxii 
R=CH3, C6H5, C6H4CI, C6H4 C6H4NO2, C6H4Br, C6H4CI, C6H4OH 
Scheme 1.1.32 
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1.2. Synthesis, Antibacterial and Antifungal Activity of Some 
New2,5-Disubstituted-l,3,4-oxadiazoles* 
A wide variety of heterocyclic systems have been explored for developing 
pharmaceutically important molecules. Among them the derivatives of oxadiazoles have 
played an important role in the medicinal chemistry. 1,3,4-Oxadiazoles have 
demonstrated a broad spectrum of biological activities in both agrochemical and 
pharmaceutical fields. The substituted oxadiazoles serve both as biomimetic and reactive 
pharmacophores and are key elements with potential activities. The therapeutic effects of 
compounds containing 1,3,4-oxadiazole rings have been studied for a number of 
pathological conditions including inflammation^^, pain^^ and hypertension^^. 
Furthermore, the synthesis of oxadiazoles has attracted wide attention due to the diversity 
of their applications as antibacterial^^, antimycobacterial^^, antifungal^^ and 
antidepressant agents^'. 2,5-Disubstituted-oxadiazoles have also attracted significant 
interest because of their application in material science for the development of electronic 
as well as optical devices . In addition, the oxadiazoles have been used as models for 
studying intramolecular interactions and structural chemical design of new molecules 
, 2 0 ; witl/improved parameters^ 
•Research paper entitled "Synthesis, characterization, and in vitro antimicrobial activities ofS-
alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-oxadiazoles and thiadiazoles" is published. (Nida 
N. Farshori, Mudasir R. Banday, Anis Ahmad, Asad U. Khan, Abdul Rauf, Bioorg. Med. Chem. 
Lett., 2010, 20, 1933-1938). 
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Various biological applications such as antimicrobial^ ,^ antifungal^, pesticidal 
and anticancer activities'^ have also been reported for seed oils, long chain alkenoic acids 
and their derivatives. The symmetrically disubstituted 1,3,4-oxadiazoles have been 
/"-^XJ^ 67 
prepared(jrorrt author's laboratory . 
The wide range of therapeutic values of alkenoic acids and oxadiazoles ring 
systems prompted us to synthesize the title compounds and '^screen) them for yai^d^ 
antimicrobial activities. The basic idea was to append the long chain 
7 
alkenyl/hydroxyalkenyl moiety of the fatty acid to the oxadiazole nucleus so as to 
( combine the beneficial effects in a single structure with expected biological activiti^ iS 
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1.3. Results and Discussion 
In a typical reaction procedure the long chain alkenoic acid hydrazides (la-d), 
used as the starting material were prepared from corresponding long chain alkenoic acids 
by esterification and further treatment with hydrazine hydrate . The reaction of la-d 
with phenyl isocyanate in dry benzene under reflux and removing excess of solvent under 
reduced pressure gave semicarbazides (2a-d). The treatment of 2a-d with phosphorus oxy 
chloride yielded 2,5-disubstituted-l,3,4-oxadiazoles (3a-d) in good yields. The reaction 
sequence is outlined in Scheme 1.3.1. 
0 O 
II PhNCO 
-U NH-NH, ^ R - ^ 
la-d 
-NH-NH—LJ-NH-
2a-d " - ^ 
POCI, 
N—N // w 
-NH t) 
3a-d 
Scheme 1.3.1. Synthesis of2,5-disubstUuted-l,3,4-oxadiazoles 3a-d 
The characterization data of semicarbazides (2a-d) and 1,3,4-oxadiazoles (3a-d) 
(A^ a 
is given in Table 1.3.1. As can be seen Jr^ Table 1.3J^he scope of the reaction using ) ^ 
x)lefmic (internal and terminal) and hydroxy fatty acids is found to be goo^/The yields of 
1,3,4-oxadiazoles are excellent and independent of the substituent present in the 
precursor. 
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Table 1.3.1. Characterization data of synthesized compounds 2a-d and 3a-d 
Compd. R Mol. Formula U^. [°C] Yield[%] Analysis (%) found (calculated) 
C H N 
2a H, C,8H2702N3 103-104 80 67.67(68.11) 8.44(8.56) 13.09(13.23) 
2b ^6 "s C25H41O2N3 101-102 79 71.95(72.25) 9.86(9.93) 10.02(10.11) 
2c ^OH 5 C25H41O3N3 111-113 77 69.23(69.57)9.50(9.56)09.65(9.73) 
OH 
2d ^3 ^ C25H41O3N3 113-114 72 69.33(69.57)9.20(9.56)09.65(9.73) 
3a H, C,8H250N3 133-134 92 72.06(72.21) 8.11(8.40) 13.90(14.03) 
3b ^6 "5 C25H39ON3 144-146 90 75.23(75.52) 9.74(9.87) 10.44(10.56) 
C H j 
3c 'OH 5 C25H39O2N3 133-136 87 72.35(72.60)9.41(9.49)10.00(10.15) 
OH 
3 d ^ V - ^ ^6 C25H39O2N3 135-137 87 72.28(72.60) 9.36(9.49) 09.97(10.15) 
The semicarbazide 2a showed IR bands at 3236 cm"' (NH, NH-NH) and 1667 
cm'' (C=0). ' H N M R was more informative, characteristic peaks were observed at 5 
13.04 (IH, s, CO-NH-AT), 9.16 (2H, br. s, CO-NHNH-CO), 8.17 (2H, d,J= 7.2 Hz, Ar-
H-276"), 7.60 (IH, t, J = 7.4 Hz, Ar-H-4") and 7.51 (2H, t,J= 7.4 Hz, Ar-H-375"). In 
'^ C NMR peaks at 6 168.2, and 165.4 were observed. 
, ^ . 
(The build up of 3a-d is evident>from their spectral data. Compound 3a, 5-(Dec-9-
enyl)-2-phenylamine-l,3,4-oxadiazole, showed IR absorption bands at 3228, 1504, 1258 
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cm'' due to stretching vibrations of NH, C=N and C-O-C functions. The ' H N M R was 
more informative in assigning the structure. Diagonastic peaks at 6 9.07 (IH, s, NH), 7.27 
(2H, d, J = 7.6 Hz, Ar-H-276"), 7.18 (IH, t, J = 7.5 Hz, Ar-H-4") and 6.98 (2H, t, J = 7.3 
Hz, Ar-H-3"/5") were observed. A triplet at 5 2.24 was observed for methylene protons a 
to oxadiazole ring. The methine proton of C-9 showed signal at 5.79. The C-10 
methylene proton designated as Hg and Hz displayed two distinct 5 values when coupled 
with adjacent C-9 methine protons. Thus, the ' H NMR showed two doublet of doublet at 
5 5.00 and 4.94 for Hz and H^ protons>respectively. In '^C NMR peaks at 6 172.9 and 
155.6 were observed for ring carbon atoms. The mass spectra showed characteristic 
molecular ion peak which were in accordance with the molecular formula. Detailed 
spectral data of the titled compounds are given in experimental section. 
Antibacterial studies 
All the newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Staphylococcus aureus (ATCC-25923), 
Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^''^°. The 
susceptibility was assessed on the basis of diameter of zone of inhibition against Gram-
positive and Gram-negative strains of bacteria. Inhibition zones were measured and 
compared with the controls. The bacterial zones of inhibition values are given in Table 
1.3.2. 
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Table 1.3.2. In vitro antibacterial activity of 5-alkenyl/hydroxyalkenyl-2-
phenylamine-l,3,4-oxadiazoles 3a-d 
Diameter of zone of inhibition ( m m ) ^ 
Compounds Gram positive bacteria Gram negative bacteria 
S. pyogenes S. aureus P. aeruginosa K. pneumoniae E.coli 
3a 
3b 
3c 
3d 
Standard 
DMSO 
18.0±0.5 
15.6±0.2 
21.2±0.3 
20.1±0.2 
23.0±0.2 
17.7±0.6 
15.3±0.2 
20.2±0.4 
21.1±0.3 
22.0±0.2 
17.3±0.8 
19.3±0.5 
25.6±0.2 
19.4±0.2 
32.0±0.3 
16.8±0.8 
14.9±0.3 
19.7±0.2 
20.2±0.1 
19.0±0.2 
19.8±0.6 
17.5±0.3 
22.8±0.3 
21.6±0.2 
27.0±0.2 
Positive control (standard); Cliloramphenicol and negative control (DMSO) measured by 
the Halo Zone Test (Unit, mm) 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The minimum inhibitory concentrations and minimum bactericidal 
concentrations (MBCs) are given in Table 1.3.3. 
24 
2,5-Disubstituted-l,3,4-oxadiazoles 
Table 1.3.3. MIC and MBC results of5-alkenyl/hydroxyalkenyl-2-phenylamine-
1,3,4-oxadiazoles 3a-d 
Compounds Gram positive bacteria Gram negative bacteria 
P. aeruginosa K. pneumoniae E. coli S. pyogenes S. aureus 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
3a 12.5 50.0 
3b 25.0 25.0 
3c 
3d 
6.25 12.5 
6.25 25.0 
Standard6.25 12.5 
6.25 25.0 12.5 50.0 12.5 25.0 12.5 50 
12.5 50.0 12.5 50.0 12.5 50.0 12.5 50 
6.25 12.5 6.25 50.0 6.25 6.25 6.25 25 
12.5 12.5 6.25 50.0 6.25 25.0 6.25 25 
6.25 12.5 6.25 12.5 6.25 12.5 6.25 12.5 
Positive control Chloramphenicol 
MIC (ng/ml) = minimum inhibitory concentration, i.e. the lowest concentration of the 
compound to inhibit the growth of bacteria completely; MBC {\ig/m\) = minimum 
bacterial concentration, i.e., the lowest concentration of the compound for killing the 
bacteria completely. 
The PBE (percentual bacteriostatc efficiency, %) was obtained as 
PBE=100/MIC 
The results have been depicted in Fig. 1.3.1. 
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• SP 
• SA 
DPA 
DKP 
• EC 
3b 3c 3d 
Compounds 
SP= S. pyogenes, SA= S. aureus, PA= P. aeruginosa, KP= K. pneumonia, EC= E. Coli 
Fig. 1.3.1 Percentual bacteriostatic efficiency (PBE%)for compounds 3a-d compared 
to control drug Chloramphenicol (Ch) 
The investigation of antibacterial screening data revealed that all the tested 
compounds have exerted significant inhibitory activity against the growth of tested 
bacteria! strains. The data pertaining to Table 1.3.3 reveal that compounds 3a-d have 
significant influence on the antibacterial profile of subject bacterial strains at 6.25 fig/ml 
concentrations. The compounds 3c and 3d were found to be almost equally potent as the 
reference drug, Chloramphenicol, in case of K. pneumoniae. The MBC of few 
compounds was found to be the same as MIC but in most of the compounds it was two or 
three folds higher than the corresponding MIC results. 
Among the synthesized oxadiazoles, the compounds with a hydroxyalkenyl chain 
substituent at 5"^  position of oxadiazoles were found to^increaseXhe antibacterial activity 
26 
2,5-DisubstUuted-l,3,4-oxadiazoles 
in compounds 3c and 3d. However the position of the hydroxy group had no significant 
effect on the magnitude of the antibacterial activity. Further, the compounds showed 
parallel activity against Gram-positive and Gram-negative bacterial strains. 
Antifungal studies 
Antifungal activity was also done by disk diffusion method^' ^^ . For assaying 
antifiingal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei and 
Trichophyton mentagrophytes (recultured) in DMSO strains were used. The fiingal 
activity of each compound was compared with Greseofulvin as standard drug. Inhibition 
zones were measured and compared with the controls. The fungal zones of inhibition 
values are given in Table 1.3.4. 
Table 1.3.4. Antifungal activity of5-Alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-
oxadiazoles 3a-d 
Compounds Diameter of zone of inhibition (mm) 
CA AF TM PM 
3a 
3b 
3c 
3d 
Standard 
DMSO 
24.2±0.4 
26.1±0.3 
23.3±0.9 
23.2±0.2 
30.0±0.2 
20.8±0.3 
23.1±0.2 
20.7±0.4 
21.6±0.4 
27.0±0.2 
16.9±0.9 
20.2±1.2 
17.5±0.2 
18.7±0.2 
24.0±0.3 
15.2±1.2 
15.9±0.3 
13.9±0.3 
16.3±0.2 
20.0±0.5 
Positive control (Greseofulvin) and negative control (DMSO) measured by the Halo Zone 
Test (Unit, mm). 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton 
mentagrophytes, PM= Penicillium marneffei. 
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The results of minimum inhibitory concentrations (MICs) and minimum 
fungicidal concentrations (MFCs) as determined by broth dilution technique are given in 
Table 1.3.5. 
Table 1.3.5. MIC and MFC of5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-
oxadiazoles 3a-d 
Compounds CA AF TM PM 
MIC MFC MIC MFC MIC MFC MIC MFC 
3a 25.0 50.0 25.0 100 12.5 50.0 12.5 25.0 
3b 6.25 25.0 6.25 12.5 12.5 25.0 6.25 25.0 
3c 25.0 100 12.5 50.0 12.5 50.0 12.5 100 
3d 12.5 25.0 25.0 50.0 25.0 50.0 25.0 100 
St. 6.25 12.5 6.25 12.5 6.25 12.5 6.25 12.5 
Positive control Greseofiilvin 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei, St.= Standard. MIC (ng/ml) = minimum inhibitory 
concentration, i.e the lowest concentration of the compound to inhibit the growth of 
fungus completely; MFC (^g/ml) = minimum fungicidal 
The ratio MFC/MIC was calculated in order to determine if the compound had a 
flingistatic (MFC/MIC> 4) or fungicidal (MFC/MIC< 4) activity and the results have 
been depicted in Fig. 1.3.2. 
28 
2,5-Disubstituted-l,3,4-oxadiazoles 
8 
7\ 
6 
5+ 
MFC/MIC 4 
3 
2 
1 
0 
3a 3b 3c 3d 
Compounds 
Gr 
CA= Candida albicans, AF= Aspergillusfumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. 
Fig. 1.3.2 MFC/MIC of compound 3a-d compared to control drug Greseofulvin (Gr) 
The antifungal screening data showed moderate to good activity. Among the 
screened compounds 3b was found to be most active against all test fungal strains. The 
compound 3b was active against P. marneffei. The MFC of most of the compounds was 
two or three folds higher than the corresponding MIC results. Most of the synthesized 
compounds showed good ftjngistatic activity against the fungal strain C. albicans. The 
data revealed that compounds 3a-d have produced the marked enhancement in the 
potency of these analogues as antifungal agents. The compounds with an internal double 
bond in the long alkenyl substituent of synthesized oxadiazoles were found to be potent 
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antifungal agents. Contrary to the antibacterial studies, the presence of the hydroxy on the 
alkenyl side chain turns out to be detrimental for the anti-fungal activity perhaps due to 
pharmacokinetic reasons. 
In conclusion the present study showed that the synthesized compounds can be used as 
template for future development through modification and derivatization to design more 
potent and selective antimicrobial agents. 
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1.4. Experimental 
Anhydrous conditions were achieved by oven drying flasks and equipments. The 
reaction progress and completion was monitored by thin layer chromatography ^olri^  on 
>lass plates (20x5 cm) vvi<^/\/l|^e^«3|^ilca gel G (Merck, Mumbai, India, 0.5mm 
thickness). Mixture of n-hexane-ethyl acetate-acetic acid (70:30:1, v/v) were used as 
leveloping solvents. Column chromatography was carried out on silca gel (Merck, 
Mumbai, India, 60-120 mesh). IR spectra were obtained on Shimadzu 8201 PC FT-IR 
using KBr pellet and nujol oil with absorption given in cm"'. 'H N M R and '^ C NMR 
spectra were recorded in CDCI3 on a Bruker DRX-400 instrument. The chemical shifts 
{8) were measured relative to TMS as an internal standard. Coupling constants {J) are 
expressed in Hz. Mass spectra were obtained on a Jeol SX-102 (FAB) spectrometer. 
Melting points were taken in open capillary and are uncorrected. 
All reagents and solvents were generally used as received from commercial 
suppliers and if required were dried and distilled before use. Undec-10-enioc (purity 
98%) and (9Z)-octadec-9-enoic (97%) acids were purchased from Fluka Chemicals 
(Bucks, Switzerland). (9Z,72/?)-12-Hydroxyoctadec-9-enoic (ricinoleic) and {9R,12Z)-9-
hydroxyoctadec-12-enoic (isoricinoleic) acids were isolated from the natural sources i.e. 
from Ricinus communis and Wrightia tinctoria seed oils respectively. 
Isolation and characterization of hydroxy fatty acids 
The naturally occurring hydroxy fatty acids have the potentiality of utilization as 
an alternative source for the production of oleochemicals. In view to this, the isolation of 
hydroxy fatty in pure form and their characterization is of prime importance. The 
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hydroxy fatty acids viz. (9Z, 12^)-12-hydroxyoctadec-9-enoic acid (ricinoleic acid) and ^ 
(9/?, 12Z)-9-hydroxyoctadec-12-enoic acid (isoricinoleic acid) were isolated from Ricinus 
communis and Wrightia tinctoria seed oils respectively. The freshly extracted s,^ ed oils 
were saponified with alcoholic KOH. After the removal of unsaponifiable matter the soap 
solution was decomposed with 10% H2SO4. The mixed fatty acids so obtained were 
partitioned according to Gunstone's partition procedure , between light petroleum and 
80% aqueous methanol. The hydroxy acid present in each methanolic layer was collected 
and most of the meth i^nol was removed under reduced pressure. The residue was taken up 
in ether and dried over sodium sulphate. Evaporation of the solvent gave the concentrate 
of hydroxy acids which on purification by column chromatography gave the 98% pure 
(9Z,12i?)-12-hydroxyoctadec-9-enoic (ricinoleic) and (9/?,12Z)-9-hydroxyoctadec-12-
enoic (isoricinoleic) acids. Further their methyl esters were prepared by MeOH/H"^  and 
were characterized on the basis of the spectral data. 
Spectroscopic data 
(9Z,12R)-I2 hydroxyoctadec-9-enoate 
IR(KBr): j4CC,174ncm"' 
'HNMR (400 MHz, CDCI3): 6 6.31 (s, 3H, OC//3), 5.42 (m, 2H, -CH=CH-), 3.84 (m, 
IH, -C^CH), 2.30 (m, IH, -CHOH-), 2.02 (m, 4H, -C//2-CH=CH-C//2-), 1.32 (br.s, 18H, 
chain C//2), 0 8^ (dist.t, 3H, C//j). 
(9R,12Z)-9-hydroxyoctadec-12-enoate 
IR (KBr); 3406, '.738 cm"' 
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'HNMR (400 MHz, CDCI3): 6 6.29 (s, 3H, OC//3), 5.37 (m, 2H, -CH=CH-), 3.82 (m, 
IH, -CHOH), 2.27 (m, IH, -CHOH-), 2.09 (m, 4H, -C//2-CH=CH-C//r), 1.30 (br.s, 18H, 
chain CH2), 0.86 (dist.t, 3H, CH3). 
General procedure for the synthesis of long chain alkenoic acid hydrazide (la-d) 
The hydrazides of long chain alkenoic acids (la-d) which are used as the starting 
material were prepared by the previously reported methods^ .^ The synthesized hydrazides 
la-d were characterized by melting points. 
Synthesis of l-(alkenoyl/hydroxyalkenoyl)-5-phenylsemicarbazide (2a-d) 
Hydrazide (la-d) (1.0 mmole) was dissolved in abs. ethanol by heating to jilkk^ a 
clear solution. An equal molar amount of phenyl isocyanate was added to it and the 
solution was refluxed for 5 h. The progress of the reaction was monitored by TLC. After 
completion of the reaction, the reaction mixture was cooled to pl^ precipitate. The 
precipitate was filtered, washed with abs. ethanol and dried to give analytically pure 
compounds 2a-d. The purity of the compounds was ascertained by TLC pe^ oiutlefn 
st<i(Ji§V using petroleum ether/ethyl acetate (4:1, v/v) and a few drops of acetic acid as-
mobil^-fhase. The newly synthesized compounds were characterized from their spectral 
data. 
Spectroscopic Data 
I-(Undec-10-enoyl)-S-phenylsemicarbazides (2a) 
White powder; Yield 80%; Mp 103-104 °C. 
71? (KBr): 3236,1667 cm"'. 
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'HNMR (400 MHz, CDC13): 6 13.04 (s, IH, CO-NH-AT), 9.16 (br. s, 2H, CO-NHNH-
CO), 8.17 (d, 2H, J= 7.2 Hz, Ar-H-276"), 7.60 (t, IH, J= lA Hz, Ar-H-4"), 7.51 (t, 2H, 
J= lA Hz, Ar-H-375"), 5.82 (tdd, IH, y„_,,.^ ^= 6.8 Hz, 7^_„^=10.0 Hz, J„_^^=17.8 Hz, 
CH2=C//-), 5.01 (dd, IH, j^^_^=10.0 Hz, j„^_„=2.% Hz, //zC=CH), 4.94 (dd, IH, 
j ^ =17.8 Hz, j„ „ = 2.8 Hz, //£C=CH-), 2.45 (t, 2H, y = 7.4 Hz, CH2-CO), 2.01 (m, 
2H, CH2=CH-Ci/2), 1.82 (m, 2H, C//2CH2-CO), 1.45-1.25 (br. s, lOH, (€7/2)5). 
'^CNMR (100 MHz, CDCI3): 5 168.2, 165.4, 139.2, 133.2, 131.3, 128.9, 128.6, 114.2, 
33.8,29.9,29.6,29.3,29.2, 29.1, 29.0,28.9. 
l-[(9Z)-Octadec-9-enoyl]-5-phenylsemicarbazides(2b) 
White powder; Yield 79%; Mp 101-102 °C. 
//?(KBr): 3222,1665 cm"'. 
'HNMR (400 MHz, CDCI3): 6 13.18 (s, IH, N//), 9.18 (br. s, 2H, N//N/f), 8.08 (d, 2H, 
J= 7.2 Hz, Ar-H-2"/6"), 7.64 (t, IH, J= lA Hz, Ar-H-4"), 7.51 (t, 2H, J= 7.2 Hz, Ar-H-
375"), 5.31 (m, 2H, CH2-C//=C//-CH2), 2.54 (t, 2H, J - 7.8 Hz, C//2-CO), 2.36 (m, 4H, 
CHrCH2=CH-C//2), 1.82 (m, 2H, CH2-CH2-CO), 1.37-1.25 (br. s, 20H, (CH2),o), 0.89 
(dist. t, 3H, terminus C//3). 
'^CNMR (100 MHz CDCI3): 5 167.4, 164.7, 139.2, 137.3, 133.2, 131.5, 128.8, 129.0, 
31.9, 30.7, 30.4, 30.1, 29.9, 29.7, 29.6, 29.4, 29.2 "two signals are hidden", 29.1, 26.6, 
22.7,14.2. 
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l-[(9Z,l2R)-l2-hydroxy-octadec-9-enyl]-5-phenylsemicarbazides(2c) 
Off-white powder; Yield 77%; Mp 111-113 °C. 
IR (KBr): 3343, 3233,1661 cm-'. 
'HNMR (400 MHz, CDCI3): 5 13.23 (s, IH, N/f), 9.17 (br. s, 2H, N / ^ / f ) , 8.12 (d, 2H, 
/= 7.4 Hz, Ar-H-276"), 7.65 (t, IH, J= 7.4 Hz, Ar-H-4"), 7.51 (t, 2H, J= 7.2 Hz, Ar-H-
375"), 5.37 (m, 2H, CH2-C//=C//-CH2), 4.87 (m, IH, C//-OH), 2.55 (t, 2H, J = 7.6 Hz, 
CH2-CO), 2.36 (m, 4H, C//2-CH2=CH-C//2), 1.83 (m, 2H, C//2-CH2-CO), 1.76 (m, IH, 
CU-OH), 1.44-1.28 (br. s, 18H, (€7/2)9), 0.88 (dist. t, 3H, terminus C//3). 
'^CNMR (100 MHz, CDCI3): 6 166.2, 163.3, 138.7, 136.3, 132.2, 128.1, 128.0, 127.8, 
70.7,40.1, 39.9, 39.7,39.4,39.2, 31.3, 30.4, 29.4, 29.2, 29.0, 28.8, 26.1, 22.0,14.1. 
l-[(9R,12Z)-9-hydroxy-octadec-12-enyl]-5-phenylsemicarbazide (2d) 
Off-white powder; Yield 72%; Mp 113-114 '^ C. 
IR (KBr); 3353, 3229,1668 cm-'. 
^H NMR (400 MHz, CDCI3): 6 13.03 (s, IH, NH), 9.09 (br. s, 2H, NHNH), 8.16 (d, 2H, 
J= 7.2 Hz, Ar-H-276"), 7.61 (t, IH, J= 7.4 Hz, Ar-H-4"), 7.52 (t, 2H, J= 12 Hz, Ar-H-
3"/5"), 5.38 (m, 2H, CH2-C//-C//-CH2), 4.89 (m, IH, C//-OH), 2.55 (t, 2H, J = 7.6 Hz, 
C//2-CO), 2.26 (m, 4H, C//rCH2=CH-C//2), 1.86 (m, 2H, C//2-CH2-CO), 1.68 (m, IH, 
CH-OH), 1.40-1.25 (br. s, 18H, (€7/2)9), 0.87 (dist. t, 3H, terminus C//3). 
'^CNMR (100 MHz, CDCI3): 5 167.6, 163.2, 138.4, 137.6, 131.2, 128.7, 128.3, 125.5, 
70.56,40.1, 39.9, 36.3, 24.8, 31.3, 29.1, 29.0, 28.9, 28.8, 28.5, 28.4, 25.1, 22.3, 14.01. 
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Synthesis ofS-(alkenyl/hydroxyalkenyl)-2-phenylamine 1,3,4-oxadiazoles (3a-d) 
l-Alkenoyl/hydroxyalkenoyl-5-phenyl carbamides (2a-d) (1.0 mmole) in 
phosphorus oxy chloride (6.0ml) were refluxed for 4 h. The progress of the reaction was 
monitored by TLC. After the completion of the reaction the resulting mixture was then 
poured into NaOHfice water solution,^suiting in deposition/that was filtered, washed, 
dried and recrystallized from aqueous ethanol and acetone (1:4, v/v) to give compounds 
3a-d. All these novel compounds were characterized from their spectral data. 
Spectroscopic Data 
5-(Dec-9 '-enoic)-2-phenylamine-l,3,4-oxadiazole (3a) 
White powder; Yield 92%; Mp 133-134 °C. 
m (KBr): 3228,1504, 1258 cm"'. 
^HNMR (400 MHz, CDCI3): 5 9.07 (s, IH, N//), 7.27 (d, 2H, J= 7.6 Hz, Ar-H-276"), 
7.18 (t, IH, J= 7.5 Hz, Ar-H-4"), 6.98 (t, 2H, J= 7.3 Hz, Ar-H-375"), 5.79 (tdd, IH, 
J , =6.6 Hz, / „ =10.1 Hz, j„ „ =16.9 Hz, CHj^C//-), 5.00 (dd, IH, j„^ ,=10.1 
H-CH2 "'"' ' 
Hz, J = 2.2 Hz, //zC=CH), 4.94 (dd, IH, j„ _„=16.9 Hz, J„^_„,= 2.2 Hz, //gC^CH-), 
2.24 (t, 2H, J = 7.5 Hz, CH2O.X0 ring), 2.00 (m, 2H, CH2=CH-C//2), 1.58 (m, 2H, CH2 P 
toring), 1.21(br,s, 10H,(C//2)5). 
"CNMR (100 MHz, CDCI3): 5 172.9, 155.6, 139.4, 139.0, 128.7, 122.2, 118.5, 114.2, 
40.6,40.2, 39.8, 39.4, 33.9, 29.2, 28.9, 25.4. 
MS (ESI): m/z = 322.3 [M+Na]^ calculated = 322.4. 
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S-[(8'Z)-Heptatadecenoic]'2-phenylamine-l,3,4-oxadiazole (3b) 
White crystals; Yield 90%; Mp 144-146 °C. 
IR (KBr): 3218,1505, 1242 cm''. 
'HNMR (400 MHz, CDCb): 5 9.39 (s, IH, N/f), 7.26 (d, 2H, J= 7.7 Hz, Ar-H-276"), 
7.17 (t, IH, J= 7.5 Hz, Ar-H-4"), 6.98 (t, 2H, J= 7.3 Hz, Ar-H-3'V5"), 5.33 (m, 2H, CH2-
CH=CH-CU2), 2.23 (t, 2li,J= 7.5 Hz, CH2 a to ring), 2.01 (m, 4H, C/Z -^CH^CH-CZ/^ ), 
1.56 (m, 2H, CH2 p to ring), 1.29 (br, s, 20H, (C//2)io), 0.87 (dist. t, 3H, terminus CHs). 
'^CNMR (100 MHz, CDCI3): 5 172.9, 152.2, 133.5, 130.4, 129.3, 125.6, 123.2, 114.2, 
40.6,40.2, 39.8, 39.4, 38.6, 38.4, 33.9, 31.8, 31.4, 29.2, 28.4, 28.2, 27.9, 22.6, 14.0. 
MS (ESI): m/z = 420.3 [M+Na] ,^ calculated = 420.5. 
(8%11 'R)-5-(ll '.Hydroxy-octadec-8'-enoic)-2-phenylamine-l,3,4-oxadiazole (3c) 
Off-white powder; Yield 87%; Mp 133-136 °C. 
IR (KBr): 3358, 3224, 1518, 1220 cm"'. 
'HNMR (400 MHz, CDCI3): 5 9.31 (s, IH, N/f), 7.62 (d, 2H, J= 7.2 Hz, Ar-H-276"), 
7.53 (t, IH, J= 7.0 Hz, Ar-H-4"), 7.41 (t, 2H, J= 7.2 Hz, Ar-H-375"), 5.37 (m, 2H, CH2-
CH^CH-CWi), 4.69 (m, IH, C//-OH), 2.38 (t, 2H, J = 7.5 Hz, C/Z^a to ring), 1.98 (m, 
4H, C//2-CH=CH-C//2), 1.78 (m, IH, CH-O//), 1.67 (m, 2H, Cft P to ring), 1.28 (br, s, 
18H, (CH2)9), 0.88 (dist. t, 3H, terminus C//j). 
'^CNMR (100 MHz, CDCI3): 5 172.1, 163.2, 138.7 "one signal hidden", 132.2, 128.1, 
128.0, 127.0, 70.7, 40.1, 39.9, 39.7, 39.5, 39.3, 31.3, 30.4, 29.1, 29.0, 28.8, 28.6, 25.1, 
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22.0, 13.6.167.2, 139.8, 139.0, 133.5, 130.0, 129.8, 127.9, 77.1, 38.6, 38.4, 33.5, 31.7, 
30.2, 29.9, 29.6, 29.3, 28.7, 28.5,28.4, 28.3, 22.4, 14.4. 
MS (ESI): m/z - 436.5 [M+Na]^ calculated = 436.59. 
(8'R,11 'Z)-5-(8'-Hydroxy-octadec-ll '-enoic)-2-phenylamine-l,3,4-oxadiazole (3d) 
Off-white powder; Yield 87%; Mp 135-137 °C. 
IR (KBr): 3353, 3217, 1494, 1225 cm-'. 
'HNMR (400 MHz, CDCI3): 5 9.88 (s, IH, N//), 8.20 (d, 2H, J= 7.3 Hz, Ar-H-276"), 
7.63 (t, IH, J= lA Hz, Ar-H-4"), 7.54 (t, 2H, J= 7.9 Hz, Ar-H-3"/5"), 5.34 (m, 2H, CH2-
C/f=C//-CH2), 4.87 (m, IH, C//-OH), 2.50 (t, 2H, J = 7.5 Hz, C/Z^a to ring), 1.98 (m, 
4H, C//2-CH=CH-C//2), 1.77 (m, IH, CH-O/f), 1.67 (m, 2H, CH2 (3 to ring), 1.28 (br, s, 
18H, (€7/2)9), 0.89 (dist. t, 3H, terminus CZ/j). 
'^CNMR (100 MHz, CDCI3): 5 172.1, 165.7, 139.1, 139.0, 133.0, 130.7, 129.4, 127.6, 
77.3, 38.6, 36.4, 30.4, 31.8, 29.8, 29.6, 29.4, 29.2, 29.0, 28.9, 28.6, 25.9, 22.2,14.3. 
MS (ESI): m/z =436.4 [M+Na] ,^ calculated = 436.59. 
Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Staphylococcus aureus (ATCC-25923), 
Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^ '^^ °. A standard 
inoculums (1-2 XIO^ c.f.u./ml 0.5 McFarland standards) was introduced on to the surface 
of sterile agar plates, and a sterile glass spreader was used for even distribution of the 
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inoculums. The discs measuring 6 mm in diameter were prepared from Whatman no. 1 
fiher paper and sterilized by dry heat at 140 °C for 1 h. The sterile discs previously 
soaked in a known concentration of the test compounds were placed in nutrient agar 
medium. Solvent and growth controls were kept. Chloramphenicol (30 ^g) was used as 
positive control and the disk poured in DMSO was used as negative control. The plates 
were inverted and incubated for 24 h at 37 °C. The susceptibility was assessed on the 
basis of diameter of zone of inhibition against Gram-positive and Gram-negative strains 
of bacteria. Inhibition zones were measured and compared with the controls. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The nutrient broth, which contained logarithmic serially two fold diluted 
amount of test compound and controls were inoculated with approximately 5 XIO c.fu. 
/ml of actively dividing bacteria cells. The cultures were incubated for 24 h at 37 °C and 
the growth was monitored visually and spectrophotometrically. The lowest concentration 
(highest dilution) required to arrest the growth of bacteria was regarded as MIC. 
To obtain the minimum bacterial concentration (MBC), 0.1 ml volume was taken 
from each tube and spread on agar plates. The number of c.fu. was counted after 18-24 h 
of incubation at 35 °C. MBC was defined as the lowest drug concentration at which 
99.9% of the inoculums were killed. The PBE (percentual bacteriostatc efficiency, %) 
was obtained as 
PBE=100/MIC 
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Antifungal studies 
Antifungal activity was also done by disk diffusion method^''^^. For assaying 
antifungal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei and 
Trichophyton mentagrophytes (recultured) in DMSO strains were used. Sabourands agar 
media was prepared by dissolving peptone (1 g), D-glucose (4 g) and agar (2 g) in 
distilled water (100 ml) and adjusting pH to 5.7. Normal saline was used to make a 
suspension of spore of fungal strain for lawning. A loopful of particular fUngal strain was 
transferred to 3 ml saline to get a suspension of corresponding species. Twenty millilitres 
of agar media was poured into each petri dish. Excess of suspension was decanted and the 
plates were dried by placing in an incubator at 37 °C for 1 h using an agar punch, wells 
were made and each well was labeled. A control was also prepared in triplicate and 
maintained at 37 °C for 3-4 days. The fungal activity of each compound was compared 
with Greseofulvin as standard drug. Inhibition zones were measured and compared with 
the controls. 
The nutrient broth, which contained logarithmic serially two fold diluted amount 
of test compound and controls was inoculated with approximately 1.6 X 10'' -6 X 10"* 
c.f u. /ml. The cultures were incubated for 48 h at 35 °C and the growth was monitored. 
The lowest concentration (highest dilution) required to arrest the growth of fungus was 
regarded as minimum inhibitory concentration (MIC). 
To obtain the minimum fungicidal concentration (MFC), 0.1 ml volume was 
taken from each tube and spread on agar plates. The number of c.f u. was counted after 
48 h of incubation at 35 °C. MFC was defined as the lowest drug concentration at which 
99.9% of the inoculums were killed. 
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The ratio MFC/MIC was calculated in order to determine if the compound had a 
fungistatic (MFC/MIC> 4) or fungicidal (MFC/MIC< 4) activity. 
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Microwave assisted 2,S-disubstituted-l,3,4-oxadiazoles 
2.1. Theoretical 
Microwave assisted synthesis in organic chemistry is an important and a well 
established area of research due to a number of advantages over conventional heating 
methods'. The microwave assisted reactions occur more rapidly, safely and with higher 
chemical yields rendering this method superior to conventional methods which require 
longer reaction periods, tedious work up and use of large quantity of solvents and 
reagents causing environmental pollution. On the other hand, microwave induced organic 
reaction enhancement (MORE) technique provides a non-conventional technique for the 
rapid synthesis of organic compounds. 
Nitrogen heterocycles of different ring sizes, with different substitution patterns 
and embedded in various molecular frameworks constitute extremely important structure 
classes in the search for bioactivity. Many compounds bearing five-membered 
heterocyclic rings in their structure have an extensive spectrum of pharmacological 
activities. Among them 1,3,4-oxadiazoles and their derivatives have attracted 
considerable interest in material and medicinal chemistry as surrogates of carboxylic 
acids, esters and carboxamides^. The 1,3,4-oxadiazole compounds have shown a wide 
array of biological activities in both agrochemical and pharmaceutical QgktS showing 
anti-convulsant^, anti-microbial"*, insecticidal^ fungicidal^, anti-inflammatory^, anti-
leishmanial^, hypotension^ and anti-tumor'° characteristics. Some of the members 
belonging to 1,3,4-oxadiazole class display 5-HT-receptor antagonists (i)", muscarinic 
receptor agonists (ii)'^, benzodiazepine receptor agonists (iii)'^ and tyrosinase 
inhibitors'"*. 
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II 
H3CO. M H 
Au H 
-CHq 
111 
A fructose based 3-acetyl-2,3-dihydro-l,3,4-oxadiazole (GLB) (iv) and its 5-
linear 5-alkyl derivatives (v) have shown some cytotoxic activities . 
H,C 
H,C 
0 
0 O 
0 ^ CH3 
O- > CH3 
CH, 
- 0 
N 
R R=linear alkyl 
IV 
The most general method involves the cyclization of diacylhydrazides with a 
variety of reagents such as thionyl chloride, phosphorus oxy chloride and sulfuric acid, 
usually under harsh reaction conditions. Further, most of these protocols are multi-step jji' 
nattare and involve long reaction times. Only a few reliable and operationally facile 
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examples have been reported for the one step synthesis of 1,3,4-oxadiazoIes, especially 
from readily available carboxylic acids and acid hydrazides'^'^. 
Thus, in an attempt to overcome these disadvantages of classical thermal reactions 
the microwave technique for the synthesis of 1,3,4-oxadiazoles has rapidly gained 
acceptance. 
The organomercurials, 2-(aryl mercurithio)-5-[4'-methylquinolinyl-2-oxy 
methyl]-1,3,4-oxadiazoles (viii) were synthesized by reacting 2-mercapto-5-[4'-
methylquinolinyl-2-oxymethyl]-l,3,4-oxadiazole (vi) in DMF, anhydrous K2CO3 and aryl 
t o 
mercuric chloride (vii) under microwave irradiation (Scheme 2.1.1). 
CH3 
N ^0CH2 0 MW 
V I vu V I U 
R= H, 4-CH3, 4-Cl, 4-Br, 4-OCH3 
Scheme 2.1.1 
A novel procedure for the synthesis of 1,3,4-oxadiazoles (x) from 1,2-
diacylhydrazines (ix) using polymer-supported burgess reagent under microwave 
conditions is described by Brain et al}'^ (Scheme 2.1.2). 
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0 O 
MW, THF R \ / ° \ ^ R i 
"-A >-^ ' ~ ' X > 
NH-NH "^ zC N_N O V—0(CH 2)2PEG 
S—NH 
EtjN 0-
IX X 
R= Ph, 2-Methoxyphenyl, 2-Chlorophenyl, 2-Nitrophenyl, 2-Thiophenyl, 2-Furyl, 3-
OjN 
Pyridyl, \ = / , PhS02CH2. 
R,= Ph, Me, NHPh. 
Scheme 2.1.2 
Wang et al?^ synthesized the 2-(4-chlorobenzoylamido)-5-aryloxymethyM,3,4-
oxadiazoles (xii) by the cyclization of l-aryloxyacetyl-4-(4-chlorobenzoyl)-
thiosemicarbazides (xi) in the presence of mercuric acetate under the condition of 
microwave irradiation (Scheme 2.1.3). 
0 
/ = y 0 V-CHzOAr 
xi xii 
Ar= CeHs, 2-CH3-C6H4, 3-CH3-C6H4, 4-CH3-C6H4, 1-Naphthyl, 4-CI-C6H4 
Scheme 2.1.3 
A series of 2,5-diaryl-l,3,4-oxadiazoles (xvi) have been synthesized by reacting a 
mixture of corresponding aromatic acid (xiii), hydrazine dihydrochloride (xiv) and 
phosphorus pentoxide (xv) in orthophosphoric acid under microwave conditions ' 
(Scheme 2.1.4). 
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Ar_Y + NH2-NH2.2HCI + P2O5 
OH 
H3PO4 A r ^ / ° v ^ A r 
^ \\ // 
MW N—N 
XIII XIV XV XVI 
Ar= C6H5, 3-OCH3-C6H4, 3-Pyridyl, 2-HO-C6H4,4-CI-C6H4. 
Scheme 2.1.4 
2-(4-Methoxylphenyloxyacetylamido)-5-aryloxymethyl-1,3,4-oxadiazoles (xix) 
were synthesized by the cycHzation of l-aryIoxyacetyl-4-(4-methoxylphenyloxyacetyl)-
thiosemicarbazides (xviii) in presence of mercuric acetate under microwave irradiation 
(Scheme 2.1.5). 
22 
OCH OCH, 
NH4SCN, PEG^OO/CHjClj 
Ar.OCH2CONHNH2 
OCHzCOHNCOHNHNCOCHzOAr 
XVIII 
MW Hg(OAc)2/AcOH 
XIX 
Scheme 2.1.5 
OCH, 
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The microwave dielectric heating of potassium sak of 2-acyldithiocarbazinic 
acids (xx) gave the 5-substituted-2-mercapto-l,3,4-oxadiazoles (xxi) in good yields 
(Scheme 2.1.6). 
NH-NH N—N 
XX xx i 
R= Ph, 4-CI-C6H4, 4-CH3C6H4, 4-Pyridyl, 4-OCH3-C6H4, C6H5CH2,4-OH-C6H4 
Scheme 2.1.6 
The 2,5-disubstituted-l,3,4-oxadiazoles (xxiv) were obtained by Mashraqui et 
al}^ by condensing monoaryl hydrazides (xxii) with acid chlorides (xxiii) in HMPA 
solvent under microwave heating (Scheme 2.1.7). 
o / J. / HMPA, lh,rt R . . „ / O ^ R i 
NH-NH2 \ , MW,40sec l_li 
xxii xxiii xxiv 
R= Ph, 4-NO2C6H4,4-MeOC6H4,4-Pyridyl. 
R= Ph, 2-Furyl, CH2Ph, CH3,2-Propyl, 2-Thienyl, 4-MeOPh. 
Scheme 2.1.7 
2,5-Disubstituted-l,3,4-oxadiazoles (xxviii) were prepared by the oxidation of 1-
aroyl-2-arylidine hydrazines (xxvii) with potassium permanganate on the surface of silica 
gel as well as in mixtures of acetone and water under microwave irradiation (Scheme 
2.1.8). 
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/? /? SiO,,HMvlW \. ,„, 
V N H , H EtOH,H^  R N=/ 
KMn04, SiO,, MW R ^ . _ / ° \ ^ R 
or Acetone, Water |;g '^ 
XXV xxvi xxvii xxviii 
R= Ph, Me, 4-CI-C6H4 
R,= Ph, 4-NO2C6H4, 4-CI-C6H4, 4-Me-C6H4, 4-MeO-C6H4, 4-MeOOC-C6H4, 4-(Me)2N-
C6H4, Me, CH3CH=CH, Ph. 
Scheme 2.1.8 
Khan et al. '^^ synthesized the 2,5-disubstituted-l,3,4-oxadiazoles (xxxi) from 3-
pyridyl hydrazide (xxix) and benzoic acid (xxx) by microwave irradiation taking alumina 
as the solid support and phosphorus oxy chloride as a dehydrating agent (Scheme 2.1.9). 
° ° POCI3 R ^ / ° \ ^ R i 
\ H - N H , OH MW l - l i 
xxix xxx xxxi 
R= 3-PyridyI Ri= Phenyl 
Scheme 2.1.9 
The reaction of isonicotinic acid hydrazide (xxxii) and corresponding 
benzaldehyde (xxxiii) under microwave conditions gave the heterocyclyl acylhydrazones 
(xxxiv). The oxidation of xxxiv with iodobenzene diacetate (IBD) gave the heterocyclyl-
1,3,4-oxadiazoles (xxxv) in a solid state^ ^ (Scheme 2.1.10). 
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\ = / NH-NH, 
EtOH 
H MW 
rv^° IBD 
\ = / W N ^ ' Solid State ' \ // 
N—N 
AT 
XXXII XXXIU XXXIV XXXV 
Ar= C6H5, 4-NO2C6H4, 0-CI-C6H4, m-N02C6H4, P-NO2C6H4, P-CH3C6H4, P-OCH3C6H4, 
0-OH-C6H4, m-Cl-C6H4,-CH=CH-C6H4 
Scheme 2.1.10 
Li et al?^ gave the solvent free synthesis of 2-aryl-5-(coumarin-3'-yl)-l,3,4-
oxadiazoles (xxxviii) in high yields by reacting the coumarin-3-carboxylic acid (xxxvi) 
n 
with ^unjsubstituted benzoic acid hydrazides (xxxvii) in presence of PEG supported 
dichlorophosphate under microwave irradiation (Scheme 2.1.11). 
o 0 
^^>. J^ ..^ NHj 
PEG"0P(0)C1, 
Solvent free, MW 
xxxvi XXXVII xxxviu 
R= H, 2-Cl, 3-NO2,4-CH30,4-1, 2-OH, 3-CH3. 
Scheme 2.1.11 
Natero et al?'^ gave the one-step synthesis of 5-phenyl-2-chloromethyl-1,3,4-
oxadiazoles (xLi) from commercially available acylhydrazides (xL) using l-chloro-2,2,2-
trimethoxyethane (xxxix) as a solvent under microwave conditions (Scheme 2.1.12). 
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CI—y OMe 
V—OMe "*" 
MeO ^ Neat V ^ 
xxxix xL xLi 
Scheme 2.1.12 
A library of 2,5-disubstituted-l,3,4-oxadiazoles (xLiv) have been synthesized 
under microwave irradiation and screened for their tyrosinase inhibition activities 
(Scheme 2.1.13). 
O /? POCl3,Al203 R ^ / ° \ ^ R l 
R ^ + R i ^ \\ // 
\ H - N H , OH MW 
xLii xLiii xLiv 
R= 3-Pyridyl, 2-MeOC6H4. 
R,= C6H5, 0-NO2C6H4, o-BrC6H4, 3-pyridyl, CH2CI, CCI3, P-CH3C6H4, 3,4,5-
Trimethoxybenzoyl, 2-C10H7. 
Scheme 2.1.13 
A single pot synthetic protocol for the synthesis of 2-sulfonamide-1,3,4-
oxadiazoles (xLvii) from 1,2-diacylhydrazine (xLv) under microwave irradiation using 
PS-BEMP and corresponding sulfonyl chloride (xLvi) is reported by Baxendale et al. 
(Scheme 2.1.14). 
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0 
HjC, 
H,C 
+ R—S 
0 C, ^ - LJ 
^ \ THF, MW 
CH3 
xLv xLvi xLvii 
Scheme 2.1.14 
Wang et al.^^ gave the single step, rapid and efficient synthesis of 1,3,4-
oxadiazoles (L) from carboxylic acids (xLviii) and acid hydrazides (xLix) by using 
commercially available PS-PPhs resin combined with microwave heating (Scheme 
2.1.15). 
O ,9 PSPPhJCCL.CN A -^^< R 
OH ^ NH-NHo CH3CN,MW l_'^ 
l\ / / 
xLviii xLix 
s 
// 
Ri= ^ ^ , " ^ , ^ ^ , " ,""0 o a ' o
CHj 
N ' 
Scheme 2.1.15 
The reaction of 9-ethylcarbazol-3-carbaldehyde (Li) with aroylhydrazines (Lii) 
under microwave condition gave the intermediate, l-aroyl-2-(9'-ethylcarbazol-3'-yl-
methylidene) hydrazines (Liii). The further treatment of Liii with potassium 
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permanganate in DMF under microwave irradiation afforded the 2-aryl-5-(9'-
ethyicarbazol-3'-yl)-l,3,4-oxadiazoles (Liv) in excellent yields'^ (Scheme 2.1.16). 
MW, neat 
NH-NHj 
C,H •2"5 
Liv 
R= H, 4-Cl, 3-NO2, 3-CH3, 2-CH3, 4-OH, 4-Br. 
Scheme 2.1.16 
5-Substituted-2-(2-methyl-4-nitro-l-imidazomethyl)-l,3,4-oxadiazoles (LvH) 
have been prepared under microwave irradiation using 2-methyl-4-nitro-l-imidazo-
acethydrazide (Lvi), aromatic acid (Lv) and phosphorus oxy chloride as the dehydrating 
agent '^' (Scheme 2.1.17). 
.0 ^0. 
R-Y + // 
OH ° 2 " ^N 
N \, NH-NH, 
POCU 
\ " 0 , N ^ \ . ^ ^ ^ C H 3 MW O^N^X^'.^^^CHs 
f N .\r^  N—N 
Lv Lvi Lvii 
R= CsHs, 4-CH3C6H4,4-OCH3C6H4,4-CIC6H4,4-CH3C6H4, C6H4N. 
Scheme 2.1.17 
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The synthesis of 5-aryl-2-(2-hydroxyphenyl)-l,3,4-oxadiazoles (Lx) by the 
reaction of salicylic hydrazide (Lviii) with carboxylic acids (Lix) in the presence of 
thionyl chloride under neat conditions is described^^ (Scheme 2,1.18). 
.NH, 
NH U^  
"OH SOCL 
MW 
OH - R 
Lviii Lix Lx 
R= H, 4-Me, 4-MeO, 3,4-(MeO)2, 3,4,5-(MeO)3, 3-Cl, 2-Br, 3-MeOC6H4CH2. 
Scheme 2.1.18 
Polshettiwar et al.^^ gave a novel, one-pot, solvent free, green protocol for the 
synthesis of 1,3,4-oxadiazoles (Lxiii) by the condensation of acid hydrazide (Lxi) and 
triethyl orthoalkanates (Lxii) using solid supported Nafion®NR50 and phosphorus 
pentasulfide in alumina as a catalyst (Scheme 2.1.19). 
.NHj 
NH 
H,C 
1 
- 0 
0 . .CH3 
Nafion®NR50 
MW 
CH3 
Lxi Lxii Lxiii 
R= H, F, OMe, 2-Furyl, 2-Thienyl, 4-Pyridyl. 
R,= H, Et, Ph. 
Scheme 2.1.19 
An efficient one pot synthesis of unsymmetric 2,5-disubstituted-1,3,4-oxadiazoles 
has been developed by Pore et al?\ The target oxadiazoles (Lxv) were formed by the 
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oxidation of acylhydrazones (Lxiv) using trichloroisocyanuric acid (TCCA) at an 
ambient temperature (Scheme 2.1.20). 
N—NH , n 
i' EtOH, rt ^^  " 
-R 
N—N 
Lxiv Lxv 
R= Ph, 4-CIC6H4,4.OCH3C6H4. 
R,= Ph, 4-OCH3C6H4, 4-CH3C6H4, 3,4-(OCH3)C6H3. 
Scheme 2.1.20 
The microwave assisted synthesis of new lanthanum (III) and praseodymium (III) 
complexes with oxadiazole functionalized dithiocarbazinates (Lxviii) is described 
(Scheme 2.1.21). 
Ethanol 
MCI, + 3LK *- [M(L)3] 
MW 
Lxvi Lxvii Lxviii 
M= La, Pr 
L= N-(5-phenyl-l,3,4-oxadiazole-2-yl)dithiocarbazinate (PODC), N-(5-o-chlorophenyl-
l,3,4-oxadiazole-2-yl)dithiocarbazinate (OCODC), N-(5-p-chlorophenyl-1,3,4-
oxadiazole-2-yl)dithiocarbazinate (PCODC), N-(5-o-methylphenyl-l,3,4-oxadiazole-2-
yl)dithiocarbazinate (MODC), N-(5-p-nitrophenyl-l ,3,4-oxadiazole-2-
yl)dithiocarbazinate (NODC). 
Scheme 2.1.21 
Han et al?^ gave the microwave assisted synthesis of novel alkyl substituted 
fructose-based oxadiazoles and investigated them for their cytotoxic activity towards 
cancer cells. The reaction of £-3-alkylhydrazono-l,2:4,5-di-0-isopropylidene-P-D-
eryr/7A-o-2-hexulopyranose (Lxix) and Z-3-alkylhydrazono-l,2:4,5-di-0-isopropylidene-P-
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D-ery//zA'o-2-hexulopyranose (Lxx) with acetic anhydride under microwave heating 
conditions gave (2i?,3a'/?,6'5,7a';?)-3-alkyl-2',2',2",2"-tetermethyl-5-methyl-2,3-dihydro-
1,3,4-oxadiazole-2-spiro-7'-(l',3'-dioxalano[4,5-c]pyrano)-6'-spiro-4"-(l ",3"-diaoxolane) 
(Lxxi)and (25,3a'i?,6'5,7a'i?)-3-alkyl-2',2',2",2"-tetermethyl-5-methyI-2,3-dihydro-l,3,4-
oxadiazole-2-spiro-7'-(r,3'-dioxalano[4,5-c]pyrano)-6'-spiro-4"-(r',3"-diaoxolane) 
(Lxxii) in good yields (Scheme 2,1.22). 
0 - " 
H.C 
0 ^ CH3 
°^ ' CH3 
-0 r^ 9^3 
' ° - ' 'CH3 
0 \ N 
f 
+ H,C' 
^"3 HN ' 
^0 N 
— O 
CH, 
R 
Lxix 
NH 
Lxx 
30 min. Ac,0, MW 
0 •"' 
0 CH3 
° \ i - C H 3 
. : ^ — 0 + 
O 0 N-Ac 
H,C 
H3C 1 ^ \ / 
CH3 y=N^ 
Lxxi Lxxii 
R= CH3, C2H5, n-CsHT, n-C4H9, n-CsH, 1, n-CeHn, n-CiHxs, n-CgHi?, n-CgHig, n-Ci 1H19, n-
C) 1H23, n-CisHsi, n-CnHss 
Scheme 2.1.22 
A novel approach to synthesize the glucose-based 3-acetyl-5-alkyl-2,3-dihydro-
1,3,4-oxadiazoles with the assistance of microwave irradiation was developed by Wang 
et al.'^^ The reaction of a mixture of ^/Zhydrazones (Lxxiii, Lxxiv) with acetic anhydride 
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under microwave irradiation above 160 C, to produce the target 1,3,4-oxadiazoles (Lxxv, 
Lxxvi), which are a pair of isomers on the C-3 of furan ring (Scheme 2.1.23). 
O-
H3C o " ^ N.. . 0 CH3 H3C o 
,Mo^c"3 + 
\ 
NH 
O 
R 
Lxxiii Lxxiv 
Acp AcONa, MW 
CH- + 
Lxxv 
R= CH3, n-CsHy, n-C7H,5, CeHs, C6H4Br, C6H40Me. 
Scheme 2.1.23 
Lxxvi 
The reaction of 5-aryl (hetaryl)tetrazoles (Lxxvii) with phenyl isocyanate 
(Lxxviii) under the conditions of microwave activation formed the corresponding 2-
anilino-5-aryl(hetaryl)-1,3,4-oxadiazoles (Lxxix) in high yields'*' (Scheme 2.1.24). 
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R H N_N 
Y-\ MW // 
N'/ X + PhNCO ^ R ^ n ' , , . . . . -NH 
^ K i ^ 0.5 h N 
Lxxvii Lxxviii Lxxix 
R=4-Me2NC6H4, 4-MeOC6H4, 4-MeC6H4, Ph, 4-CIC6H4, 4-NO2C6H4, 2-Pyridyl, 3-
Pyridyl, 4-Pyri(lyl, 2-Furyl. 
Scheme 2.1.24 
Xu et al."'^ reported the microwave assisted synthesis and antifungal activity of 
2,5-disubstituted-l,3,4-oxadiazoles containing azulene moiety. The 5-aryl-2-(3-
methyla2ulen-l-yl)-l,3,4-oxadiazoles (Lxxxii) were obtained by the microwave 
irradiation of corresponding hydrazide (Lxxxi) with appropriate carboxylic acids in 
presence of phosphorus oxy chloride (Scheme 2.1.25). 
NHj.NHj ^ y . \ ArCOOH/POCI, 
•CO2CH3 ^ '/ \ -'-• MW 
N—N 
Lxxx Lxxxi Lxxxii 
Ai-CeHs, 4-MeC6H4, 4-CIC6H4, 4-OHC6H4, 2-BrC6H4, 2-OHC6H4, CeHsCH^CH, 4-
MeCeHjCH^CH. 
Scheme 2.1.25 
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2.2. A Facile One-pot Synthesis of Novel 2,5-Disubstituted-
1,3,4-oxadiazoIes under Conventional and Microwave 
Conditions and Evaluation of their in vitro Antimicrobial 
Activities 
1,3,4-Oxadiazole is apparently among the most significant heterocycle cores. The 
1,3,4-oxadiazole derivatives may act as ester and amide bioisosteres and hence are of 
interest in pharmaceutical and agrochemical fields'*^ . The wide range of biological 
activities associated with 1,3,4-oxadiazoles include anti-viral"*"*, antimicrobial , 
antineoplastic'*^ fungicidal^ , inhibition of tyrosinase''*' and cathepsin K'*^ . Also, much 
attention has been focused on the oxadiazole core Fl-systems as electron-transporting and 
hole-blocking materials in the area of organic light-emitting diodes (OLEDs) . Further 
1,3,4-oxadiazole heterocycles can contribute substantially in increasing the 
pharmacological activity by participating in hydrogen bonding interactions with the 
48 
receptors . 
Several methods have been reported in literature for the synthesis of 1,3,4-
oxadiazoles'^ '^^ .^ Most of these protocols are multi-step in nature and generally involve 
the cyclization of acid hydrazides with a variety of reagents, such as, phosphorus oxy 
chloride, sulfuric acid and thionyl chloride, usually under harsh conditions. Recently a 
few efficient examples have been reported for the synthesis of 1,3,4-oxadiazoles, 
especially from readily available carboxylic acids and acid hydrazides. However, these 
protocols use expensive catalysts and require longer times for the completion of the 
reaction '^•^ .^ Consequently, the development of effective methods for the rapid and 
concise synthesis and modification of oxadiazole motif need to be developed. 
64 
Microwave assisted 2,5-disubstituted-l,3,4-oxadiazoles 
The application of microwave irradiation in organic synthesis for conducting 
reactions at highly accelerated rates is an emerging technique . In fact, in recent years, 
the use of microwaves have become popular among synthetic organic chemists both to 
improve classical organic reactions (shortening reaction times and/or improving yields) 
as well as to promote new reactions. 
The substantial reduction in the reaction times under microwave irradiation and 
the pharmacological importance of 1,3,4-oxadiazole ring systems prompted us to 
synthesize the 2,5-disubstituted-l,3,4-oxadiazoles bearing an 
alkanyl/alkenyl/hydroxyalkenyl chain substituent at 5"^  position and evaluate them for 
their antimicrobial activity. To the best of our awareness this contribution reports for the 
first time the simple and straightforward synthesis of 1,3,4-oxadiazoles under microwave 
condition having a long chain substituent at C-5. 
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2.3. Results and Discussion 
Due to the beneficial pharmacological properties of certain molecules containing 
1,3,4-oxadiazole moiety the synthesis of new 1,3,4-oxadiazole derivatives using 
procedures in which some aspect of green chemistry could be met is desirable. Our main 
strategy in this work was to synthesize new 1,3,4-oxadiazole derivatives with potential 
biological activities, using microwave-induced organic reaction enhancement 
methodology, which is extremely fast, cleaner than conventional reactions and lead to a 
higher atom economy (less chemical waste). 
The conventional synthesis of the target 2,5-disubstituted-l,3,4-oxadiazoles (3a-i) 
was achieved by refluxing a mixture of fatty acid hydrazide (la-f) and appropriate 
carboxylic acid (2a-b) in presence of phosphorus oxy chloride (Scheme 2.3.1). The 
product yields and the reaction times required for the completion of the reaction under 
reflux conditions are given in Table 2.3.1. As, can be seen from Table 2.3.1, the reaction 
time ranged within 8-14 h. 
O O POCI3 N—N 
+ Ri^ 11 V 
NH-NH2 OH Reflux R ^ ^ O ^^ 
la-f 2a-b 3a-l 
Scheme 2.3.1. Conventional synthesis of2,5-disubstituted-l,3,4-oxadiazoles 3a-l. 
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Table 2.3.1. 2,5-Disubstituted-l,3,4-oxadiazoles 3a-l. 
Entry R Ri Product Time(h.) Yield(%) 
1 HE bH 3a 10 82 
2 6 5 OH 3b 11 84 
OH ^ OH 3c 14 78 
OH y W /o 
3 % OH 3d 14 79 
HsC^ > < l ^CHj ^Q 
y W /O 
11 OH 3e 8 86 
HjC W , Y " ^0' 
Br OH 3f 8 85 
z H \ ^ ^ ^ ^^H2 
-CI 
HO^ ^O 
CM, 
HO^ ^O 
OH / !5^ -=' 
,CI 
,CI 
3g 11 80 
6 ' ' 5 ^ ^ 3h 12 82 
'^  OH 5 ^ ^ 3i 13 75 
10 ^ V ^ % v ^ 3j 14 78 
11 11 ^-^ 3k 9 85 
12 ''''' '' Br ^ - ^ 31 9 83 
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Further to explore the probabiHty of getting the pharmacophoric important moiety 
in higher yields and in shorter reaction times, our attention turned towards employing the 
microwave irradiation. The application of microwave energy to organic compounds for 
conducting synthetic reactions at highly accelerated rates is an emerging technique. 
Infact, in recent years, microwave has become popular among synthetic organic chemists 
both to improve classical organic reactions, shortening reaction times and/or improving 
yields, as well as to promote new reactions. Under microwave conditions, the reactions 
were carried out by irradiating a mixture of fatty acid hydrazide (la-f) with the 
appropriate carboxylic acid (2a-b), supported on neutral alumina, using phosphorus oxy 
chloride as the cyclizing agent (Scheme 2.3.2 ). 
° / P0Cl3,AlA N-N 
NH-NH2 OH MW R ^ N Q / ^ R I 
la-f 2a-b 3a-l 
Scheme 2.3.2. Synthesis of2,5-disubstituted-l,3,4-oxadiazoles (3a-l) under microwave 
irradiation. 
At first, the condensation reaction of hydrazide of undec-10-enoic acid ( la) with 
2-furoic acid (2a) was chosen as a model to optimize the conditions for the preparation of 
compounds 3a-l (Table 2.3.2). In order to determine the optimum conditions for the 
synthesis of oxadiazoles, variations in molar ratios of reagents, the microwave irradiation 
time and the power level of microwave setup were investigated. 
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Table 2.3.2. Optimization of the microwave-assisted condensation of la and 2a on 
neutral alumina 
la 2a 3a 
Entry Support Molar Time Power Yield 
Ratio(la/2a) (Min.) (%) "^^  
1 
2 
3 
4 
Neutral alumina 
Neutral alumina 
Neutral alumina 
Neutral alumina 
0.2/0.5 
0.5/0.8 
0.8/1.0 
1.0/1.0 
5 
7 
12 
16 
30 
40 
50 
60 
45 
52 
71 
90 
After some experimentation, we found a set of conditions that generally provided 
the products in good yields. The optimum conditions were set up and the target 2,5-
disubstituted-l,3,4-oxadiazoles (3a-l) were synthesized in appreciable yields (Table 
2.3.3). 
As per our requirement, the strategy was successfully worked out. All the 
reactions proceeded in shorter reaction time and an appreciable increment in the product 
yield was observed as compared to conventional reaction conditions. The generality and 
ability of this methodology in the synthesis of 2,5-disubstituted-l,3,4-oxadiazoles was 
demonstrated by using a variety of structurally divergent fatty acid hydrazides and 
carboxylic acids. The scope of the reaction using saturated, olefin (internal and terminal) 
and hydroxy fatty acid hydrazides was found to be good. Moreover, the nature of 
hydrazide and the carboxylic acid did not show strongly obvious effects in terms of 
yields. The synthesized compounds were characterized by IR, 'H NMR, '^C N M R and 
mass spectral analysis. 
69 
Microwave assisted 2,S-disubstituted-l,3,4-oxadiazoles 
Table 2.3.3. 2,5-Disubstituted-l,3,4-oxadiazoles (3a 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 
la 
lb 
Ic 
Id 
le 
If 
la 
lb 
Ic 
Id 
le 
If 
2 
2a 
2a 
2a 
2a 
2a 
2a 
2b 
2b 
2b 
2b 
2b 
2b 
1/2" 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
PowerCro)" 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
Time(h.)' 
16 
16 
17 
17 
15 
15 
19 
19 
20 
20 
18 
17 
-I) under microwave conditions 
Product 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
Yield(%)" 
90 
90 
85 
87 
92 
93 
89 
90 
86 
88 
91 
91 
^ All reactions were carried out using fatty acid hydrazides (leq) with respect to 
carboxylic acids and POCI3 under microwave irradiation. 
'' Microwave equipment multimode was used. 
' Monitored by TLC. 
'^ All yields refer to isolated products and the products were characterized by IR, 'H 
NMR, 'X NMR and mass spectral analysis. 
The spectra of compound 3a showed the IR absorption bands at 1668, 1568, 1240 
cm"' due to C=C, C=N and C-O-C functions. The 'H NMR was more informative in 
assigning the structure. Diagnostic peaks at 8 7.64, 7.32 and 6.55 were observed for the 
fiaran ring system. A triplet at 5 2.36 was observed for the methylene protons a to the 
oxadiazole ring. The methine proton of C-9 showed a signal at 5.82. The C-10 methylene 
protons designated as WE and Hz displayed two distinct 6 values when coupled with 
adjacent C-9 methine protons. Thus, the 'H NMR showed two doublet of doublet at 6 
5.01 and 4.94 for Hz and Hf protons respectively. In the '^ C NMR peaks at 6 172.4 and 
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168.2 were observed for the ring carbon atoms. The mass spectrum was also consistent 
with the assigned molecular formula. 
Similarly, the spectra of compound 3g showed the IR absorption bands at 1665, 
1563, 1242 cm"' due to C=C, C=N and C-O-C functions. A characteristic IR band at 748 
cm"' was also observed for the aromatic ring system. The 'H N M R was more informative 
in assigning the structure. Diagnostic peaks at 5 7.98, 7.46 and 7.33 were observed for the 
aromatic ring system. A triplet at 2.35 was observed for the methylene protons a to the 
oxadiazole ring. The methine proton of C-9 showed a signal at 5.80. The C-10 methylene 
protons designated as He and Hz displayed two distinct 5 values when coupled with 
adjacent C-9 methine protons. Thus, the 'H NMR showed two doublet of doublet at 5 
4.98 and 4.93 for Hz and H^ protons respectively. The '^ C NMR showed characteristic 
peaks at 5 172.9 and 168.4 for the oxadiazole ring carbon atoms. The mass spectrum was 
also consistent with the assigned molecular formula Detailed spectral data of the titled 
compounds are given in experimental section 
Antibacterial studies (x C KNAVA 
The newly prepared compounds were screened for their antibacterial activity against 
Escherichia coll (ATCC-25922), Methicillin resistant Staphylococcus aureus (MRSA 
+Ve), Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^ "*' . The 
susceptibility was assessed on the basis of diameter of zone of inhibition against Gram-
positive and Gram-negative strains of bacteria. Inhibition zones were measured and 
compared with the controls. Ciprofloxacin was used as the standard drug. The bacterial 
zones of inhibition values are given in Table 2.3.4. 
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Table 2.3.4. Antibacterial activity of2,S-disubstituted-l,3,4-oxadiazoles 3a-l 
Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
Standard 
DMSO 
Diameter of zone 
Gram positive 
S. pyogenes 
11.4±0.4 
21.3±0.4 
19.U0.5 
13.4±0.4 
16.2±0.4 
22.5±0.2 
14.5±0.4 
17.1±0.2 
20.1±0.3 
20.2±0.4 
12.4±0.5 
21.4±0.3 
23.0±0.2 
-
; bacteria 
MRS A* 
11.1±0.3 
20.8±0.3 
18.3±0.4 
13.2±0.4 
15.5±0.2 
21.6±0.4 
14.4±0.4 
16.6±0.3 
19.5±0.2 
19.7±0. 3 
12.1±0.5 
20.5±0.4 
22.0±0.2 
-
of inhibition (mm) 
Gram negative bacteria 
p. aeruginosa 
13.2±0.2 
23.4±0.2 
21.1±0.4 
16.1±0.6 
13.2±0.3 
27.3±0.6 
16.1±0.6 
14.1±0.4 
22.2±0.3 
22.3±0. 2 
14.2±0.4 
26.2±0.4 
32.0±0.3 
-
K. pneumoniae 
11.5±0.3 
19.4±0.5 
17.1±0.5 
13.6±0.2 
15.5±0.4 
22.5±0.2 
13.6±0.2 
15.5±0.4 
18.2±0.3 
18.3±0.5 
11.7±0.5 
21.4±0.4 
19.0±0.2 
-
E. coli 
12.1 ±0.4 
20.9±0.4 
18.5±0.3 
14.3±0.2 
16.5±0.3 
23.4±0.5 
14.3±0.2 
16.5±0.3 
19.6±0.2 
19.8±0.4 
12.1±0.5 
22.3±0.4 
27.0±0.2 
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by the 
Halo Zone Test (Unit, mm). * Methicillin resistant Staphylococcus aureus (MRSA +Ve), 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The number of c.f.u. was counted after 18-24 h of incubation at 35 °C. MBC 
was defined as the lowest drug concentration at which 99.9% of the inoculums was 
killed. The minimum inhibitory concentrations and minimum bactericidal concentrations 
are given in Table 2.3.5. 
72 
Microwave assisted 2,5-disubstituted-l,3,4-oxadiazoles 
Table 2.3.5. MIC and MBC results of2,5-disubstituted-l,3,4-oxadiazoles 3a-L 
Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 
-» Standard 
Gram positive bacteria 
S. pyogenes MRSA * 
MIC 
50 
25 
25 
50 
25 
12.5 
50 
25 
25 
25 
50 
12.5 
12.5 
MBC 
100 
50 
100 
100 
100 
25 
100 
100 
100 
50 
100 
25 
12.5 
MIC 
50 
12.5 
25 
50 
50 
12.5 
50 
25 
25 
12.5 
50 
12.5 
6.25 
MBC 
>100 
50 
50 
100 
100 
50 
100 
50 
50 
25 
>100 
25 
12.5 
I 
P. aerh 
MIC 
50 
12.5 
25 
50 
25 
12.5 
50 
25 
12.5 
12.5 
100 
12.5 
12.5 
( 
tginosa 
MBC 
>100 
50 
100 
100 
100 
50 
100 
100 
100 
50 
>100 
25 
25 
Gram negative 
K. pneumoniae 
MIC 
100 
50 
50 
50 
25 
12.5 
25 
25 
25 
25 
100 
12.5 
6.25 
MBC 
>100 
100 
50 
100 
100 
50 
100 
100 
50 
100 
>100 
50 
25 
bacteria 
E.coli 
MIC 
100> 
25 
25 
50 
50 
12.5 
50 
50 
25 
25 
100 
12.5 
6.25 
MBC 
100 
100 
100 
>100 
100 
50 
>100 
100 
100 
100 
>100 
50 
12.5 
Positive control Ciprofloxacin. 
MIC (^g/ml) = minimum inhibitory concentration, i.e the lowest concentration of the 
compound to inhibit the growth of bacteria completely; 
MBC (|.ig/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely. 
The investigation of antibacterial screening data revealed that all the tested 
compounds showed moderate to good bacterial inhibition. Good inhibitory results were 
obtained against S.pyogenes, S.aureus and E.coli species. The structure activity data 
showed that variously substituted 1,3,4-oxadiazoles 3a-l have varying degree of 
microbial inhibition. The antibacterial activity seemed to be dependent on both the 
substituents. The presence of chlorobenzyl substituents at C-5 of the oxadiazole ring 
system in compounds 3a-I was found to enhance the bacterial inhibition effects. Further, 
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a marked enhancement in the antibacterial activity was observed for the compounds 
bearing a bromo or a hydroxy group in the long chain substituent at C-2 of the oxadiazole 
moiety. The compounds 3c, 3d, 3f, 3i, 3j and 31 shov e^d good inhibition against 
S.pyogenes, S.aureus and E.coli species. The oxadiazoles 3f, 3j and 31 showed activity 
nearly equivalent to that of Ciprofloxacin. The MICs and MBCs also revealed good 
antibacterial activity. / 
Antifungal stufUes Q.(- \ I 
Antifungal activity was also done by disk diffusion method. For assaying 
antifungal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei and 
Tricliophyton mentagrophytes (recultured) in DMSO by agar diffusion method^ '^^ ^ The 
fungal activity of each compound was compared with Greseofulvin as standard drug. 
Inhibition zones were measured and compared with the controls. The fungal zones of 
inhibition values are given in Table 2.3.6. 
The minimum inhibitory concentrations (MICs) and minimum fungicidal 
concentrations (MFCs) are given in Table 2.3.7. 
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Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
. ' > ^ . 
^ ,y* Standard 
DMSO 
X 
Table 2.3.6. Antifungal activity of2,5-disubstituted-l,3,4-oxadiazoles 3a-l. 
Diameter of zone 
CA 
19.9±0.3 
26.1±0.3 
23.1±0.3 
21.1±0.3 
22.8±0.5 
26.2±0.4 
22.2±0.4 
23.9±0.6 
24.1±0.5 
27.2±0.4 
21.3±0.3 
27.1±0.3 
30.0±0.2 
AF 
18.5±0.5 
21.1±0.2 
20.2±0.5 
18.5±0.4 
19.6±0.6 
21.6±0.5 
19.7±0.3 
20.7±0.2 
21.3±0.3 
22.1±0.2 
19.6±0.4 
22.7±1.2 
27.0±0.2 
of inhibition (mm) 
TM 
16.4±0.2 
18.3±0.3 
16.7±0.4 
14.7±0.5 
17.1±0.3 
18.2±0.4 
15.8±0.9 
18.1±0.2 
17.8±0.5 
19.4±1.2 
16.4±0.2 
19.3±0.7 
24.0±0.3 
PM 
11.9±0.3 
13.7±0.2 
13.1±0.4 
13.2±0.4 
13.3±0.6 
14.1±0.3 
14.3±0.2 
14.3±0.6 
14.2±0.9 
14.8±0.3 
12.9±0.3 
15.1±0.2 
20.0±0.5 
Positive control (Greseofulvin) and negative control (DMSO) measured by the Halo Zone 
Test (Unit, mm). 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. 
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Table 2.3.7. MIC and MFC of2,S-disubstituted-l,3,4-oxadiazoles 3a-l 
Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
3k 
31 „ 
Standard i 
CA 
MIC MFC 
50 
12.5 
12.5 
25 
25 
6.25 
25 
25 
12.5 
12.5 
50 
6.25 
6.25 
100 
25 
100 
100 
100 
12.5 
100 
50 
50 
25 
100 
12.5 
25 
AF 
MIC 
50 
25 
25 
50 
25 
25 
50 
25 
25 
25 
50 
6.25 
12.5 
MFC 
>100 
50 
50 
100 
100 
12.5 
100 
50 
50 
50 
100 
12.5 
12.5 
TM 
MIC 
50 
25 
25 
25 
25 
25 
25 
25 
25 
25 
50 
12.5 
6.25 
MFC 
100 
50 
50 
>100 
100 
100 
100 
100 
50 
50 
100 
25 
25 
PM 
MIC 
50 
25 
25 
25 
25 
25 
25 
25 
25 
12.5 
50 
12.5 
12.5 
MFC 
>100 
100 
100 
100 
100 
50 
100 
100 
100 
100 
100 
25 
25 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. MIC (ng/ml) = minimum inhibitory concentration, i.e the 
lowest concentration of the compound to inhibit the growth of fungus completely; MFC 
(|ig/ml) = minimum fungicidal concentration, i.e., the lowest concentration of the 
compound for killing the fungus completely. 
The antifungal screening data showed moderate to good activity. The 2,5-
disubstituted-l,3,4-oxadiazoles 3a-l showed same antifungal activity trends as for the 
bacterial strains. The good inhibition results were obtained against C. albicans, A. 
fumigatus and P. marneffei fungal strains. Moderate activity was obtained in case of T. 
mentagrophytes fungal strains. The compounds 3f, 3j and 31 were found to be the most 
potent antifungal agents. The MBC of few compounds was found to be the same as MIC 
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but in most of the compounds it was two or three or four folds higher than the 
corresponding MIC results. 
Thus, the nature of substituents has a strong influence on the extent of 
antibacterial and antifungal activities. The data analysis revealed that all the compounds 
have produced a marked enhancement in the potency of these analogues as antibacterial 
and antifungal agents. 
3 „ i A?aff A. X 
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lA, Experimental 
The sources of all fatty acids and instrumentation details are same as given in 
Chapter 1 (pg. 31). The microwave irradiations were carried out using a modified 
domestic microwave oven. 
General procedure for the synthesis of fatty acid hydrazides (la-d) 
The hydrazides of long chain alkenoic acids (la-d) used as the starting material 
were prepared by previously reported method^ .^ The synthesized hydrazides were 
characterized by their melting points. 
General procedure for the conventional synthesis of2,5-disubstituted-l,3,4-oxadiazoles 
3a-l 
Phosphorus oxy chloride (5 ml) was added to a mixture of substituted carboxylic 
acid (0.01 mol) and fatty acid hydrazide (0.01 mol) in abs. ethanol. The reaction mixture 
was refluxed for 8-14 h on a water bath. After the completion of the reaction, the contents 
were cooled at room temperature and poured into crushed ice. The precipitated crude 
product was washed with 10% solution of NaHCOsland raijpdt recrystallized from 95% 
ethanol (Table 2.3.1) 
General procedure for the synthesis of2,5-disubstituted-l,3,4-oxadiazoles (3a-l) under 
solvent-free microwave conditions. 
A mixture of fatty acid hydrazide (0.01 mol), carboxylic acid (0.01 mol) and 
alumina (1.50g) were mixed and ground in a mortar and pestle until a fine homogenous 
powder was obtained (5 min). Phosphorus oxy chloride (5 ml) was added. The mixture 
was irradiated under microwave irradiation for the required time (Table 2.3.3). After the 
completion of the reaction (TLC analysis), ice cold water (10 ml) was added to the 
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reaction mixture and the precipitated crude product was filtered. The crude 1,3>4-
oxadiazole was washed with 10% solution of NaHCOa and further purified by column 
chromatography over silica gel using petroleum ether-diethyl ether mixture as eluent. 
The synthesized 2,5-disubstituted-l,3,4-oxadiazoles (3a-l) were characterized 
from their spectral data (IR, 'H NMR, '^C N M R and mass spectra). 
Spectroscopic data 
5-(Dec-9 *-enoic)-2-furyl-l,3,4-oxadiazole (3a) 
//f(KBr): 1668, 1568, 1240 cm-'. 
^HNMR (400 MHz, CDCI3): 8 7.64 (m, IH, furan 5"-H), 7.32 (m, IH, furan 2"-H), 6.55 
(m, IH, furan 4"-H), 5.82 (tdd, IH, j ^ ,^ ,^  = 6.6 Hz, j ^ „ =10.2 Hz, j ^ _ ^ =17.0 Hz, 
CH2=C//-), 5.01 (dd, IH, / =11.8 Hz, ,, = 1.9 Hz, //zC=CH), 4.94 (dd, IH, 
j„ =16.7 Hz, / „ = 2.2 Hz, //£C=CH-), 2.36 (t, 2H, 7 = 7.4 Hz, CH2 a to ring), 2.02 
(m, 2H, CH2=CH-C//2), 1.64 (m, 2H, CH2 p to ring), 1.40-1.25 (br, s, lOH, (C/f2)5). 
'^CNMR (100 MHz, CDCI3): 5 172.4, 168.2, 142.7, 139.4, 139.0, 114.7, 111.6, 40.2, 
39.8, 38.3, 37.9, 31.3, 29.7,28.4, 26.8. 
MS (ESI): m/z = 297.08 [M+Naf, calculated = 291.\2.^ 
(8'Z,11 'R)-5-(ll '-Hydroxy-octadec-8'-enoic)-2-furyl-l,3,4-oxadiazole (3c) 
IR (KBr): 3358, 1668, 1554, 1247 cm"'. 
'HNMR (400 MHz, CDCI3): 5 7.61 (m, IH, furan 5"-H), 7.28 (m, IH, furan 2"-H), 6.53 
(m, IH, furan 4"-H), 5.37 (m, 2H, CH2-C//=C//-CH2), 3.69 (m, IH, C//-OH), 2.38 (t, 
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2H, J = 7.5 Hz, C//2a to ring), 2.10 (m, IH, CH-0//), 1.96 (m, 4H, C//rCH=CH-Cf/2), 
1.58 (m, 2H, CH2 p to ring), 1.28 (br, s, 18H, (CH2)9), 0.86 (dist. t, 3H, terminus CH3). 
"CA^A«(100MHz,CDCl3):6 172.3, 168.6, 142.8, 131.1, 124.9, 111.8, 70.5,40.3,38.9, 
38.6, 31.5, 31.3, 29.0,28.9,28.3, 27.9,27.3,26.4,26.1, 22.6, 14.2. 
MS (ESI). m/z=-4l\A7 [M+Na] ,^ calculated = 411.18. 
(8%11 'Z)-5-(8'-Hydroxy-octadec-ll '-enoic)-2-furyl-l,3,4-oxadiazole (3d) 
/^(KBr): 3353, 1669, 1557, 1251 cm"'. 
'HNMR (400 MHz, CDCI3): 6 7.63 (m, IH, furan 5"-H), 7.30 (m, IH, furan 2"-H), 6.55 
(m, IH, furan 4"-H), 5.36 (m, 2H, CHi-CH^CH-CHi), 3.65 (m, IH, C//-OH), 2.36 (t, 
2n,J= 7.5 Hz, C//2a to ring), 2.08 (m, IH, CH-0//), 1.98 (m, 4H, CZ/rCH^CH-CZ/^), 
1.54 (m, 2H, CH2 p to ring), 1.30 (br, s, 18H, (C//2)9), 0.88 (dist. t, 3H, terminus CH3). 
'^CNMR (100 MHz, C^Ch): 6 \72.5, 168.1, 142.7, 131.9, 125.1, 111.1, 70.6,40.3, 38.7, 
38.3, 31.7, 31.6,29.5,28.7,28.4,27.6, 27.4, 26.8,26.3,22.5, 14.1. 
MS (ESI): m/z =411.17 [M+Naf, calculated = 411.18. 
5-Pentadec-2-furyl-l,3,4-oxadiazole(3e). 
IR (KBr): 1667,1571,1249 cm"'. 
'HNMR (CDCI3): 6 7.63 (m, IH, furan 5"-H), 7.32 (m, IH, furan 2"-H), 6.54 (m, IH, 
furan 4"-H), 2.36 (t, 2H, J=7.4 Hz, CH2 a to ring), 1.69 (m, 2H, CH2 p to ring), 1.25 (br, s, 
24H, (C//2)i2), 0.87 (dist. t, 3H, terminus CH3). 
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'^CNMR (100 MHz, CDCI3): 5 172.1, 168.2, 142.2, 111.7, 40.6, 40.4, 40.2, 40.0, 39.8, 
39.6, 33.9, 33.7, 29.2, 28.9, 28.7,26.4,25.4,25.1, 14.0. 
MS (ESI): m/z = 369.15 [M+Na]^ calculated = 369.17. 
5-fl-BromopentadecJ-2-furyl-l,3,4-oxadiazole (3J). 
IR (KBr): 728,1665,1569, 1248 cm-'. 
'HNMR (CDCI3): 6 7.65 (m, IH, furan 5"-H), 7.33 (m, IH, furan 2"-H), 6.56 (m, IH, 
furan 4"-H), 2.38 (t, 2H, J=7A Hz, C//^a to ring), 1.65 (m, 2H, C//2P to ring), 1.29 (br, s, 
24H, (C//2)i2), 0.87 (dist. t, 3H, terminus CH3). 
'^CNMR (100 MHz, CDCI3): 6 172.5, 168.5, 143.0, 111.6, 52.1, 40.7, 40.5, 40.1, 39.2, 
38.9, 34.0, 33.3, 29.0,28.7,28.1,26.3, 24.9, 25.5, 14.1. 
MS (ESI): m/z = 448.04 [M+Na] ,^ calculated = 448.07. 
5-(Dec-9 '-enoic)-2-chlorobenzyl-l,3,4-oxadiazole (3g) 
IR (KBr): 1665, 1563, 1242, 748 cm''. 
'HNMR (400 MHz, CDCI3): 6 7.99 (m, IH, Ar-H-3"), 7.47 (m, 2H, Ar-H-475"), 7.34 
(m, IH, Ar-H-6"), 5.80 (tdd, IH, J„_„^ .^  = 6.6 Hz, j„.„ =10.2 Hz, J„_«,=16.9 Hz, 
CH2=C//-), 4.98 (dd, IH, j^.„=11.8 Hz, j„ _„ = 1.9 Hz, HzC^CH), 4.93 (dd, IH, 
j„ =16.7 Hz, / „ = 2.2 Hz, HEC=CH-), 2.35 (t, 2H, J = 7.4 Hz, C//2a to ring), 2.02 
(m, 2H, CH2=CH-CH2), 1.63 (m, 2H, CH2 P to ring), 1.29-1.40 (br, s, lOH, {CH2)5). 
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'^CNMR (100 MHz, CDCI3): 6 172.9, 168.4, 139.6, 131.4, 128.7, 128.3, 125.8, 122.6, 
114.3,40.1, 39.7, 38.6, 37.4, 32.0, 29.5,28.6, 26.6. 
MS (ESI), m/z = 341.5 [M+Na]^ calculated = 341.6. 
5-f(8 'Z)-Heptatadecenoic]-2-chlorobenzyl-l,3,4-oxadiazole (3h) 
IR (KBr): 1667, 1562,1248, 743 cm-'. 
'HNMR (400 MHz, CDCI3): 6 7.98 (m, IH, Ar-H-3"), 7.46 (m, 2H, Ar-H-475"), 7.33 
(m, IH, Ar-H-6"), 5.34 (m, 2H, CH2-C//=C//-CH2), 2.33 (t, 2H, J = 7.4 Hz, CH2 a to 
ring), 2.03 (m, 4H, CH2-CH=CH-CH2), 1.62 (m, 2H, CH2 p to ring), 1.26 (br, s, 20H, 
(C//2)io), 0.87 (dist. t, 3H, terminus C//j). 
"CNMR (100 MHz, CDCI3): 5 172.4, 168.3, 131.6, 131.4, 128.9, 128.6, 125.7, 125.3, 
122.2,40.9, 40.5, 38.6, 38.3, 33.6, 32.7, 31.8, 30.5, 29.8, 28.7, 21.9, 20.6,20.3,14.0. 
MS (ESI), m/z = 439.65 [M+Na] ,^ calculated = 439.67. 
(8%11 'R)-5-(ll '-Hydroxy-octadec-8'-enoic)-2-chtorobenzyl-l,3,4-oxadiazole (3i) 
IR (KBr): 3352,1665,1569,1243, 745 cm"'. 
'HNMR (400 MHz, CDCI3): 5 7.90 (m, IH, Ar-H-3"), 7.42 (m, 2H, Ar-H-475"), 7.29 
(m, IH, Ar-H-6"), 5.27 (m, 2H, CH2-C//=C//-CH2), 3.58 (m, IH, C//-OH), 2.34 (t, 2H, J 
= 7.4 Hz, C//2a to ring), 2.09 (m, IH, CH-O/f), 1.98 (m, 4H, C//2-CH=CH-C//2), 1.56 
(m, 2H, CH213 to ring), 1.25 (br, s, 18H, (CH2)9), 0.81 (dist. t, 3H, terminus CH3). 
"CNMR (100 MHz, CDCI3): 5 172.4, 168.3, 131.6, 131.1, 128.6, 128.5, 125.9, 125.2, 
122.6, 70.1, 40.2, 38.5, 37.9, 31.8, 31.1, 29.3, 28.7, 27.4, 27.0, 26.3, 26.0, 22.5, 14.1. 
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MS (ESI): m/z = 455.62 [M+Na]^ calculated = 455.66. 
(8'R,11 'Z)-5-(8'-Hydroxy-octadec-ll '-enoic)-2-chlorobenzyl-l,3,4-oxadiazole (3j) 
IRiKBr): 3353, 1667, 1565, 1244, 741 cm"'. 
'HNMR (400 MHz, CDCI3): 5 7.91 (m, IH, Ar-H-3"), 7.40 (m, 2H, Ar-H-4"/5"), 7.27 
(m, IH, Ar-H-6"), 5.29 (m, 2H, CH2-CH=CH-CH2), 3.56 (m, IH, C//-OH), 2.30 (t, 2H, J 
= 7.4 Hz, CH2ato ring), 2.11 (m, IH, CH-0//), 1.95 (m, 4H, C//2-CH=CH-C//2), 1.57 
(m, 2H, CH2 p to ring), 1.22 (br, s, 18H, (CH2)9), 0.81 (dist. t, 3H, terminus CH3). 
'^CNMR (100 MHz, CDCI3): 8 172.6, 168.7, 131.9, 131.1, 128.6, 128.3, 125.5, 125.2, 
122.1, 70.1,40.6, 38.5, 37.5, 31.8, 31.0,29.3, 28.1, 27.4,27.0, 26.9, 26.5, 22.5, 14.1. 
MS (ESI): m/z =455.62 [M+Na]\ calculated = 455.66. 
S-Pentadec-2-chiorobenzyl-l,3,4-oxadiazole (3k). 
IR (KBr): 1663, 1565, 1244, 743 cm"". 
'HNMR (CDCI3): 5 8.00 (m, IH, Ar-H-3"), 7.47 (m, 2H, Ar-H-475"), 7.34 (m, IH, Ar-
H-6"), 2.35 (t, 2H, J=7.4 Hz, CH2 a to ring), 1.64 (m, 2H, CH2 P to ring), 1.27 (br, s, 24H, 
(C//2))2), 0.87 (dist. t, 3H, terminus C//j). 
'^CNMR (100 MHz, CDCI3): 6 172.2, 168.1, 131.3, 128.7, 128.5, 125.9, 122.3, 40.3, 
40.1,40.0, 39.6, 39.3, 33.5, 33.0, 29.1, 28.3,26.9, 25.1, 25.0, 14.0. 
MS (ESI): m/z = 413.64 [M+Na]^ calculated = 413.65. 
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S-fl-BromopentadecJ- 2-chlorobenzyl-l,3,4-oxadiazole (31), 
IR (KBr): 1668, 1569, 1249, 748, 726 cm-'. 
'HNMR (CDCI3): 6 8.00 (m, IH, Ar-H-3"), 7.47 (m, 2H, Ar-H-475"), 7.35 (m, IH, Ar-
H-6"), 2.37 (t, 2H, J=7.4 Hz, CH2 a to ring), 1.66 (m, 2H, CH2 p to ring), 1.26 (br, s, 24H, 
(C//2)i2), 0.88 (dist. t, 3H, terminus CH3). 
'^C NMR (100 MHz, CDCI3): 5 172.5, 168.3, 131.5, 128.6, 128.3,125.6, 122.7, 52.4, 
40.6, 40.4, 39.9, 39.2, 37.9, 34.6, 33.1,29.6, 28.7, 28.0, 26.4, 24.6, 25.1, 14.0 
MS (ESI): m/z = 492.53 [M+Na]\ calculated = 492.55. 
Anal. Found: C, 55.42; H, 08.76; N, 10.76. CsHasNaOBrrequires C, 55.66; H, 08.81; N, 
10.81%. 
Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Methicillin resistant Staphylococcus aureus 
(MRSA +Ve), Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and 
Klebsiella pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^ '*'^ ^ 
Ciprofloxacin (30 |ig) was used as positive control. While the disk poured in DMSO was 
used as negative control. The susceptibility was assessed on the basis of diameter of zone 
of inhibition against Gram-positive and Gram-negative strains of bacteria. Inhibition 
zones were measured and compared with the controls. The bacterial zones of inhibition 
values are given in Table 2.3.4. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The lowest concentration (highest dilution) required to arrest the growth of 
bacteria was regarded as minimum inhibitory concentration (MIC). MBC was defined as 
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the lowest drug concentration at which 99.9% of the inoculums was killed. The minimum 
inhibitory concentrations and minimum bactericidal concentrations are given in Table 
2.3.5. 
Antifungal studies 
Antifungal activity was also done by disk diffusion method. For assaying 
antifungal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei and 
Trichophyton mentagrophytes (recultured) in DMSO by agar diffusion method^ '^^ .^ The 
fungal activity of each compound was compared with Greseofulvin as standard drug. 
Inhibition zones were measured and compared with the controls. The fungal zones of 
iiJiibition values are given in Table 2.3.6. The lowest concentration (highest dilution) 
required to arrest the growth of fungus was regarded as minimum inhibitory 
concentration (MIC). MFC was defined as the lowest drug concentration at which 99.9% 
of the inoculums was killed. The minimum inhibitory concentrations and minimum 
fungicidal concentrations are given in Table 2.3.7. 
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CHAPTER-8 
tMadlazoias 
2,5-Disubstituted-l,3,4-thiadiazoles 
3.1. Theoretical 
Understanding five membered heterocycles is a long standing objective because 
these heterocycles constitute the primary skeletons of more than half of the compounds 
produced by nature and they play a vital role in biological activities'. During recent years 
there has been much investigation of the five membered heterocycles. 1,3,4-Thiadiazoles, 
having one sulfur and two nitrogen atoms, many of which have been found to be 
pharmacologically active .^ The advent of sulfur drugs and the discovery of mesoionic 
compounds further accelerated the rate of progress in the field of sulfur containing 
heterocycles. 
A large number of compounds containing 1,3,4-thiadiazole moiety have been 
investigated as precursors to therapeutically interesting drug candidates because of their 
diverse properties such as antimicrobial\ antitubercular"*, anticancer^ anti-inflammatory , 
anti-convulsant ,^ analgesic ,^ anti-secretory ,^ antidepressant and anxiolytic agents . 
Moreover much interest has also been focused on the cardiotonic", diuretic'^ and 
herbicidal'^  activities displayed by the compounds incorporating this heterocyclic system. 
The heterocyclic mercaptans incorporating 1,3,4-thiadiazoles have been found to possess 
anti-proliferative activities against human cancer cell lines''' and tumor associated 
carbonic anhydrase isoenzymes I, II and IX'^ Nitroheteroaryl-1,3,4-thiadiazole 
derivatives based on megazole have shown impressive antimicrobial and antiparasitic 
activity particularly against trypanosomatic protozoa'^. The Nitroimidazolyl-1,3,4-
thiadiazole based compounds have been reported as anti-leshmanial agents. The 
compounds of 1,3,4-thiadiazole series have been found to exhibit antiphlogistic (i) and 5-
LO and CO inhibitory (ii) properties'^. 
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MesC, 
CMe, 
MejC N—N 
r-v^Ty^ 
HO 
n ^s' 
CMe, 
n=0, 1 
II 
The 1,3,4-thiadiazoles and its derivatives have become very useful compounds in 
medicine'^. The acetazol (iii), a carbonic anhydrase inhibitor'^  is used systematically (i.e. 
an oral medication) for the treatment of glaucoma. It is believed to reduce the intraocular 
pressure by lowering the fluid formation in the eye. 
H-,C 
NH-
N — N 
// W 
-SO2NH2 
III 
The substituted 1,3,4-thiadiazoles have been very useful in agriculture and many 
fields of technology such as dyes^ *^ , lubricating compositions^', analytical reagents , 
optically active liquid crystals^ ,^ photographic materials^ "* and many other uses. The 2-
amino-5-phenyl-l,3,4-thiadiazole (APT) (iv) and its derivatives are found to inhibit 
,25 
corrosion of steel and copper . 
N—N 
'/ W 
•NH, 
IV 
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The macrocyclic polyether compounds containing a 1,3,4-thiadiazole moiety (n-
MCTH) (v) has been used in the corrosion inhibition of C38 carbon steel in acidic 
media^^ 
CH5 CHo 
^ I 
,0 Oi 
V n= 1-5 
The meracpto-5-^-amino-1,3,4-thiadiazole derivatives have been studied for their 
electrochemical behaviors at carbon paste electrode^ .^ The poly(2-amino-5-mercapto-
1,3,4-thiadiazole) (PMAT) (vi) film has been used for selective determination of L-
,28 
cysteine and folic acid 29 
H2N-
N—N 
// W 
, / ' 
N—N 
// W 
-N ("/ 
N-
N—N 
// W / 
N — N 
// W 
-NH, 
VI 
The 2,5-dimercapto-1,3,4-thiadiazole and its analogs have been found to possess a 
broad range of potential applications such as solid state organic crystals, bioorganic 
catalysis etc . The thiadiazoles containing the imine (-C=N-) group have long been of 
interest as luminophores for optical applications owing to their electron accepting 
nature 
31 
The immobilization of 5-amino-1,3,4-thiadiazole-thiol (ATT) onto analogue of 
heulandite (vii) for divalent toxic metals removal has also been reported^ .^ 
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HEU—O^ 
HEU—O^Si 
HEU—O^ 
vi i 
The discovery of the diverse pharmacological and material properties of 1,3,4-
thadiazoles and its derivatives has stimulated a substantial interest in the chemistry and 
synthesis of these important heterocycles and their analogs. 
Xinping et al^^ synthesized 6-aryl-3-(5-methylisoxazole-3-yl)-5-triazolo[3,4-6]-
1,3,4-thiadiazole (ix) from 4-amino-5-mercapto-3-(5-methylisoxazole-3-yl)-l,2,4-triazole 
(viii) by treating with various aromatic acids in presence of phosphorus oxy chloride 
(Scheme 3.1.1). 
ArCOOH 
POCI3 
•^  O Ar 
VIII IX 
Ar= 4-Br-C6H4, CeHj, 4-NO2-C6H4,4-CH3O-C6H4 
Scheme 3.1.1 
The synthesis of 6-aryl-3-cinchophenyl-l,2,4-triazolo[3,4-6]-l,3,4-thiadiazoles 
(xi) from 3-cinchophenyl-4-amino-5-thio-l,2,4-triazole (x) by treating with aromatic acid 
in phosphorus oxy chloride was reported by Pengfei et al?'^ (Scheme 3.1.2). 
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ArCOOH 
POCl, 
XI 
Ar= 4-Br-C6H4, 4-CI-C6H4. 
Scheme 3.1.2 
The reaction of 4-amino-5-(3-chlorobenzo[6]thien-2-yl)-3-mercapto-l,2,4-triazole 
(xii) with acetic anhydride under reflux condition for 18 h yielded the cyclized product 3-
(3-chlorobenzo[6]thien-2-yl)-6-methyl-l,2,4-triazolo [3,4-ft] [l,3,4]-thiadiazole (xiii)^ ^ 
(Scheme 3.1.3). 
ACjO 
XII XIII 
Scheme 3.1.3 
Zheng et al.^^ reported the synthesis of 2-amino-5-aryloxymethyl-l,3,4-
thiadiazoles (xvi) under microwave conditions from thiosemicarbazide (xv) and 
aryloxyacetic acid (xiv) (Scheme 3.1.4). 
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ArO—y S 
V - O H + H2N—-^ 
MW, 8 min 
NH-NH2 PEG0P(0)Cl2 ^^^ 
N—N 
'/ W 
-NH, 
XIV XV XVI 
Ar= C6H4, 2-CH3-C6H4,4-CI-C6H4, 1-Naphthyl. 
Scheme 3.1.4 
The condensation of triazoles (xvii) with heteroaromatic acids (xviii) in the 
presence of phosphorus oxy chloride produced various triazolo thiadiazoles (xix) 
(Scheme 3.1.5) while its condensation with heteroaromatic aldehydes (xx) afforded a 5,6-
dihydrotriazolo thiadiazole derivative (xxi)^ ^ (Scheme 3.1.6). 
N—N 
J V^  
NH, 
O^^^OH 
POCU 
xvui XIX xvu 
R= Phenyl, Methyl, H. 
Ar= 2-Chloro-5-methoxy phenyl, 3,4-Dimethoxy benzyl, 2-Methyl-3-fliranyl 
Scheme 3.1.5 
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Ar' 
N—N 
// w 
I 
NH2 
xvii 
H 
-SH + Ar' Toluene sulfonic acid Ar' )» 
DMF 
XX 
N—N 
// v 
N-
H 
XXI 
Ar' 
Ar'= 3-Phenyl-4-quinolinyl, 4-Quinolinyl, 2,6-Dihydroxy-4-pyridinyl, 5-Methoxy-3-
indolyl methyl. 
Ar= 2-Chloro-5-methoxy phenyl, 3,4-Dimethoxy benzyl, 2-Methyl-3-furanyl. 
Scheme 3.1.6 
A fast and efficient microwave assisted synthesis of 2-arylamino-5-(l-
adamantyl)-l,2,4-triazolo[3,4-6][l,3,4]-thiadiazoles (xxiii) is achieved by the 
desulfurization of corresponding N,V-disubstituted thioureas (xxii)^ ^ (Scheme 3.1.7). 
Desulfurization 
NH-Ar 
xx i i XXIU 
Ar= C6H5,4-Br-C6H4,4-CI-C6H4, 3-F-C6H4,4.F-C6H4. 
Scheme 3.1.7 
Aamir et al.^^ reported the synthesis of 5-[2-(4-/-butylphenyl)ethyl]-2-
alkyl/arylamino-l,3,4-thiadiazoles (xxv) from thiosemicarbazide (xxiv) by gradually 
adding to it a cold solution of concentrated sulphuric acid (Scheme 3.1.8). 
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H,C 
H2SO4 H,C 
NH-R 
XXIV XXV 
R= NHCH2CH2CH2CH3, NH-CeH, 
Scheme 3.1.8 
Aryl-A^-{[({4-[2-(2-chlorophenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-phenyl}-
carbonylamino)-amino]-thioxomethyl}-amides (xxvi) when stirred in concentrated 
sulphuric acid gave aryl-7V-5-{4-[2-(2-chlorophenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-
phenyI}-l,3,4-thiadiazole-2-yl-amides (xxvii) in excellent yields'*'' (Scheme 3.1.9). 
XXVI XXVU 
Ar= C6H5, C6H5CH2, 2-CI-C6H4, 2-NO2-C6H4, 4-CI-C6H4. 
R= 2-CI-C6H4. 
Scheme 3.1.9 
Pintilie et al.'^^ synthesized the 2-[l-(3-3-nitrobenzoylamino)-3-(methylthio)]-
propyl-5-(alkyl/phenyl) amino-l,3,4-thiadiazoles (xxix) from l-[A^-(3-nitrobenzoyl)-D,L-
methionyl]-4-alkyl/phenyl-thiosemicarbazides (xxviii) by stirring at room temperature 
with concentrated sulphuric acid (Scheme 3.1.10). 
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H3CS—C2H4 0 S 
HN NH-NH R 
H3CS—C2H4 N—W 
H2SO4 
XXIX XXVl l I 
R= CH3, CeHs, 4-CH3-C6H4,4-Br-C6H4, CH2-CH-CH2. 
Scheme 3.1.10 
The synthesis of 5-[(biphenyl-4-yloxy)methyl]-2-aryl amino-l,3,4-thiadiazoles 
(xxxi) from A '^[2-(biphenyl-4-yloxy)ethanoyl]-V-aryl-thiosemicarbazides (xxx) was 
reported by Kumar et al.'^^ (Scheme 3.1.11). 
0 NH-NH 
V NHAr H^SO, 
w / /-\ ^°-
N—N 
NHAr 
XXX XXXI 
Ar= CeHs, 4-F-C6H4, I-CI-CSHA, 4-CI-C6H4. 
Scheme 3.1.11 
The A^-ethyl-5-substituted-l,3,4-thiadiazol-2-amines (xxxiii), with high 
cytotoxicity were synthesized from A -^ethyl hydrazinecarbothioamides (xxxii) in sulfuric 
acid medium''^  (Scheme 3.1.12). 
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HN 
. / ^^CH, 
conc.H2S04 
0°C N(r-="= 
XXXII XXXIll 
R= C6H5, (CHa)4,4-CH3-C6H4. R,= H, (CH2)4. 
Scheme 3.1.12 
The thiosemicarbazide of 6-chloro-2-aminobenzothiazole (xxxiv) on cyclization 
with different carboxylic acids in phosphorus oxy chloride provided the corresponding 2-
aryl-5-(6 -chloro-1,3 -benzothiazole-2-yl-amino)-1,3,4-thiadiazole (xxxv) of 
pharmaceutical importance'*''(Scheme 3.1.13). 
RCOOH 
POCI3 
xxxiv xxxv 
R= Phenyl, 4-Chlorophenyl, 2,4-Dichlorophenyl, 4-Nitrophenyl, 2-Aminophenyl, 3-
Pyridyl. 
Scheme 3.1.13 
Padmavathi et al.^^ converted 2-arylsulfonylmethyl/arylmethanesulfonyImethyI-5-
aryl-l,3,4-oxadiazoles (xxxvi) to 2-arylsulfonylmethyl/arylmethanesulfonyImethyl-5-
aryl-I,3,4-thiadiazoles (xxxvii) by treatment with a two fold excess of thiourea in 
tetrahydrofuran (Scheme 3.1.14). 
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Thiourea °5^-^ . 
THF 
xxxvi xxxvii 
n= 0, 1 R= H, 4-CI. Ri= H, 2-CI. 
Scheme 3.1.14 
The reaction of ester (xxxviii) with hydrazine in ethanol gave the aroyl hydrazides 
(xxxix) which were converted to 5-substituted-2-mercapto-l,3,4-thiadiazoles (xLi) via 
potassium aroyl dithiocarbazates (xL) (Scheme 3.1.15). 
^ < 
XXXVIII 
"^2^5 NH^NH^.HjO 
C,H„ reflux K 
NH-NHa 
y-sK 
KOH/EtOH NH-NH j^^g^^ pj^ ^^^ ^ g ^ 
*• R -
CS, K 05 °C 
XXXIX xL 
w // 
N—N 
xLi 
R= Ar and ArHet-
Scheme 3.1.15 
Augustine et al'^'' have given the propylphosphonic anhydride (T3P) mediated 
synthesis of 1,3,4-thiadiazoles (xLiv) by the reaction of carboxylic acid (xLii), hydrazide 
(xLiii) and P2S5 in triethylamine (TEA) (Scheme 3.1.16). 
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OH NH-NH2 T3P,TEA R ^ / ^ x ^ R , 
^• 
xLii xLiii xLiv 
R= 4-Me-Ph, 4-CN-Ph, Cyclopentyl, Cyclobutyl, 4-NO2-C6H4, 5-Br-furan-2-yl. 
R,= 3-F-C6H4, 5-Br-pyridin-3-yl, 3-Me-4-N02-C6H3, t-Bu, Me. 
Scheme 3.1.16 
Various 1,4-bis(6-substituted)-[l ,2,4]triazolo[3,4-Zj][l ,3,4]thiadiazoles (xLviii) 
were synthesized from terphtlialic dihydrazide (xLv) via the formation of bis-potassium 
dithiocarbazinate (xLvi) and l,4-phenylene-bis(4-amino-4//-l,2,4-triazole-3-thiol) 
(xLvii/^ (Scheme 3.1.17). 
HM-N^ \ ^ NH-NH2 Ethanol K^S^ NH-NH \ = / NH-NH S-K* 
xLv xLvi 
NH^-NH^ 
xLvii xLviii 
Ar= 2-CI-C6H4, 4-NO2-C6H4. 
Scheme 3.1.17 
Abdelhamid et al.'*^ reported the synthesis of 2,3-dihydro-l,3,4-thiadiazoles (Li) 
by stirring a mixture of appropriate hydrazonoyl haHde (xLix) with 2-(benzofuran-2-
ylcarbonyl)-3-mercapto-3-methylsulfanylacrelonitrile (L) in ethanol (Scheme 3.1.18). 
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\ Ph . \\ / + 
N — N H 
SCH, 
C2H5OH 
xLix L Li 
R= CO2-C2H5, CONHC6H5, COCH3, COC6H5. 
Scheme 3.1.18 
A novel approach to 3,6-disubstituted[l,2,4]triazolo[3,4-6][l,3,4]thiadiazoles 
(Liv) using silica-supported dichlorophosphate as a recoverable cyclodehydrant, 
carboxylic acids (Lii) and thiocarbohydrazide (Liii) as starting material is described by Li 
and Zhao^° (Scheme 3.1.19). 
u 
OH 
H2N—NH NH2 SiOi-OPOClj 
MW, 8 min. 
N. 
N 
Liv Lii Liii 
R= C6H5, 4-CH3OC6H4, 2-CH3-C6H4, 2-CI-C6H4, Fur-2-yl. 
Scheme 3.1.19 
The biologically active 3,6-disubstituted-[l,2,4]-triazolo-[3,4-
6][l,3,4]thiadiazoles (Lvi) were obtained by refluxing a mixture of 4-amino-5-benzyl-
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4//-l,2,4-triazole-3-thiol (Lv), aryl/aroyl acid and phosphorus oxy chloride for 8-12 h^' 
(Scheme 3.1.20). 
N—N 
(/ \ 
I 
NH, 
Lv 
R.COOH 
N—N 
// V 
R-
POCL 
N S 
N-
Ri 
Lvi 
R= C6H5-CH2, C6H5-OCH2, 2-OHC6H4. 
R,= C6H5CONHCH2, 2-Br-C6H4, 2-C6H5CO-C6H4, C10H7CH2, C8H6NCH2, C6H5COCH2 
CH2. 
Scheme 3.1.20 
The interaction of alkyl dithioester (Lvii) with hydrazonyl halide (Lviii) in 
ethanol containing triethylamine at reflux temperatures gave l,5-dihydro-l,3,4-
thiadiazoles (Lix)" (Scheme 3.1.21). 
H3C 
^sC, > = N ^ SR R 
N H ^ + 
H,C 
Lvii 
R= CH2, CHzPh. 
R2= COCH3, COOEt, C6H5CO. 
N 
\ 
NH-R, 
Lviii 
EtjN 
•*- N ^  
N- OH 
CHa S "^N 
N—N Ri 
Ph 
Lix 
R,= CeHs, 0-CH3C6H4, P-CIC6H4. 
X= CI, Br. 
Scheme 3.1.21 
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Efimova et al.^^ examined the microwave-assisted reaction of 5-aryl(hetaryl)-
tetrazoles (Lx) with phenyl isothiocyanate (Lxi) and obtained the corresponding 2-
aryl(hetaryl)-5-phenylamino-l,3,4-thiadiazoles (Lxii) (Scheme 3.1.22). 
H 
N—N 
N 
Ph—N MW 
S 170°C, 0.5h 
N—N 
NH 
.Ph 
Lx Lxi Lxii 
R= 4-Me2NC6H4,4-Me20C6H4, 4-MeC6H4, Ph, 4-CIC6H4,4-O2NC6H4, Pyridine-2-yl. 
Scheme 3.L22 
The condensation of bis-aldehyde (Lxiii) with 2-amino-5-mercapto-l,3,4-
thiadiazole (Lxiv) and further cyclization in presence of dibromoalkanes afforded the 
azathia crown macrocycles containing two 1,3,4-thiadiazoles rings as subunits (Lxv) 
(Scheme 3.L23). 
54 
H,N' 
" ^ ^ ^ ^ ^ 
Lxiii 
X=(CH2)2,(CH2)3,(CH2)4. 
N—N // w 
Lxiv 
N—N 
'I V 
Br-Y 
-SH KOH/EtOH 0 ^ / O . 
" - ^ 
N — N 
'I V 
Br < ^ (^ 
^ ^ 
Lxv 
Y=(CH2)2,(CH2)4. 
Scheme 3.L23 
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Lamani et al.^^ reported the synthesis of 2-amino-5-benzo[-£/]isoxazol-3-
ylmethyl-[l,3,4]thiadiazole (Lxviii) by refluxing l,2-benzisoxazole-3-acetic acid (Lxvi) 
with thiosemicarbazide (Lxvii) in presence of phosphorus oxy chloride (Scheme 3.1.24). 
+ H z N - ^ 
NH-NH, POCI3 
Reflux 
Lxvi Lxvii Lxviii 
Scheme 3.1.24 
The pharmacologically important 3-[(3-substituted[l,2,4]triazolo[3,4-6]-
[ 1,3,4]thiadiazol-6-yl)methyl]-1 //-pyrazalo[3,4-c/lpyrimidine-4,6-dithione (Lxxi) were 
obtained by stirring a mixture of [l//-pyrazolo[3,4-c/]pyrimidine-2,4-dithione-5-
yl]acetonitrile (Lxx), 4-amino-5-substituted[l,2,4]triazole-3-thiol (Lxix) and phosphoric 
acid at lOO^ C for 2 h^ ^ (Scheme 3.1.25). 
SH 
N = ( HN > r \ . 
/ \ + 1 > 
u H 
^\ PPA 
100°C 
H 
R 
Lxix Lxx 
R= CH3, CHzPh, CH2-0-Ph(p-Cl). 
Lxxi 
Scheme 3.1.25 
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The refluxing reaction of l,2-bis(4-chloro-5//-l,2,3-dithiazol-5-ylidene)hydrazine 
(Lxxii) in PhCl and benzyltriethylammonium iodide (Lxxiii) under an argon atmosphere 
afforded the l,3,4-thiadiazole-2,5-dicarbonitrile (Lxxiv)^^ (Scheme 3.1.26). 
Nr^'^s 
c\ N—N 
Lxxii 
CI 
+ BnEtjNI PhCl 
s> 
Argon 
Lxxiii 
\ \ / / 
N—N 
Lxxiv 
Scheme 3.1.26 
Umamatheswari et al.^^ reported the synthesis of 5-spiro-(3-methyl-2,6-diphenyl 
tetrahydropyran-4-yl)-4,5-dihydro-[l,3,4]-thiadiazoie (Lxxvii) by the treatment of 
respective thiosemicarbazone (Lxxv) with freshly distilled acetic anhydride (Lxxvi) 
(Scheme 3.1.27). 
HjC^ CH3 K 
^"^ Reflux, lOh ° 
^ ^ ^ 
Lxxv Lxxvi 
Scheme 3.1.27 
Lxxvii 
CH, 
" ^ ^ 
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The 2,5-diphenyl-l,3,4-thiadiazole containing vinyl monomers [PTBEMA 
(Lxxviii), PVPT (Lxxix), PTPEMA (Lxxx)] and their polymers with considerable 
fluorescent properties have been synthesized . 
^ V .s, / ^ (r\= 
N—N 
J \-. 
"^—0 y 
0 
CH2 
< 
CH3 
Lxxviii 
2-[4-(5-Phenyl-l,3,4-thiadiazole-2-yl)-benzyloxyl]ethylmethacrylate(PTBEMA) 
H,C 
N—N 
Lxxix 
2-Phenyl-5-(4-vinylphenyl)-l,3,4-thiadiazole(PVPT) 
^:=/ W // \=y ^ o CH, 
N—N 
O CH3 
Lxxx 
2-[4'(S-Phenyl-l,3,4-thiadiazole-2-yl)phenoxy]ethylmethacrylate(PTPEMA) 
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Li et al.^^ synthesized the 3,6-disubstituted-l,2,4-triazolo[3,4-6]-l,3,4-
thiadiazoles (Lxxxii) and screened them for their inhibitory activity to E. coli methionine 
aminopeptidase (fi'cMetAPI). The synthesis was achieved by refluxing 4-amino-5-[2-(4-
chlorophenoxymethylbenzimidazole)-1 -methylene]-3-mercapto-1,2,4-triazole (Lxxxi) 
with various aromatic acids in presence of phosphorus oxy chloride (Scheme 3.1.28). 
Aromatic acid 
N 
\ 1^ IN P0CI3 v / / \\ 
N 
I 
NH2 
\ 
N= 
Lxxxi Lxxxii 
^ C H , 
Y= C6H5, CH3C6H4, CH3OC6H4, CIC6H4, FC6H4,02NC6H4, ^ 
Scheme 3.L28 
The reaction of 4-alkyl/aryl-l-((6-(4-bromophenyl)imidazo[2,l-6]thiazol-3-
yI)acetyl)-3-thiosemicarbazide (Lxxxiii) with concentrated sulfuric acid at room 
temperature resuhed in the formation of corresponding 2-alkyl/arylamino-5-((6-(4-
bromophenyl)imidazo[2,1-Z7]thiazol-3-yl)thiazol-3-yl)methyl)-l ,3,4-thiadiazoIes 
(Lxxxivf' (Scheme 3.L29). 
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Lxxxiii Lxxxiv 
R= CH3, C2H5, C3H7, C4H9, CH2CH= CH2, CgHs, C6H4-Br, C6H4-CI, C6H4-CH3. 
Scheme 3.1.29 
A facile protocol for the synthesis of 5-substituted-2-amino-l,3,4-thiadiazoles 
(Lxxxvii) in water has been described by Aryanasab et al.^^. The synthesis involved the 
reaction of acid hydrazide (Lxxxvi) with dithiocarbamate (Lxxxv) (Scheme 3.1.30). 
R1-NH R^ H2N-NH Et3N,Hp R fj-\ 
M 0 reflux S 
Lxxxv Lxxxvi Lxxxvii 
R,= Ph, 3,4-Cl2C6H3, n-Bu, PhCH2, (/?)-1-Phenylethyl, Adamantyl. 
R2= CH2CH2CN, Et. 
R3= Ph, PhCH2,4-MeC6H4, 4-Pyridine, 2-HOC6H4. 
Scheme 3.1.30 
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3.2. Synthesis, Antibacterial and Antifungal Activity of Some 
New2,5-Disubstituted-l,3,4-thiadiazoles* 
The ever increasing demand for novel medicinally active compounds and the 
laborious process of lead discovery and optimization have resulted in the continuous 
search for simple and efficient compounds containing such useful scaffolds. Among the 
well known heterocyclic systems the derivatives of thiadiazoles possess broad-spectrum 
biological activities and many other uses^ '^^ '*. The therapeutic effects of compounds 
containing 1,3,4-thiadiazole rings have been studied for a number of pathological 
conditions including inflammation ,^ pain^ and depression"'. This scaffold represents a 
pharmacophore itself as it has been observed in several substances showing activity 
against a broad range of therapeutic targets. Furthermore, the synthesis of thiadiazoles 
has attracted wide attention due to the diversity of their applications as antimicrobial, 
anti-tubercular'', anticancer^ and anticonvulsant^  agents. 
The thiosemicarbazides have been effectively used as synthons for the synthesis 
of various nitrogen heterocyclic. The semicarbazide moiety gives a platform for various 
cyclocondensation as well as addition cyclization reactions to take place. Bearing in mind 
the aforementioned pharmacological applications associated with 1,3,4-thiadiazoles 
extensive research activity is being pursued towards the synthesis of thiadiazoles 
decorated with different functional groups. The present stratagem is aimed in the 
•Research paper entitled "Synthesis, characterization, and in vitro antimicrobial activities ofS-
alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4'Oxadiazoles and thiadiazoles" is published. (Nida 
N. Farshori, Mudasir R. Banday, Anis Ahmad, Asad U. Khan, Abdul Rauf, Bioorg. Med. Chem. 
Lett., 2010,20, 1933-1938). 
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direction of developing new 1,3,4-thiadiazoles having alkenyi/hydroxyalkenyl and 
phenylamine moieties as substituents.The structures of the synthesized compounds have 
been characterized by IR, 'H NMR, '•'C NMRand Mass (spectroscopy) 
Further the increasing number of muhidrug resistant pathogens led us to screen 
the newly synthesized derivatives against the representative panel of Gram-positive, 
Gram-negative bacteria and fungi. 
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3.3. Results and Discussion 
The typical reaction procedure for the synthesis of 3a-d involved the reaction of 
long chain alkenoic acid hydrazide (la-d) with phenyl isothiocyanate to furnish the 
corresponding thiosemicarbazides (2a-d) which on dehydrative cyclization by AC2O 
produced 2,5-disubstituted-l,3,4-thiadiazoles (3a-d) in excellent yields. To the prior, the 
long chain acid hydrazides (la-d) were synthesized from corresponding long chain 
alkenoic acids by esterification and further treatment with hydrazine hydrate . The 
reaction sequence is outlined in Scheme 3.3.1. 
O O S 
RJ1_NH-NH, ' " ^ ^ ' ^ RJLNH-NH J L N H -
la-d 2a-d "^^ 
Acp 
^ ^ ^ 
3a-d 
Scheme 3.3.1. Synthesis of2,S-disubstituted-l,3,4-thiadiazoles 3a-d 
The characterization data of 2,5-disubstituted-l,3,4-thiadiazoles (3a-d) is given in Table 
3.3.1. 
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Table 3.3.1. Characterization data of synthesized 5-alkenyl/hydroxyalkenyl-2-
phenylamine-l,3,4-thiadiazoles 3a-d. 
Compd. R Mol. Formula M.p. [°C] Yield[%] Analysis (%) found (calculated) 
H N 
z^-yf^-^^>^H, 
3a H, C18H25SN3 134-135 95 68.30(68.53) 7.78(7.98) 13.07(13.31) 
3b ^6 "5 C25H39SN3 138-140 91 72.23(72.59) 9.44(9.49) 10.10(10.15) 
3c OH = C25H39OSN3136-138 85 69.61(69.89)9.04(9.14)09.78(9.78) 
3(1"^^^^"='^^''"' C25H39OSN3 139-141 83 69.54(69.89)9.02(9.14)09.72(9.78) 
The data in Table 3.3.1 reveals that the yields of the 1,3,4-thiadiazoIes 3a-d are 
found to be excellent and are independent of the substituents present in the precursor. The 
scope of the reaction using olefinic (internal and terminal) and hydroxy acids was found 
to be good. The newly synthesized compounds were analyzed for C, H and N content and 
the structures were confirmed on the basis of IR, ' H N M R , '^C N M R and mass spectral 
data. 
5-(Dec-9'-enyl)-2-phenylamine-l,3,4-thiadiazole 3a gave significant IR bands at 
3221 cm'' (NH), 1488 cm"' (C-N) and 707 cm"' (C-S-C). ' H NMR peak at 6 12.20 (IH, 
s, NH), 8.16 (2H, d, y = 8.5 Hz, Ar-H-276"), 7.55 (IH, t, J = 7.3 Hz, Ar-H-4") and 7.44 
(2H, t, y = 7.8 Hz, Ar-H-375") were observed. In addition to normal fatty acid chain 
peaks a signal of methine proton of C-9 at 5 5.73 was observed. The C-10 methylene 
designated as HE and Hz displayed two distinct 6 values when coupled with C-9 methine 
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protons. The spectrum showed two doublets of doublet at 8 4.98 and 4.85 for Hz and Hf 
protons respectively. In '"'C NMR peaks at 6 165.2 and 153.0 were observed for ring 
carbon atoms. The mass spectra showed characteristic molecular ion peak which were in 
accordance with the molecular formula. The newly synthesized compounds have been 
confirmed by their spectral data. 
Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Staphylococcus aureus (ATCC-25923), 
Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^ '^^ .^ The 
susceptibility was assessed on the basis of diameter of zone of inhibition against Gram-
positive and Gram-negative strains of bacteria. Inhibition zones were measured and 
compared with the controls. The bacterial zones of inhibition values are given in Table 
3.3.2. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The minimum inhibitory concentrations (MICs) and minimum bactericidal 
concentrations (MBCs) are given in Table 3.3.3. 
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Table 3.3.2. Antibacterial activity of5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-
thiadiazoles 3a-d. 
Compounds 
3a 
3b 
3c 
3d 
Standard 
DMSO 
Diameter of: 
Gram positive bacteria 
S. pyogenes 
13.5±0.3 
13.1±0.7 
22.9±0.8 
21.1±0.2 
23.0±0.2 
-
S. aureus 
13.1±0.5 
12.9±0.3 
21.6±0.3 
20.8±0.4 
22.0±0.2 
-
zone of inhibition (mm). 
P. aeruginosa 
17.2±0.4 
16.3±0.6 
29.2±0.2 
25.9±0.6 
32.0±0.3 
-
Gram negative bacteria 
K. pneumoni 
12.8±0.2 
12.1±0.5 
22.7±0.6 
19.9±0.9 
19.0±0.2 
-
ae E.coli 
15.2±0.4 
14.8±0.4 
25.5±0.5 
22.9±0.2 
27.0±0.2 
-
Positive control (standard); Chloramphenicol and negative control (DMSO) measured by 
the Halo Zone Test (Unit, mm) 
Table 3.3.3. MIC and MBC results of 5-alkenyl/hydroxyalkenyl-2-phenylamine-
1,3,4-thiadiazoles 3a-d 
Compounds Gram positive bacteria Gram negative bacteria 
S. pyogenes S. aureus P. aeruginosa K. pneumoniae E. coli 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
3a 25.0 50.0 
3b 12.5 100 
3c 6.25 12.5 
3d 6.25 25.0 
Standard6.25 12.5 
12.5 25.0 
12.5 25.0 
6.25 12.5 
6.25 12.5 
6.25 12.5 
12.5 25.0 
12.5 25.0 
6.25 12.5 
6.25 25.0 
6.25 12.5 
25.0 50.0 
25.0 50.0 
6.25 6.25 
6.25 6.25 
6.25 12.5 
25.0 100 
25.0 50 
6.50 12.5 
6.25 12.5 
6.25 12.5 
Positive control Chloramphenicol. MIC (^g/ml) = minimum inhibitory concentration, i.e. 
the lowest concentration of the compound to inhibit the growth of bacteria completely; 
MBC (^ig/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely. 
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The PBE (percentual bacteriostatc efficiency, %) was obtained as 
PBE=IOO/MIC 
The results have been reported in Fig. 3.3.1. 
3a 3b 3c 3d 
Compounds 
DSP 
QSA 
DPA 
DKP 
• EC 
SP= S. pyogenes, SA= S. aureus, PA= P. aeruginosa, KP= K. pneumonia, EC= E. Coli 
Fig. 3.3.1 Percentual bacteriostatic efficiency (PBE%)for compounds 3a-d compared 
to control drug Chloramphenicol (Ch) 
The investigation of antibacterial screening data revealed that all the tested compounds 
showed moderate to good bacterial inhibition. The structural activity study showed that the 
synthesized 1,3,4-thiadiazoles have varying degree of microbial inhibition. Compounds 3c 
and 3d showed good inhibition against all Gram-positive and Gram-negative bacterial strains 
at 6.25 ^g/ml concentrations. The compounds 3c and 3d were found to be almost equally 
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potent as the reference drug, Chloramphenicol, in case of K. pneumoniae. The MBC of few 
compounds was found to be the same as MIC but in most of the compounds it was two or 
three folds higher than the corresponding MIC results. Among the synthesized thiadiazoles, 
the compounds with a hydroxyalkenyl chain substituent at 5^^ position of thiadiazoles were 
found to increase the antibacterial activity in compounds 3c and 3d. However the position of 
the hydroxy group had no significant effect on the magnitude of the antibacterial activity. 
Further, the compounds showed parallel activity against gram-positive and gram-negative 
bacterial strains. 
Antifungal studies 
In another set of experiments, the synthesized 1,3,4-thiadiazoles were also 
screened for their antifungal activity. The antifungal activity was assessed against 
Candida albicans, Aspergillus fumigatus, Penicillium marneffei and Trichophyton 
mentagrophytes (recultured) in DMSO by agar diffusion method^ '^^ .^ The fungal activity 
of each compound was compared with Greseofulvin as standard drug. Inhibition zones 
were measured and compared with the controls. The fungal zones of inhibition values are 
given in Table 3.3.4. 
The minimum inhibitory concentrations (MICs) and minimum fungicidal 
concentrations (MFCs) were determined by broth dilution technique and the results are 
given in Table 3.3.5. 
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Table 3.3.4. Antifungal activity of5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-
thiadiazoles 3a-d 
Compounds 
3a 
3b 
3c 
3d 
Standard 
DMSO 
Diameter of zone 
CA 
19.5±0.5 
27.2±0.2 
25.1±0.7 
24.9±1.4 
30.0±0.2 
-
AF 
16.5±0.4 
23.8±1.2 
22.4±0.3 
21.8±0.2 
27.0±0.2 
-
of inhibition (mm) 
TM 
14.1±0.3 
20.3±0.7 
18.9±0.5 
19.0±0.2 
24.0±0.3 
-
PM 
10.2±0.5 
16.1±0.2 
15.1±0.9 
15.2±1.2 
20.0±0.5 
-
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. 
Positive control (Greseofulvin) and negative control (DMSO) measured by the Halo Zone 
Test (Unit, mm). 
Table 3.3.5. MIC and MFC of5-alkenyl/hydroxyalkenyl-2-phenylamine-l,3,4-
thiadiazoles 3a-d 
Compounds < 
MIC 
3a 25.5 
3b 6.25 
3c 12.5 
3d 25.0 
St. 6.25 
CA 
MFC 
50.0 
12.5 
25.0 
50.0 
12.5 
AF 
MIC 
25.0 
6.25 
12.5 
25.0 
6.25 
MFC 
100 
25.0 
50.0 
50.0 
12.5 
TM 
MIC 
25.0 
6.25 
12.5 
25.0 
6.25 
MFC 
50.0 
12.5 
25.0 
100 
12.5 
PM 
MIC MFC 
25.0 100 
6.25 12.5 
25.0 50.0 
25.0 100 
6.25 12.5 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei, St.= Standard. MIC (|ig/ml) = minimum inhibitory 
concentration, i.e the lowest concentration of the compound to inhibit the growth of 
fiingus completely; MFC ()ag/ml) = minimum fungicidal. 
Positive control Greseofulvin 
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The ratio MFC/MIC was calculated in order to determine if the compound had a 
fungistatic (MFC/MIC> 4) or fungicidal (MFC/MIC< 4) activity and the results have 
been summarized in Fig. 3.3.2 
4 
3.5 
3 
2.5 
MFC/MIC 2 
1.51 
1 
0.5 
0 
• i ~ i 
-^
-'-
— L ^ i 1 1 -
"V f~ 
^ 1 
3a 3b 3c 3d 
Compounds 
Gr 
CA= C. albicans, AF= A. fumigatus, TM= T. mentagrophytes and PM= P. marneffei. 
Fig. 3.3.2 MFC/MIC of compound 3a-d compared to control drug Greseofulvin (Gr) 
The antifungal screening data showed moderate to good activity. The excellent 
inhibition results were obtained against all the test strains by compound 3b. Moderate activity 
was shown by compounds 3c and 3d against the tested fungal strains. The compound 3a 
showed significantly lower inhibitory activity. The compound 3b showed maximum activity 
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against C. albicans, A. fumigates and T. metagrophyte strains. The MFC of most of the 
compounds was two or three folds higher than the corresponding MIC results. Most of the 
synthesized 1,3,4-thiadiazoles showed good fungistatic activity against the fungal strain C. 
albicans. Hence it could be concluded that the higher anti-fungal potency of the compound 3b 
may be attributed to the presence of an internal double bond in the long chain alkenyl 
substituent of the synthesized 1,3,4-thiadiazoles. Contrary to the antibacterial studies, the 
presence of the hydroxy on the alkenyl side chain turns out to be detrimental for the anti-
fungal activity perhaps due to pharmacokinetic reasons. 
Thus, the synthesized compounds can be used as template for future development 
through investigation regarding the structure-activity relationship, toxicity and their biological 
effects to design more potent and selective antimicrobial agents for therapeutic use. 
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3.4. Experimental 
The sources of all the fatty acids and instrumentation details are the same as given 
in Chapter 1 (pg. 31). 
General procedure for the synthesis of long-chain alkenoic acid hydrazide (la-d) 
The hydrazides of long chain alkenoic acids (la-d) which are used as the starting 
material were prepared by the previously reported methods^ .^ 
Synthesis of l-(alkenoyl/hydroxyalkenoyl)-5-phenylthiosemicarbazide (2a-d) 
l-Alkenoyl-5-phenylthiosemicarbazides (2a-d) were prepared by the reported 
literature method^". The synthesized compounds, 2a-d, were characterized by their 
melting points and spectral data. The spectral data of 2a and 2c is given below. 
l-(Undec-10-enoyl)-5-phenylsemicarbazides (2a) 
White powder; Yield 80%; Mp 104-107 °C. 
//f(KBr): 3236, 1667, 1236 cm''. 
'HNMR (400 MHz, CDCI3): 5 11.04 (s, IH, CS-NH-Ar), 9.35 (br. s, 2H, CO-NHNH-
CS), 8.14 (d, 2H, J= 7.2 Hz, Ar-H-276"), 7.56 (t, IH, J= 7.4 Hz, Ar-H-4"), 7.48 (t, 2H, 
J= 7.4 Hz, Ar-H-3'V5"), 5.85 (tdd, IH, j ^ .. = 6.8 Hz, j^ „ =10.0 Hz, j„ „ =17.8 Hz, 
CH2=C//-), 5.04 (dd, IH, 7„^ _„=10.0 Hz, j„.„ =2.8 Hz, //zC=CH), 4.91 (dd, IH, 
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J„^_„=17.S Hz, 7^ _^  = 2.8 Hz, //£C=CH-), 2.42 (t, 2H, J = 7.4 Hz, CH2-CO), 2.03 (m, 
2H, CH2=CH-C//^), 1.85 (m, 2H, C//2CH2-CO), 1.45-1.25 (br. s, lOH, {CH2)5). 
'^CNMR (100 MHz, CDCI3): 8 168.2, 165.4, 139.2, 133.2, 131.3, 128.9, 128.6, 114.2, 
33.8,29.9, 29.6,29.3,29.2, 29.1, 29.0, 28.9. 
l-[(9Z,12R)-12-hydroxy-octadec-9-enyl]-5~phenylsemicarbazides (2c) 
Off-white powder; Yield 77%; Mp 148-150 °C. 
IR (KBr): 3343, 3233, 1661, 1237 cm"'. 
'HNMR (400 MHz, CDCI3): 5 11.07 (s, IH, CS-N//-Ar), 9.32 (br. s, 2H, CO-N//N//-
CS), 8.14 (d, 2H, J= 7.4 Hz, Ar-H-2"/6"), 7.59 (t, IH, J= 7.4 Hz, Ar-H-4"), 7.50 (t, 2H, 
J= 7.2 Hz, Ar.H-375"), 5.32 (m, 2H, CH2-C//=C//-CH2), 4.83 (m, IH, C//-OH), 2.51 (t, 
2H, J = 7.6 Hz, CH2-CO), 2.36 (m, 4H, CH2-CH2=CH-CH2), 1.87 (m, 2H, CH2-CH2-
CO), 1.71 (m, IH, CH-OH), 1.44-1.28 (br. s, 18H, (CH2)9), 0.86 (dist. t, 3H, terminus 
CH3). 
'^CNMR (100 MHz, CDCI3): 6 166.4, 163.7, 138.7, 136.3, 132.2, 128.1, 128.0, 127.8, 
70.7,40.1, 39.9, 39.7, 39.4, 39.2, 31.3, 30.4, 29.4,29.2, 29.0, 28.8, 26.1, 22.0, 14.1. 
Synthesis of 2-Phenylamine-5-(alkenyl/hydroxyalkenyl)-l,3,4-thiadiazoles (3a-d) 
One mmole of compounds (2a-d) in acetic anhydride (AC2O) (6.0 ml) was 
refluxed for 5 h. The resulting mixture was poured into crushed ice (lOOgm) with stirring. 
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The product thus obtained was filtered, washed with cold water, dried and recrystallized 
from aqueous ethanol and acetone (1:4 ml v/v) to give analytically pure compounds 3a-d. 
These novel compounds 3a-d, prepared according to the above procedure were 
characterized from their spectral data. 
Spectroscopic Data 
2-Phenylamine-5-(dec-9 '-enoic)-l,3,4-thiadiazole (3a) 
White powder; Yield 95%; Mp 134-135 ''C. 
IR (KBr): 3221, 1488, 707 cm"'. 
'HNMR (CDCI3): 5 12.20 (s, IH, N//), 8.16 (d, 2H, J= 8.5 Hz, Ar-H-276"), 7.55 (t, IH, 
J= 7.3 Hz, Ar-H-4"), 7.44 (t, 2H, J= 7.8 Hz, Ar-H-3'V5"), 5.73 (tdd, IH, j ,. = 6.7 Hz, 
H — C / / j 
J„.„^=10.\ Hz, J„_„^-16.9 Hz, CH2=C//-), 4.98 (dd, IH, J^^_^=10.1 Hz, j„_^ = 2.1 
Hz, HzC=CU), 4.85 (dd, IH, J„^_„=16.9 Hz, J„,_„^ = 2.1 Hz, //gC^CH-), 2.98 (t, 2H, J = 
7.5 Hz, C//2a to ring), 1.96 (m, 2H, CUj^CU-CH:), 1.76 (m, 2H, CH2 p to ring), 1.25 
(br.s, 10H,(C//,)5). 
'^CNMR (CDCI3): 5 165.2, 153.0, 139.1, 133.4, 131.3, 129.8, 127.9, 114.2, 33.7, 29.1, 
28.9,28.8,28.7,28.4,26.0,25.8. 
ESI-MS found [M+Na]^ 338.2; C18H25SN3 [M+Na]* requires 338.47. 
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2-Phenylamine-5-(Z) (heptadec-8 '-enoic)-l,3,4-thiadiazole (3b) 
White powder; Yield 91%; Mp 138-140 °C. 
//f(KBr): 3219, 1468,701 cm-'. 
^HNMR (CDCI3): 8 12.10 (s, IH, N//), 8.14 (d, 2H, J= 8.5 Hz, Ar-H-276"), 7.55 (t, IH, 
J= lA Hz, Ar-H-4"), 7.45 (t, 2H, J= 7.8 Hz, Ar-H-3"/5"), 5.30 (m, 2H, CHi-CH^CH-
CH2), 2.98 (t, 2H, J = 7.7 Hz, C//2a to ring), 2.36 (m, 4H, CH2-CH2=CH-CH2l 1.76 (m, 
2H, CH2 (3 to ring), 1.28 (br. s, 20H, {CH2U), 0.80 (dist. t, 3H, terminus CH3). 
'^CNMR (CDCI3): 6 165.4, 158.0 "one signal hidden", 139.1, 137.2, 133.2, 131.3, 128.8, 
128.6, 31.9, 29.9, 29.7, 29.5"two signals are hidden", 29.4"two signals are hidden", 29.3, 
29.1,28.7,26.4,22.7,14.2. 
ESI-MS found [M+Na]^ 436.3; C25H39SN3 [M+Na]^  requires 436.6. 
2-Phenylamine-5-f(8'Z,ll 'R)-ll '-hydroxy-heptadec-8'-enylJ-l,3,4-thiadiazole (3c) 
White powder; Yield 85%; Mp 136-138 ^C 
IRiKBr): 3310, 3219, 1467, 695 cm"'. 
'HNMR (CDCb): 5 12.37 (s, IH, N//), 8.23 (d, 2H, J= 8.5 Hz, Ar-H-276"), 7.62 (t, IH, 
J= 7.4 Hz, Ar-H-4"), 7.52 (t, 2H, J= 7.8 Hz, Ar-H-3"/5"), 5.37 (m, 2H, CU2-CH=CH-
CH2), 3.59 (s, IH, CH-OH), 3.00 (t, 2H, J = 7.5 Hz, CH2 a to ring), 2.38 (m, 4H, CH2-
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CH2=CH-C//2), 1.83 (m, 2H, CH2 P to ring), 1.71 (m, IH, CW-OH), 1-26 (br. s, 18H, 
{CH2)9), 0.87 (dist. t, 3H, terminus C//j). 
'^CNMR (CDCI3): 6 170.9, 165.0, 133.3, 131.1, 130.7, 130.2, 128.8, 128.5, 73.9, 34.1, 
31.5, 29.8, 29.7, 29.5, 29.3, 29.1, 28.9, 27.1, 25.2, 23.1, 22.5, 21.3, 14.6. 
ESI-MS found [M+Na]^ 452.4; C18H39OSN3 [M+Na]^ requires 452.6 
2-Phenylamine-5-l(8'R,ll 'Z)-8'-hydroxy-heptadec-ll '-enylJ-I,3,4-thiadiazole (3d) 
Off-white powder; Yield 83%; Mp 139-141 '^ C 
IR (KBr): 3322, 3236, 1461, 699 cm"'. 
'HNMR (CDCI3): 6 12.17 (s, IH, N//), 8.31 (d, 2H, J= 8.4 Hz, Ar-H-276"), 7.43 (t, IH, 
J= 7.4 Hz, Ar-H-4"), 7.25 (t, 2H, J= 7.4 Hz, Ar-H-375"), 5.36 (m, 2H, CH2-CH=CH-
CH2), 3.57 (s, IH, C//-OH), 2.81 (t, 2H, J = 7.5 Hz, CH2 a to ring), 2.23 (m, 4H, CH2-
CH2=CH-C//2), 2.04 (m, 2H, CH2 p to ring), 1.71 (m, IH, CH-OH), 1.33 (br. s, 18H, 
(CH2)9), 0.90 (dist. t, 3H, terminus CH3). 
'^CNMR (CDCI3): 6 168.9, 163.1, 137.6, 133.2, 131.2, 128.7, 128.3, 125.5, 70.56, 40.1, 
39.9, 36.3, 24.8, 31.3, 29.1, 29.0, 28.9, 28.8, 28.5, 28.4, 25.1, 22.3, 14.01. 
ESI-MS found [M+Na]^ 452.5; C18H39OSN3 [M+Na]^  requires 452.6. 
Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Staphylococcus aureus (ATCC-25923), 
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Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^' . 
Chloramphenicol (30 ng) was used as positive control and the disk poured in DMSO was 
used as negative control. The susceptibility was assessed on the basis of diameter of zone 
of inhibition against Gram-positive and Gram-negative strains of bacteria. Inhibition 
zones were measured and compared with the controls. The bacterial zones of inhibition 
values are given in Table 3.3.2. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The minimum inhibitory concentrations and minimum bactericidal 
concentrations (MBCs) are given in Table 3.3.3. The PBE (percentual bacteriostatc 
efficiency, %) was obtained as 
PBE=100/MIC 
The results have been reported in Fig. 3.3.1. 
Antifungal studies 
Antifungal activity was also done by disk diffusion method. For assaying 
antifungal activity Candida albicans, Aspergillus fumigatus, Penicillium marneffei and 
Trichophyton mentagrophytes (recultured) in DMSO by agar diffusion method ' . The 
fungal activity of each compound was compared with Greseofulvin as standard drug. 
Inhibition zones were measured and compared with the controls. The fungal zones of 
inhibition values are given in Table 3.3.4. 
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The minimum inhibitory concentrations (MICs) and minimum fungicidal 
concentrations (MFCs) as determined by broth dilution technique are given in Table 
3.3.5. 
The ratio MFC/MIC was calculated in order to determine if the compound had a 
fungistatic (MFC/MIC> 4) or fungicidal (MFC/MIC< 4) activity and the results have 
been summarized in Fig. 3.3.2. 
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CHAPTER-4 
3-Substituted-l,6-dihydro-l,2,4-triazin-5-(2H)-ones 
4.1 Theoretical 
Triazinone is a J^\mL^ heterocyclic compound which is structurally similar to 
fragment of some natural macromolecules. As a widely used biologically active 
compound the derivatives of triazinone exhibit anticancer', antidiuretic and neuro-
depressant^ , antimicrobial, cardiotonic as well as blood platelet aggregation-inhibition 
o^tm^\s\ The biological effects of 1,2,4-triazinone derivatives are largely determined by 
ifnnT 
^7 
their ability to take up lose proton;. 
The 1,2,4-triazinone derivative (i) is a useful antifungal agent. It can be 
administered parenterally, orally or locally to warm blooded animals in foBU-of 
solid pharmaceutical preparations^. 
N — ^ 
M 
N—N 
V ^ 
The 2-aryl-l,2,4-benzotriazin-3-ones class of compounds have established 
/- T - ^ ^ . ^ 7 
themselves as (attractive) antimicrobial and antiviral drugs . The azoloannealed 
triazinones (ii) has been proved to be neuraminidase inhibitors^. They have also displayed 
high activity against different kind of viruses including influenza and bird flu (culture 
H5Nlf''°. The 1,2,4-triazinone has recently much attention as a core structure of 
vardenafil (levitra) (Hi), a potent and effective PDE5 inhibitor for the treatment of erectile 
disfunction". 
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HiC. ^N 
II 111 
In the field of agriculture, the 1,2,4-triazinone class of compounds are used as 
insecticides, herbicides, plant growth regulators and \ increasing crop yields ,12,13 
Pymetrozine (iv), represents a typical triazinone compound, which has high efficiency, 
low toxicity and is environment friendly''*. Another herbicide metribuzin (v) is widely 
used for the control of grasses and broad-leaved weeds in soyabean, sugarcane and 
numerous other crops'^ 
H3C. . N . 
Ao 
iv V 
The various methods for the synthesis of 1,2,4-triazinone derivatives are reported 
by numerous workers. A common method for the synthesis of 1,2,4-triazinones is the 
cyclization of a-(acylamine) carboxyhydrazides'^ . The reaction of nitrilimines with a-
aminoacetonotrile affords 1,2,4-tria2inone in excellent yield'^. Further, 
cyclocondensation reactions of nitrilimines with 2- hydrazinoacetate or with a-amino 
esters represent an important synthetic route for the preparation of 1,2,4-triazinone 18,19 
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The synthesis of various 1,2,4-triazinone derivatives employing amidrazones and a-halo 
acid esters has been reported . 
6-Aryl-3-pyridyl-l,2,4-triazinone (ix) have been prepared by the reaction of a 
keto-carboxyUc acid or its ester (vi) with 2-pyridyl-hydrazine (vii), via the formation of 
an intermediate (viii) in presence of an inert solvent. The synthesized 1,2,4-triazinone 
exhibit a strong antifungal activity against the pathogenic fungi Trichophyton rubrum and 
Candida albicans^ (Scheme 4.1.1). 
vi vii viii ix 
R= H, C1-C4 Alkyl Ar= C6H4X, d-Cg Alkyl, Ci-Cg Alkylthio, Hydroxyl, 
Amino. 
Scheme 4.1.1 
Various synthetic routes to access a variety of novel 1-aryl-2//,4//-tetrahydro-
l,2,4-triazin-3-one analogs from various starting materials have been developed by 
Bhatia et al^^ .The synthesis of parent structure l-phenylperhydro-l,2,4-triazin-3-one 
(xii), a selective inhibitor of 5-LO in broken cell, intact cell and human blood assay, was 
achieved by the reaction of 2-chloroethyl isocyanate (x) with (3-fluorophenyl)hydrazine 
(Scheme 4.1.2). 
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0 
> 
R2 CI 
Et3N, H^NNHR, 
CH2CI2 
0 NH-
^^—NH 
^ HN 
R2 CI 
-Ri 
Nal, DMF 
^ • 
75 °C 
0 u 
HN N—Ri 
R2 
XI XII 
Ri= 3-Fluorophenyl R2= H 
Scheme 4.1.2 
Zou et al}^ gave the synthesis of l,10-phenanthrolino[5,6-e]-l,2,4-triazin-3-one 
(xiv) by heating a mixture of phenanthroline-5,6-dione semicarbazone (xiii) with acetic 
acid and ammonium acetate (Scheme 4.1.3). 
acetic acid 
NH4AC 
XIII XIV 
Scheme 4.1.3 
The refluxing of a mixture of 9-amino-7-(4 -chlorophenyl)-8,9-dihydro-8-imino-
6HJH-[l]benzopyrano[3,4:5,6]-pyrano[2,3-d]-pyrimidine-6-one (xv), ethyl 
chloroacetate, methanol and sodium metal for 6 h gave 15-(4-chIorophenyl)-3,4-dihydro-
2//,14//,l 5//-[l ]benzopyrano[3',4':5,6]-pyrano[2,3-cf]-pyrimido-[ 1,6-6][l ,2,4]-triazine-
3,14-dione (xvi)" (Scheme 4.1.4). 
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. ^ \ /NH2 
NH 
N ^ ^ N - ' N ^ ° 
^^ ClCH2C02Et 
XV XVI 
Ar= C6H4CI-P 
Scheme 4.1.4 
Heim-Riether et al.'^'* synthesized the imidazo[5,l-/][l,2,4]-triazinones (xix) 
which are of pharmaceutical importance as isosteres of purine. The key step involved the 
formation of 7V-aminoimidazoles (xviii) from 3//-imidazoles (xvii) by treatment with 
lithium hexamethyldisilazane and o-(diphenylphosphinyl)hydroxylamine, and further 
cyclization with formamide to yield corresponding imidazotriazinones (xix) (Scheme 
4.1.5). 
9*^ 3 o H3C ^ 
l.LHMDS 
OEt ^ N' ^ 
2. Ph2P(0)ONH2 V_N OEt 
xvu XVIU XIX 
Scheme 4.1.5 
A facile method for the synthesis of substituted bis(indole)-l,2,4-triazinones 
(xxii) is given by Garg et al.^^ The access to the target triazinones involved the 
cyclocondensation reaction between amidrazone (xx) and ketoester (xxi) functionalities 
in presence of MgS04 in methanol and refluxing in DMF (Scheme 4.1.6). 
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NH, 
MeO 
H,C 
XX XXI XXII 
Scheme 4.1.6 
The conversion of nitroguanidine imidacloprid (xxiii) to its methyltriazinone 
derivative (xxv) via the formation of its aminoguanidine (xxiv) derivative is described by 
Kanne et al^^ (Scheme 4.1.7). 
CL 
Y "H 
Zn powder CI 
0,N / ' 
2NNH2, NH4CI, C2H5OH 
XXill 
r^ 
'^ Y''^ ^^  
^N 
H2N 
XXIV 
CI 
ethyl pyruvate, toluene, reflux 
N. ^ x J ^ / N N 
xxv 
Kl' CH3 
Scheme 4.1.7 
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The l,2,4-triazolo[3,4-/|[l,2,4]triazinone (xxvii) was synthesized from the 
reaction of the corresponding hydrazine derivative (xxvi) with carbon disulfide^^ 
(Scheme 4.1.8). 
0 
cs. 
N 
XXVI 
HoN' " N ' 
I 
H 
xxvii 
NH 
Scheme 4.1.8 
The diazotization of o-(alkylazo)anilines (xxviii) gave the o-
(alkylazo)aryldiazonium tetrafluoroborates (xxix) which on further reaction with an 
excess of sodium cyanate in MeCN yielded the 2-alkyl-l,2,4-benzotriazin-3(2//)-ones 
(xxx)^ * (Scheme 4.1.9). 
NH, 
Alk 
NalMCO Ri 
MeCN 
^ N 
XXVHl 
Alk= Bu', Me R,= H, Br, CI 
XXIX XXX 
R2= H, Br 
Scheme 4.1.9 
R3= H, Br, CI, Me 
A simple and high yielding method for the integration of a 1,2,4-triazole ring with 
l,2,4-triazine-5-one is developed by Kamble et al^^. The bromination and 1,3-dipolar 
cycloaddition reaction of 3-arylsyndone (xxxi) formed 3-aryl-5-methyl-2-oxo-A - 1,3,4-
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oxadiazoles (xxxii). The reaction of (xxxii) with semicarbohydrazide formed an 
intermediate (xxxiii) which underwent cycUzation with pyruvic acid in presence of acetic 
acid fused with sodium acetate to yield 6-methyl-4-(3-methyl-5-oxo-l -aryl-l,5-dihydro-
l,2,4-triazol-4-yl)-3-oxo/thioxo-3,4-dihydro-2//-l,2,4-triazin-5-one (xxxiv) (Scheme 
4.1.10). 
h l .Br, inAc,0, 0°C 2. 60 °C w N ^  NHjNHCXNHNHj ethanol, reflux 
XXXI 
CH3 
xxxii 
CH3 
-NH 
NH 
NH-
XXXIII 
CHXOCOOH, AcOH/NaOAc reflux 
R ,0 X 
Y H 
CH3 o CH, CH3 o 
xxxiv 
R= C6H5, P-CH3C6H4, P-OCH3C6H4, P-CIC6H4, p-BrC6H4 
Scheme 4.1.10 
x=o, s 
The reaction of diethyl aminomalonate (xxxv) with dimethylformamide dimethyl 
acetal gave the amidine (xxxvi) which on condensation with hydrazine afforded the 
dihydrotriazinone (xxxvii). The (xxxvii) could be oxidized to corresponding triazinone 
(xxxviii) by treatment with iodobenzene diacetate (Scheme 4.1.11). 
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Q. O H 
, 7~°^ ' I.NaOEt.EtOH E t O ^ OB H.NNH,, EtOH N^^N^° 
^|. ^ O E ' 2. (MeO)jCHNMe,, benzene \=^ \ ^ ^ N ' ' ^ ^ 
XXXVI 
XXXV XXXVII 
Phl(OAc) EtOH 
.N. / O 
I 
. \ 
OEt 
d 
XXXVIII 
Scheme 4.1.11 
Sanudo et al?^ gave the synthesis of a new class of dipeptidyl ureas, 3-hydroxy-6-
oxo[l,2,4]triazin-l-yl alaninamides (xLiii). The Ugi reaction of cyclohexyl/benzyl 
isocyanide (xLi), benzoyl-/4-methoxybenzoyl formic acid (xL) and semicarbazones 
(xxxix) gave the Ugi adduct (xLii), which on stirring with sodium ethoxide in ethanol 
gave the desired triazinone (Scheme 4.1.12). 
NH, "3 H,C 
HN" HN' 
rMn2 
0 = ^ H 3 C ^ ^ 0 " ^ ^ > ^ ^ 0 
XXXIX 
HO ^N^ ^Ph 
xL xLi xLii xLiii 
Scheme 4.1.12 
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32 
6-Amino-3-benzylmercapto-l ,2,4-triazolo[3,4-/][l ,2,4]-triazin-8(7//)-one (xLvi) 
were synthesized by stirring a solution of 6-amino-3-thio(2//)-l,2,4-triazolo-[3,4-
/][l,2,4]-triazin-8(7//)-one (xLiv) and benzyl bromide (xLv) in methanolic ammonia 
(Scheme 4.1.13). 
0 O 
X . « „,.„.. 
HN N + \ /r\. NH3/CH3OH ^^ 
H,N^ N 
xLiv xLv xLvi 
Scheme 4.1.13 
The synthesis of 6-methyl-2,5,5-trihydro-3-oxo-4-amino-l,2,4-triazine (xLix) 
from 2-oxo-5-methyl-l,3,4-oxadiazol-3-acetone (xLvii) via the formation of 6-methyl-
2,5,5-trihydro-3-oxo-4-acetamide-l,2,4-triazine (xLviii) is given by Zhang et al. 
(Scheme 4.1.14). 
CH3 
/ / 
H,C-
K / W H3C. „^.-v. ,NH /CH3 
-N b^ NH,NH,H.H,0 V ^ ? T HCl ''^''^^ 
> = 0 " N^ A 0 " i' 
xLvii xLviii 
Scheme 4.1.14 
xLix 
The exposure of amidrazone (L) to ketoester (Li) in presence of MgS04 in DMF 
afforded the anti- (Lii) and 5yn-triazinone (Liii) as the major and minor products 
respectively"''* (Scheme 4.1.15). 
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Li Lii Liii 
Scheme 4.1.15 
Dalloul et al^^ gave the synthesis of 4,5-dihydro-l,2,4-triazinones (Lvii) by the 
reaction of an a-amino ester (Lv) with nitrilimines (Liv). The synthesis proceeded via the 
formation of an open-chain amidrazone ester intermediate (Lvi) which underwent 
cyclization to yield the title 1,2,4-triazinones (Scheme 4.1.16). 
0 
0 /N—N" V_nM<. 
PhHN \p 
Liv Lv 
R= H, Me, Ph, CHMcj, CHjPh 
THF 
^' 
r.t. 
Ar 
/ 
0 N—NH 
PhHN NH-<f 
// 
0 
Lvi 
X= H, CI, Br, F, Me 
Sche me 4.1.16 
- MeOH 0^  
PhHN'' 
Ar 
N—N 
NH 
Lvii 
The substituted 4,5-dihydro-l,2,4-triazin-6-ones (Lx) were prepared by the direct 
interaction of hydrazonyl halides (Lviii), nitrilimines precursors with a-amino esters in 
presence of triethylamine as a base or by treatment of amidrazones (Lix) with a-
-35 haloesters (Scheme 4.1.17). 
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H2NCH2C02Me 
O Y 
Lviii Ar 
r 
N—N 
/ / 
N 
H 
/ ^ < ^ 
Lx 
ZCH2CO2R 
O NH, 
Lix 
X= H, CI, Br, F, Me Y=Cl,Br Z=Cl,Br R=Me,Et 
Ar= Me, Ph, PhNH, 2-Naphthyl 
Scheme 4.1.17 
Thaher et al/'^ reported the synthesis of dihydro-l,2,4-triazin-6-one containing 
nitroarginine moiety. The reaction of nitrilimines (Lxi) with nitroarginine methyl ester 
(Lxii) at room temperature, through a cyclocondensation reaction yielded l-aryl-3,5-
disubstituted-l,2,4-triazin-6-ones (Lxiii) (Scheme 4.1.18). 
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Lxi Lxii Lxiii 
R= CH3, OCH3 Ar= CgHsX X= p-Cl, p-H, p-OH, o-COOH, p-COCHs 
Scheme 4.1.18 
An efficient method for the incorporation of '^ N-isotope into l,2,4-triazolo[5,l-
c][l,2,4]triazines have been developed by Shestalcova et al. . The diazoles (Lxv) were 
obtained by the treatment of 2-i?-amino-l,2,4-triazole (Lxiv) with H'^ NO2 (86% label) 
under acidic conditions. The reaction of (Lxv) with ethyl nitroacetate in presence of 
sodium carbonate gave the salt (Lxvi) which was acidified to give the [5- N]-6-nitro-
l,2,4-triazolo[5,l-c][l,2,4]-triazin-7-ones (Lxvii) (Scheme 4.1.19). 
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OEt 
N—NH 
• N ^ 
Lxiv 
H'^ NO, 
~NH, R-
N—NH 
N 
Lxv 
N 
N 
NO, 
Na2C03 
R= H, SMe 
Scheme 4.1.19 
The reaction of amidrazone (Lxviii) with formaldehyde in presence of p-
toluenesulfonic acid yielded 4-(2-chloropenyl)-2-phenyl-6-(piperidin-l-yl)-3,4-dihydro-
l,2,4-triazin-5(2//)-one (Lxix)^* (Scheme 4.1.20). 
NH 
CI 
N^ .Ph H2C=0,TsOH 
' NH 
N N 
I 
N 
/ Ph 
, N . 
Lxviii Lxix 
Scheme 4.1.20 
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MuUick et al. gave the synthesis of 5,6-diphenyl-l,2,4-triazine-3(2//)-
thioxo/one (Lxxi) by the reaction of benzyl (Lxx) with an equimolar amount of 
semicarbazide or thiosemicarbazide in presence of acetic acid (Scheme 4.1.21). 
r < ^ ^ - ^ 
^ Semicarbazide/Thiosemicarbazide 
acetic acid N ^X 
^ ^ ^ 
^ ^ ^ 
Lxx Lxxi 
X = S , 0 
Scheme 4.1.21 
The synthesis of 8-(4-chlorophenyl)-2,6-dioxo-l,3,4,6-tetrahydro-2//-pyrido[l,2-
b][l,2,4]-triazine-7,9-dicarbonitrile (Lxxiii) was achieved by refluxing a mixture of 4-
aryl-1,6-diamino-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile (Lxxii) and 
monochloroacetic acid in DMF'*'^  (Scheme 4.1.22). 
NH, 
N" CICH^COOH 
DMF 
Lxxii 
Scheme 4.1.22 
Lxxiii 
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4.2. Facile One-pot Synthesis and in vitro Antimicrobial 
Activity of Novel 3-Substituted-l,6-dihydro-l,2,4-triazin-
5-(2i/)-ones. 
In the recent years the chemistry of triazinone derivatives has been a subject of 
great interest due to the use of such ring systems as the core structure in many 
heterocyclic compounds covering a wide range of pharmacological applications. Several 
reports'*''"^^ have revealed that 1,2,4-triazinone derivatives possess significant biological 
activities, such as antimicrobial, antibacterial, fungicide, pesticide, herbicide and crop 
protection, as well as blood platelet aggregation-inhibition. Researchers have also 
reported"*^ "*^  that certain 1,2,4-triazin-6-one possess antitumor^activity against ovarian 
cancer, leukemia, breast cancer and small and large lung cancer cells. Apart from the 
pharmacological applicability, the 1,2,4-triazinones have also received significant 
attention as ligands to transition metals. The reaction of 1,3,5-trisubstituted 4,5-dihydro-
1,2,4-triazine oximes with metal acetates afforded various complexes depending on the 
reagents and conditions used ' . 
In continuation to the research work done in our laboratory"*'' , involving the 
synthesis of various derivatives of fatty acids, of synthetic and biological importance, we 
here report a facile one-pot synthesis of various l,6-dihydro-l,2,4-triazin-5(2//)-ones, 
bearing a long alkanyl/alkenyl/hydroxy alkenyl chain at C-3. In this chapter, we for the 
first time report a simple and effective synthesis of various I,6-dihydro-l,2,4-triazinone 
derivatives using various fatty acid hydrazides and chloroacetamide as the starting 
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material. The reaction described herein has a remarkable synthetic utility and is a 
valuable addition to the synthesis and manipulation of fatty acid derivatives because it 
makes the target compounds available in one step starting from fatty acid hydrazides. The 
newly synthesized compounds were also screened for their antibacterial and antifungal 
activities against a panel of Gram-positive and Gram-negative strains of bacteria and 
selected fiingal strains. 
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4.3. Results and Discussion 
To the prior the fatty acid hydrazides, la-f used as the starting materials were 
prepared from the fatty acids following the previously reported method '^. The 3-
substituted l,6-dihydro-l,2,4-triazin-5-(2/f)-ones 3a-f were synthesized by the 
cyclocondensation of long chain saturated and olefmic carboxylic acid hydrazides (la-f) 
with chloroacetamide (2) in A'.jV-dimethylformamide (DMF) under reflux conditions for a 
duration of 26-30 h (Scheme 4.3.1). 
NH-NH, c i - ^ DMF, Reflux ° ^ ~NH 
W J. /7—NHo 1 1 
O O 
la-f 2 3a-f 
Scheme 4.3.1. Synthesis of3-substituted-l,6-dihydro-l,2,4-triazin-5-(2H)-ones 3a-f 
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Table 4.3.1. 3-Substituted'l,6-dihydro-l,2,4-triazin'5-(2H)-ones 3a-f 
Entry 
1 
2 
3 
4 
5 
6 
Starting from 
la, 2 
lb, 2 
lc ,2 
Id, 2 
le,2 
If, 2 
R 
z^^^^^^Jr^^H^ 
HE 
"* OH ^ 
OH 
3 6 
11 
Br 
Product 
3a 
3b 
3c 
3d 
3e 
3f 
Yield(%) 
78 
85 
67 
78 
82 
85 
As can be seen from Table 4.3.1, the scope of the reaction using saturated, 
olefinic (internal and terminal) and hydroxy acid hydrazides was found to be good. The 
yields of synthesized 3-substituted-l,6-dihydro-l,2,4-triazin-5-(2/f)-ones (3a-f) did not 
depend on the length of chain of acid hydrazide and were found to be appreciable in all 
cases. The synthesized compounds were identified on the basis of elemental analysis, IR, 
'H NMR and mass spectral data. 
The structure of compound 3a was confirmed by the appearance of absorption 
band at 3224 cm"' due to N-H stretch. Another absorption band at 2921 cm'' was due to 
aliphatic stretch. The absorption band for C=0 group was observed at 1675 cm''. The 
other prominent absorption band observed in the IR spectrum was at 1599 cm"' 
corresponding to C=N group. The 'H NMR spectrum of 3a was more informative and 
showed a singlet at 8 2.52 ppm attributable to CH2 protons of the triazinone ring. The NH 
protons resonated as two broad singlets at 6 9.45 ppm and 5 8.60 ppm. The methine 
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proton of C-9 showed a signal at 6 5.71. The C-10 methylene protons designated as WE 
and Redisplayed two distinct 5 values when coupled with adjacent C-9 methine proton. 
Thus, the ' H N M R showed two doublet of doublet at 5 4.91 and 4.84 for Hz and H^ 
protons respectively. Further evidence for the formation of l,6-dihydro-l,2,4-triazin-5-
(2//)-ones (3a-f) were obtained by recording the mass spectrum. The mass spectrum of 
compound 3a showed the molecular ion peak at m/z 237.32 corresponding to the 
molecular formula C13H23N3O. Similarly, the structures of compounds 3b-f were 
confirmed from their spectral data and elemental analysis in a straight forward maimer. 
Detailed spectra of title compounds are given in experimental section. 
Antibacterial studies 
All the synthesized compounds were further tested for their antibacterial activity 
by disk diffusion assay ' with slight modifications against an assortment of two Gram-
positive {S. pyogenes and S. aureus) and three Gram-negative {P. aeruginosa, K. 
pneumoniae and E. coli) strains of bacteria. Ciprofloxacin was used as the standard drug 
whereas DMSO was used as the negative control. The screening data was obtained as 
diameter of zone of inhibition and the results are summarized in Table 4.3.2. The 
investigation of antibacterial screening data revealed that all the tested compounds 
showed moderate to good bacterial inhibition. The data pertaining to Table 4.3.2 showed 
that the compounds 3c, 3d and 3f have a significant influence on the anti-bacterial profile 
of 5. pyogenes, S. aureus and E. coli species at 6.25 |ig/ml concentrations. 
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Table 4.3.2 Antibacterial activity of newly synthesized compounds (3a-f} 
Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
Standard 
DMSO 
S. pyo 
11.3 
14.1 
17.1 
17.1 
9.2 
18.6 
23.0 
-
Diameter of zone 
Gram positive bacteria 
^genes S. aureus P. 
11.2 
13.3 
16.3 
16.5 
8.9 
17.3 
22.0 
-
; of inhibition (mm) 
Gram negative bacteria 
aeruginosa K. pneumoniae 
15.1 
13.1 
21.1 
21.2 
12.9 
24.9 
32.0 
-
10.6 
12.5 
15.3 
15.6 
8.6 
18.4 
19.0 
-
E. coli 
13.2 
15.5 
18.5 
18.7 
10.9 
21.2 
27.0 
-
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by the 
Halo Zone Test (Unit, mm) 
The Fig. 4.3.1 indicates that the in-vitro screening of synthesized compounds 
gives promising results as compared to the reference dug Ciprofloxacin. 
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Compound 
SP= S. pyogenes, SA= S. aureus, PA= P. aeruginosa, KP= K. pneumonia, EC= E. Coli 
Fig. 4.3. J. Percent inhibition for compounds 3a-fover reference drug 
against bacterial strains. 
The MICs and MBCs of the synthesized compounds were also determined by 
broth dilution technique and the results are given in Table 4.3.3. The MBC of few 
compounds was found to be the same as MIC but in most of the compounds it was two or 
three folds higher than the corresponding MIC results. 
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Table 4.3.3. MIC and MBC results of synthesized compounds (3a-J) 
Compounds Gram positive bacteria Gram negative bacteria 
S. pyogenes S. aureus P. aeruginosa K. pneumoniae E. coli 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
3a 100 >100 100 >100 100 100 100 100 >100 >100 
3b 50 100 50 100 100 >100 50 >100 50 >100 
3c 50 100 50 50 50 100 50 100 50 100 
3d 12.5 25 12.5 25 25 50 25 50 25 100 
3e 100 >100 >100 >100 100 100 100 100 100 100 
3f 25 50 12.5 50 25 25 25 50 25 50 
Standard 12.5 12.5 6.25 12.5 12.5 25 6.25 25 6.25 12.5 
Positive control Ciprofloxacin; MIC (ng/ml) = minimum inhibitory concentration, i.e. the 
lowest concentration of the compound to inhibit the growth of bacteria completely; MBC 
(|ig/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely. 
Antifungal studies 
In another set of experiments, the synthesized compounds 3a-f were also 
examined for their antifungal activity '^*'^ ^ against Candida albicans, Aspergillus 
fumigatus. Trichophyton mentagrophytes and Penicillium marneffei fungal strains and the 
results in the form of diameter of zone of inhibition are tabulated in Table 4.3.4. The 
antifungal screening data revealed that the compounds showed moderate activity. Among 
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the screened compounds 3d and 3f showed good fungicidal activity against C. albicans, 
A. fumigatus and P. marneffei fungal strains. 
Table 4.3,4. Antifungal activity of synthesized compounds (3a-f), 
Compounds 
3a 
3b 
3c 
3d 
3e 
3f 
Standard 
DMSO 
CA 
15.8 
16.1 
16.3 
22.9 
15.1 
23.9 
30 
-
Diameter of zone 
AF 
12.9 
13.1 
13.2 
22.8 
11.8 
20.6 
27 
-
of inhibition (mm) 
TM 
8.7 
9.9 
10.9 
17.1 
8.1 
17.1 
24 
-
PM 
7.1 
6.9 
7.1 
12.6 
7.2 
12.9 
20 
-
Positive control (Greseofulvin) and negative control (DMSO) measured 
by the Halo Zone Test (Unit, mm). CA= Candida albicans, AF= 
Aspergillus fumigatus, TM= Trichophyton mentagrophytes, PM= 
Penicillium marneffei. 
The Fig. 4,3.2 depicts the antifungal potency of synthesized compounds over 
reference drug Greseofulvin in terms of % inhibition. 
157 
3-Substituted-l,6-dihydro-l,2,4-triazin-5-(2H)-ones 
ro-gK-
% 
60 
50 -
40 
inhibition 30-
20-
10 
0 
a 
fl 
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DTM 
DPIVI 
3a 3b 3c 3d 3e 3f 
Compound 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. 
Fig 4.3.2. Percent inhibition of compounds 3a-fover reference drug against 
fungal strains. 
The MICs and MFCs of compounds 3a-f were determined and the results are 
given in Table 4.3.5. The data in Table 4.3.5 reveals that MFC of most of the 
compounds was two or three folds higher than the corresponding MIC results. 
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Table 4.3.5. MIC and MFC of synthesized compounds (3a-J). 
Compounds CA AF TM PM 
MIC MFC MIC MFC MIC MFC MIC MFC 
3a 50 100 100 >100 100 100 100 >100 
3b 50 100 50 50 50 100 50 100 
3c 25 25 25 50 25 100 25 100 
3d 12.5 25 12.5 50 25 50 25 50 
3e 100 100 100 >100 100 100 50 100 
3f 12.5 25 12.5 25 12.5 25 12.5 25 
Standard 6.25 25 12.5 12.5 6.25 25 12.5 25 
CA= Candida albicans, AF= Aspergillus fumigatus, TM= Trichophyton mentagrophytes, 
PM= Penicillium marneffei. MIC (i^g/ml) = minimum inhibitory concentration, i.e. the 
lowest concentration of the compound to inhibit the growth of fungus completely; MFC 
((xg/ml) = minimum fungicidal concentration, i.e., the lowest concentration of the 
compound for killing the fiangus completely. 
The antimicrobial screening data also revealed that the compounds 3a-f have 
produced a marked enhancement in the potency of the 1,2,4-triazinone analogs as 
antibacterial and antifungal agents. 
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4A Experimental 
The sources of all the fatty acids and instrumentation details are same as given in 
Chapter 1 (pg. 31). 
General procedure for the synthesis of 3-alkanyl/alkenyl/hydroxyl alkenyl-l,6-dihydro-
l,2y4-triazin-5-(2H)-one (3a-f) 
The fatty acid hydrazides, la-f (0.01 mol) and chloroacetamide, 2 (0.01 mol) were 
refluxed in DMF (180 ml) for 26-30 h. After the completion of the reaction (monitored 
by TLC), the reaction mixture was concentrated, cooled and poured in ice cold water 
(100 gm). The ^dgji^ triazinone whioh sqjarated out was filtered and dried. Further 
purification by column chromatography over silica gel using petroleum ether-diethyl 
ether mixture as eluent afforded the compounds 3a-f (Scheme 4.3.1). The novel 
compounds 3a-f were characterized from their spectral data. 
Spectroscopic Data 
3-(Dec-9'-enyl)-l,6-dihydro-l,2,4-triazin-5-(2H)-one (3a) 
Brown powder; Yield 78%; Mp 151-153 °C. 
IR (KBr): 3224, 2921, 1675, 1599 cm"'. 
'H NMR (400 MHz, CDCI3): 5 9.27 (s, IH, N/f), 7.42 (s, IH, N//), 5.71 (tdd, IH, 
^H-YH, "^-^ "^' ^-«. =*0-2 Hz, J„^,^ =17.0 Hz, CH2=C//-), 4.91 (dd, IH, J„^_„=\0.\ Hz, 
y„ _„ =2.2 Hz, HzC-CH), 4.84 (dd, IH, J,^_„=\6.1 Hz, J„^^„^=2.2 Hz, //fC^CH), 2.52 
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(s, 2H, QH2 of triazinone ring), 2.26 (t, 2H, J=1A Hz, CH2 a to ring), 1.95 (m, 2H, 
CH2=CH-C//2), 1.55 (m, 2H, C/Z p^ to ring), 1.24 (br.s, lOH, (C/Z^ Os)-
MS (ESI): m/z = 260.0 [M+Na] ,^ calculated = 260.1. 
Anal. Found: C, 65.45; H, 09.68; N, 17.56. C13H23N3O requires C, 65.79; H, 09.75; N, 
17.70%. 
3-(Z)-(Heptatadec-8'-enyl)-I,6-dihydro-l,2,4-tnazin-5-(2H)-one(3b). 
Brown solid; Yield 85%; Mp 150-153 ^C. 
IR (KBr): 3219,2920, 1680,1597 cm''. 
'HNMR (CDCI3): 5 9.55 (s, IH, NH), 8.02 (s, IH, NH), 5.31 (m, 2H, CH2-CH=CH-
CH2), 2.58 (s, 2H, CH2 of triazinone ring), 2.24 (t, 2H, J=7A Hz, CH2 a to ring), 1.99 
(m, 4H, C//2-CH-CH-C//2), 1.59 (m, 2H, CH2 p to ring ), 1.25 (br. s, 20H, (C//2)io), 0.87 
(dist. t, 3H, terminus C//j). 
MS (ESI): m/z = 358 [M+Na]^ calculated = 358.17. 
Anal. Found: C, 71.39; H, 10.74; N, 12.43. C20H37N3O requires C, 71.60; H, 11.10; N, 
12.52%. 
3-[(8% 11 'R)-ll '-Hydroxyoctadec-8'-enyl]-l,6-dihydro-l,2,4-triazin-5-(2H)-one (3c). 
Sticky Solid; Yield 67%; Mp 153-154 ''c. 
IR (KBr): 3224, 2925, 1732, 1597 cm''. 
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'HNMR (CDCI3): 5 9.45 (s, IH, N//), 8.04 (s, IH, N/f), 5.38 (m, 2H, CHi-CH^CH-CUi 
) , 3.57 (m, IH, C//-OH), 2.57 (s, 2H, CH2 of triazinone ring), 2.24 (t, 2H, J-7.5 Hz, CH2 
a to ring), 2.15 (m, IH, CU-OH), 2.01 (m, 4H, C//2-CH=CH-C//2 ), 1.55 (m, 2H, CH2 P 
to ring), 1.25 (br, s, 18H, (07/2)9), 0.87 (dist. t, 3H, terminus C/Zj). 
MS (ESI): m/z = 374 [M+Na]\ calculated = 374.16. 
Anal. Found: C, 68.05; H, 10.47; N, 11.77. C20H37N3O2 requires C, 68.34; H, 10.60; N, 
11.95%. 
3-f(8% 11 'Z)-8'-Hydroxyoctadec-ll'-enyl)-l,6-dihydro-l,2,4-triazin-5-(2H)-one (3d). 
Brown powder; Yield 78%; Mp 152-154 °C. 
IR (KBr): 3228, 2920, 1683, 1606 cm-'. 
^HNMR (CDCI3): 8 9.59 (s, IH, N/f), 8.00 (s, IH, N//), 5.34 (m, 2H, CH2-C//-C//-CH2 
), 3.58 (m, IH, C//-OH), 2.57 (s, 2H, CH. of triazinone ring), 2.25 (t, 2H, J=7.4 Hz, C//2 
a to ring), 2.01 (m, 4H, C//2-CH=CH-C//2), 2.12 (m, IH, CW-OH), 1.58 (m, 2H, C//213 
to ring), 1.29 (br, s, 18H, (€7/2)9), 0.87 (dist. t, 3H, terminus CHs). 
MS (ESI): m/z = 374 [M+Na]\ calculated = 374.16. 
Anal. Found: C, 61M; H, 10.40; N, 11.71. C20H37N3O2 requires C, 68.34; H, 10.60; N, 
11.95%. 
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3-Pentadec-l,6-dihydro-l,2,4-triazin-5-(2H)-one (3e). 
Brown powder; Yield 82%; Mp 148-150 °C. 
IR (KBr): 3207, 2920, 1678, 1596 cm"'. 
'HNMR (CDCI3): 8 9.38 (s, IH, N//), 8.00 (s, IH, N//), 2.56 (s, 2H, CH2 of triazinone 
ring), 2.20 (t, 2H, J=1A Hz, CH2 0.io ring), 1.61 (m, 2H, C//. |3 to ring), 1.25 (br, s, 24H, 
(CH2)\2l 0-87 (dist. t, 3H, terminus C/Zj). 
MS ^ E^/;.- m/z = 232 [M+Na]^ calculated = 332.15. 
Anal. Found: C, 69.71; H, 11.26; N, 13.45. CjsHjsNaO requires C, 69.86; H, 11.38; N, 
13.57%. 
3-fl-BromopentadecJ-l,6'dihydro-l,2,4-triazin-5-(2H)-one (3J). 
Brown powder; Yield 85%; Mp 150-152 °C. 
JR (KBr): 3228, 2920, 1678, 1596, 724 cm"'. 
'HNMR (CDCI3): 5 9.32 (s, IH, NH), 8.02 (s, IH, NH), 2.59 (s, 2H, CH2 of triazinone 
ring), 2.24 (t, 2H, 7=7.4 Hz, C//2a to ring), 1.60 (m, 2H, CH2 P to ring), 1.25 (br, s, 24H, 
iCH2)i2), 0.87 (dist. t, 3H, terminus CH3). 
MS (ESI): m/z = 411 [M+Na]^ calculated = 411.05. 
Anal. Found: C, 55.42; H, 08.76; N, 10.76. CgHasNsOBr requires C, 55.66; H, 08.81; N, 
10.81%. 
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Antibacterial studies 
The newly prepared compounds were screened for their antibacterial activity 
against Escherichia coli (ATCC-25922), Staphylococcus aureus (ATCC-25923), 
Pseudomonas aeruginosa (ATCC-27853), Streptococcus pyogenes and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion method^ '^^ .^ 
Ciprofloxacin was used as positive control. While the disk poured in DMSO was used as 
negative control. The susceptibility was assessed on the basis of diameter of zone of 
inhibition against Gram-positive and Gram-negative strains of bacteria. Inhibition zones 
were measured and compared with the controls. The bacterial zones of inhibition values 
are given in Table 4.3.2. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The minimum inhibitory concentrations (MICs) and minimum bactericidal 
concentrations (MBCs) are given in Table 4.3.3. 
Antifungal studies 
Antifungal activity was also done by disk, diffusion method. The antifungal 
activity was assayed against Candida albicans, Aspergillus fumigatus, Penicillium 
marneffei and Trichophyton mentagrophytes (recultured) by agar diffusion method^'''^l 
The fungal activity of each compound was compared with Greseofulvin which was used 
as a standard drug. Inhibition zones were measured and compared with the controls. The 
fungal zones of inhibition values are given in Table 4.3.4. 
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The minimum inhibitory concentrations (MICs) and minimum fungicidal 
concentrations (MFCs) as determined by broth dilution technique are given in Table 
4.3.5. 
The percent inhibition (% inhibition) values of antibacterial (Fig. 4.3.1) and 
antifungal (Fig. 4.3.2) activity for different synthesized compounds over reference drug, 
were calculated using the following formula 
% inhibition = ^ - ^ x 100 
a 
where a stands for the zone of inhibition of positive control (reference drug), 
and P stands for the zone of inhibition of synthesized compounds. 
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Fatty acid alkenoates 
5.1 Theoretical 
The esterification of carboxylic acids with alcohol is one of the most fundamental 
and important reactions in organic synthesis. The reaction gains its popularity due to the 
wide utility of esters in the field of organic, bio-organic and related fine chemical 
synthesis. The esters owing to their stability and easy interconvertibility serve to be the 
common intermediate in a large number of chemical reactions. 
The fatt><ester analogs have received little attention despite of the fact that such 
molecules have shown diverse biological activities such as anfioxidant\ antifeedent^, 
bacterial^, herbicidal'*, anti-inflamammatory^ and neuroprotective activities^. Some fatty 
acids have also been effectively used in the treatment of cardiovascular, dermatis^ 
hepatic and renal disorders*. Thus fatty acid esters, due to their/great^ biological 
importance can be explored as new pharmacophores for the development of potential 
pharmaceutical molecules. 
A large number of methods have been reported for the esterification of fatty 
acids . The esterification reaction is usually performed by reacting fatty acids with a 
suitable alcohol in presence of different catalysts. A large number of catalysts such as 
alkyl chloroformate and EtsN'", phenyl dichlorophosphate", Si02/NaHS04'^ amberlyst 
15'^ USY zeolite'\ MoOj/ZrOz'^ MgS04/H2S04'^ salycilic resin/FeCb'^ Si02'^ 
celite/CsF'^ dowex SOWXZ "^, beta zeolite^', H>hH^^ CH2N2 in ether^\ CH3S03H^^ 
S0Cl2^^ ZrCl4^^ PPh3/CH3CN/NC5H4-N=N-C5H4N", anhydride/iPr2NEt/(+)-
BTM/CH2CI2 etc. have been involved in this transformation. Inspite of the fact that a 
variety of catalyst are available the iV,A^-dicyclohexyl-carbodiiamide (DCC) remains the 
1 
most widely used because most of the reported methods suffer from |^om9 'drawback or 
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the other which include, the use of transition metal, long reaction time, high temperature 
etc. 
b 
Garazd et al?'^ reported the synthesis of 7-Boc-aminoacyloxy-3-phenoxy-2-
trifluoromethylchromone (ii) from 7-hydroxy-3-phenoxy-2-trifluoromethylchromone (i) 
and Boc-promoted amino acid using DCC and a catalytic amount of 4-
dimethylaminopyridine (DMAP) (Scheme 5.1.1). 
DCC/DMAP 
Boc-Ala 
I 11 
Scheme 5.1.1 
New organosilane compounds (v) containing cholesteryl group have been 
synthesized by esterification reaction between 3,3,5,5-tetramethyl-3,5-disila-4-oxa-
cyclohexane-1-carboxylic acid (iii) and (o-hydroxyalkyl cholesteryl carbonate (iv) in 
presence of DCC and DMAP. (Their ip^ase behaviours have also been investigated^*^ 
(Scheme 5.1.2). 
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H,C 
HaC-Si 
III 
HaC 
H3C—Si 
+ HO 
• ( ^ o A 
DCCDMAP 
H3C °^(-4o-^o 
IV 
n=l-4 
Scheme 5.1.2 
Sonpatki et al}^ developed an improved method by synthesizing new keto-ester in 
presence of DCC and DMAP. 2-Bromothiophene (vi), succinic anhydride and anhydrous 
aluminium chloride in nitrobenzene were stirred at -5 to -10 °C to yield the y-keto acid 
(vii). The y-keto acid reacted with dodecan-1-ol in presence of DCC and DMAP in 
dichloromethane to give the y-keto ester (vlii) (Scheme 5.1.3). 
JO 
(i) Succinic ahjydride 
AICI3 
(ii)18%aq. HCl 
Dodecan-1-ol 
DCC,DMAP 
CH2CI2 
H25C12O 
VI Vl l 
Scheme 5.1.3 
VIII 
173 
Fatty acid alkenoates 
The synthesis of liquid crystalline promoter (x) was achieved by Dardel et al. by 
the reaction of (ix) with 4-hydroxycyanobiphenyl in presence of DCC and DMAP at 
room temperature (Scheme 5.1.4). 
"^--t^o-ryj HO—( ' \ ^ \ CN , . , ^ \ / X " ' \=/\^/ V / \ 
\ = / \)H DCC/DMAP ^ ' ^ ^ 
CHCl, 
CN 
IX X 
Scheme 5.1,4 
A new approach to the design of systems for specific and nonspecific transport of 
nucleoside analogs using spacers with moderately labile ester bonds has been 
developed . Azidothymidine (xii) and geraniol monosuccinate (xi) in anhydrous ethyl 
acetate; DCC and DMAP to yield geraniol-azidothymidine succinate (xiii) as the major 
product, which possessed considerable antiviral potential (Scheme 5.1.5). 
XI 
R= 
XII 
HoC 
Xl l l 
Scheme 5.1.5 
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Greetings et al. synthesized natural compounds like hydroxytyrosol (xiv) and 
reacted them with three equivalents of steric acid (xv) and DCC in presence of DMAP to 
obtain a triester (xvi) (Scheme 5.1.6). 
o 
+ 3 H3C, 
XIV XV XVI 
Scheme 5.1.6 
The synthesis of 4-benzyloxybenzyl crotonate (xix) was achieved by condensing 
4-benzyloxybenzyl alcohol (xvii) and crotonic acid (xviii) in presence of DCC and 
DMAP in dichloromethane under argon at room temperature '^* (Scheme 5.1.7). 
H3C—r. 0 
OH 
P D C C D M A P 
XVII XVIII XIX 
Scheme 5.1.7 
The synthesis and liquid crystal properties of aryl esters of laterally substituted 5-
pyrimidinecarboxylic acids has been reported by Mikhaleva^^ The addition of DMAP 
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and DCC to a suspension of acid (xx) and the appropriate phenol yielded the aryl ester 
(xxi) (Scheme 5.1.8). 
R R 
N=< 
XX xxi 
R= CH3, OCH3 Ar= 4-BU-C6H4, 4-CN-C6H4 
Scheme 5,1.8 
Abd-El-Aziz and coworkers reported the functionalization of azo dye moieties 
with organoiron complexes. The organoiron benzothiazole complex (xxiv) was formed 
by a condensation reaction of cyclopentadienyliron complex (xxii) containing a carbonyl 
group with the terminal hydroxy group of the benzothiazole azo dye (xxiii) using DCC 
and DMAP (Scheme 5.1.9). 
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CI, 
^^X^ HO 
I^eTF," 
H,C 
u-TV-^. ^-/^ 
^ \-ii 
DCCDMAP 
Scheme 5.1.9 
Kavganko et al}^ synthesized the esters (xxvi) in excellent yields by reacting 1-
(4-hydroxyphenyl)-2-octen-l-one (xxv) with aromatic acid in presence of DCC and 
DMAP (Scheme 5.1.10). 
O Q 
C5H1-1 ArCOOH 
DCCDMAP 
C5H11 
xxv XXVI 
Ar= 4-F-C6H4, 4-NC-C6H4,4-C3H7-C6H4, 4-C6H13-C6H4 
Scheme 5.1.10 
The synthesis and anti-cancer activity of fatty acid esters of podophyllotoxin 
against human cancer cell lines has been described^*. The coupling of a (o-hydroxy fatty 
acid (xxviii) with C4-a-hydroxy function of podophyllotoxin (xxvii) in dry 
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dichloromethane, DMAP and DCC gave the ester (xxix) in quantitative yields (Scheme 
5.1.11). 
O + R A ° DCC O bn DMAP 
XXVII XXVIII XXIX 
R= (CH2)9-OH, (CH2)n-OH, (CH2),4-OH, (CH2),5-OH 
Scheme 5.1.11 
4-Substituted-aryl-16-bromohexadecanoate (xxxii) were prepared from readily 
available starting material by Angelova and coworkers^^. 16-Bromohexadecanoic acid 
(xxx) acid, benzyl alcohol (xxxi) and DMAP were stirred in dry ether under argon 
atmosphere. DCC was added in a few portions in solid and the mixture was stirred at 
room temperature to obtain the desired ester (xxxii) (Scheme 5.1.12). 
O 
Ar DMAP ^^ 1 ^ 
O 
Br, OH + HO-
13 
"Ar 
xxx xxxi XXXII 
R= 4-OCH3-C6H4, 4-NO2-C6H4, 4-CN-C6H4, 4-CI-C6H4 
Scheme 5.1.12 
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Tuchnaya et al.'^ reported the synthesis of mixed disuccinates of 1,12-
dodecanediol, 3'-azido/2',3'-didehydro-3-deoxythyniidine (xxxv) using DMAP and DCC 
(Scheme 5.1.13). 
0 
RO 
OH 
XXXV 
H3C o ^ K . - ^ H3C n ^ K . ' - ' 
r41 
Scheme 5.1.13 
Yuan et al.'*' synthesized 12a-deoxoartemisinyl ester 4'-0-demethyl-4p-(4"-
nitroanilino)-4-desoxypodophyllotoxin (xxxviii). A mixture of 4'-0-dimethyl-4p-(4"-
nitroanilino)-4-desoxypodophyllotoxin (xxxvi), artesunate (xxxvii), DMAP and DCC in 
dichloromethane was stirred for 6 h at 0°C to obtain the title ester, which acted as a 
topoisomerase inhibitor possessing multi target specificity (Scheme 5.1.14). 
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xxxvi xxxvu xxxvui 
Ar= 4-NO2-C6H4 
Scheme 5.1.14 
The pyridine acid ester derivatives of podophyllotoxin and 4'-
demethylepipodophyllotoxin have been prepared and assessed for their antitumor 
activities'*^ (Scheme 5.1.15). 
+ Ar - ^ 
DCC 
OH DMAP 
xxvii, xxxix xL xLi 
R= CH3, H Ai= 4-C5H4N, 3-(2-Cl)-C5H3N, 3-(6-Cl)-C5H3N 
Scheme 5.1.15 
r43 Ponedel'kina et al. obtained the azidothymidine hemisuccinate (xLiii) by the 
reaction of azidothymidine (xii) with succinic anhydride (xLii) in presence of DMAP. 
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The carboxy group was further activated by the transformation of hemisuccinate (xLiii) 
to A^-hydroxysuccinimide ester (xLv) via reaction with an equimolar amount of A'-
hydroxysuccinimide (xLiv) and DCC at 0-20 °C for 10-20 min (Scheme 5.1.16). 
Xll xLii xLiii 
u A 
I N—O 
xLiii + 
A DCC 
N—OH 
W CH,C1, 
O 
xLiv xLv 
r44 
Scheme 5.1.16 
Koskinen et al.'*'* treated the alcohols (xLvi) with monoester of malonic acid 
(xLvii) in presence of DCC and DMAP to provide the corresponding malonates (xLviii) 
(Scheme 5.1.17). 
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R, 
R-
OH 
+ HO ^ v ^ ^ORg DCCDMAP^ ^^ 
HoC 
xLvi 
Ri= 
o o 
xLvii 
CH2CI2 
Ro O O 
O OR-, 
CH, 
.CH, .CH, 
Scheme 5.1.17 
R^= 
xLviii 
w // 
CH, 
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5.2.1.Synthesis, Characterization and Preliminary 
Antimicrobial Activity of 7-Hydroxy-coumarin 
Derivatives 
Morbidity and mortality because of enteric bacterial infections are the major 
health problems in some areas like Indian subcontinent, portions of South America and 
tropical fractions of Africa'* .^ Every year millions of people are killed due to food 
poisioning, rheumatic, salmonellosis and diarrhea caused by some Gram-positive and 
Gram-negative bacterial strains. The pharmacological drugs available for the treatment of 
above diseases are either too expensive or have undesirable side effects or 
contraindicatio^f^. Furthermore, some microbial strains resistant to the available drugs 
have also begun to appear. Therefore, it is desirable to search for new lead molecules 
which can be effectively used against microbial infections. 
Natural plant drugs are frequently considered to be less toxic and freer from side 
effects than synthetic ones. Among the most significant classes of natural compounds, an 
important position is occupied by oxygen-containing heterocylic compounds, coumarins. 
Coumarin is a parent organic compound of a class of naturally occurring phytochemicals 
found in many plant species. They form an important group of organic compounds that 
are used as additives to food and cosmetics*^, optical brightening agents'^ ^ and dispersed 
fluorescent and laser dyes^". The derivatives of coumarin usually occur as secondary 
metabolites in various plant species and are found to act as plant growth regulators '. 
*Research paper entitled "7-Hydroxy-coumarin derivatives: synthesis, characterization and 
preliminary antimicrobial activities" is published. (Nida N. Farshori, Mudasir R. Banday, Anis 
Ahmad, Asad U. Khan, Abdul Rauf, Med. Chem. Res., DOI 10.1007/s00044-010-9347-9). 
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7-Hydroxy coumarin (7-HC); a benzopyrone in nature, is an /elite /class of 
compounds. It is a major human metabolite; which plays a role as dietary antioxidant. 
Coumarin and its derivatives are biologically active compounds and have found 
application in several therapeutic areas. Medically, coumarin glycosides (eg. Apterin, 
xLix) have been shown to dialate the coronary artery and also found to possess anti-
tumor and antimetastatic activities'^. Skimmin (7-O-B-glucopyranosylumbeliferone, L), 
an 0-glycosylated derivative of coumarin is found to show promising neuroprotective 
effects . Dicumarol, another coumarin glycoside better known as warfarin (Li), has 
found commercial application as an anticoagulant '^*. 
GIcO^ ^y^ ^ 0 ^ / O 
Apterin (xLix) 
Coumarin Glycosides, 
Skimmin (L) 
R= NHAc, OEt, COjEt or 
COOH: n=l or 2 
Warfarin (Li) Lipid Lowering Agent (Lii) 
Biologically important coumarin derivatives 
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The coumarin heterocyclic ring is a common feature of various bioactive 
compounds such as calanoHdes A & B (Liii, Liv), which act as HIV protease inhibitors 
and AChE inhibitors'^. Recent studies have revealed that coumarin and its derivatives 
exhibit several other medicinal applications such as anti-HIV and anti-tumor'^, 
antiamoebic , tubercluostatic , antimicrobial'^, insecticidal^^, anthelmintic*', 
hypnotics*^, blood glucose reducing agents*'' and lipid-lov '^ering agents*"* (Lii). 
Optimization of coumarin based structures has resulted in marketed medicines such as 
novobiocin and chlorobiocin, commonly used as antibiotics. Further, it has also been 
found that other coumarin compounds, after suitable structural modification can be used 
as drugs and incorporation of the coumarin nuclei may be am important synthetic strategy 
in drug discovery'*''***. 
H3C 
CHq 
0 - ^ 0 
Calanolide A (Liii) Calanolide B (Liv) 
Coumarin derivatives as anti-HIV agents. 
Bearing in mind the wide range of bioactivities associated with coumarins and 
fatty-ester analogs it was thought worthwhile to synthesize new coumarin esters. Thus the 
purpose of the study was to synthesize new coumarin esters with long chain (C-11 or C-
18) acid incorporated at C-7 hydroxy group of the coumarin and to find their novel 
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bioactivity by an in vitro evaluation against a panel of Gram-positive and Gram-negative 
strains of bacteria and some fungal strains. 
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5.2.2. Results and Discussion 
Fatty acids and their derivatives have been reported as antimicrobial agents^^. It 
is expected that the incorporation of the hydroxy and non-hydroxy FA chain may 
increase the antimicrobial activity of certain organic moieties**. The present study is 
based on the synthesis, characterization and evaluation of antimicrobial activities of 7-
HC derivatives derived from different fatty acids. A typical procedure in a single step 
involves the reaction of 7-hydroxy coumarin with fatty acid in the presence of DCC and 
4-dimethyl aminopyridine (DMAP) in dichloromethane by stirring at room temperature 
to fiamish corresponding 7-0-coumarinyl alkenoates (Scheme 5.2.2.1). The completion 
of the reaction was checked by thin layer chromatography (TLC). The reaction time 
varied from 2-3 h. The purity of the compounds was checked by TLC and the 
compounds under the study were characterized by the spectral data. 
« - < 
1-4 
O 
+ 
OH HO' 
DCC/DMAP X. 
• ^ « = ^ o - ^ o ' 5 = " ^ ^ 0 
6-9 
O ^ ^ O 
Scheme 5.2.2.1. Synthesis of 7-0-coumarinyl alkenoates (6-9). 
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Table 5.2.2.1. 7-0-cumarinyl alkenoates, 6-9. 
Compound R Yield 6-9 (%) 
l<f,6 *^ E 9 1 
^ ( > - s = ^ ^ " ^ 
2^ 7 6 ^'5 89 
¥ 
V 
•46H ^ 85 
OH 
CH, 
3 '^6 87 
As evident from the Table 5.2.2.1, the scope of the reaction using olefinic 
(internal and terminal) and hydroxy fatty acids was found to be good and the products 
6-9 (7-0-coumarinyl alkenoates) were obtained in excellent yields. It may also be 
observed that the yields are independent of the substituent present in the precursor. 
In general, the IR spectra showed ester peak at 1729 cm"' and CH2 (methylene) 
peak at 2921 and 2849 cm"'. In the ' H N M R spectra, the signals of the respective 
protons of the prepared derivatives were verified on the basis of their chemical shifts, 
multiplicities, and coupling constants. The spectra of all the compounds showed peaks 
at d 6.39-7.69 ppm corresponding to the protons of 7-hydroxy coumarin. The '^ C NMR 
spectra of all the compounds were also in good agreement. Characteristic molecular ion 
peaks [M+Na]^ was observed for all the compounds under study. A detailed spectral 
description for compound 6 is discussed below. 
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IR spectrum of compound 6 revealed characteristic band at 1729 c m ' (ester 
C-O stretching). In the ' H - N M R the olefmic protons, CirH2=Cio-H were observed at 
dH 5.81 (tdd, IH, J,^._,.= 6.8, J,^._„^= 16.8, J.^'-nr 10-4, CH2=C//-), 4.99 (dd, IH, 
J^^.,o.= 16.8,J^^_^^= 3.2, //zC=CH), 4.93 (dd, IH, J^^_,„,= 10.4, J„^_„^= 3.2, 
^£C=CH-) and were correlated with observations in the '^ C NMR which gave signals 
at dC 139.18 and 114.24 respectively. Besides these a characteristic carbon signal for 
the fatty acid chain at dC 171.68 (d-, ester C=0) was recorded. The structure was 
further supported by its mass spectral data, which showed a molecular ion peak at 
[M+Na]^ 351.2 consistent with the molecular formula C20H24O4. The COSY data also 
gave good support to the assigned structure. Similarly other compounds were 
characterized from their spectral data. Spectral studies have illustrated that the change 
in the nature of FA at C^ has not significantly influenced the pattern of proton and 
carbon signals of the 7-HC moiety. 
A variety of acylated 7-hydroxycoumarins were investigated in the early 1970s 
for antibiotic and antifungal activity^ .^ Acyl groups in the study included acetyl, 
proparJ^ k l^ and butan^yl. These compounds were found to possess activity against a 
number of fungal strains (MIC approximately 125 ug/ml) and Gram negative bacteria 
(MIC sub 500 ug/ml). It was observed that the ester derivatives of 7-hydroxycoumarins 
increased the antimicrobial activity of 7-hydroxycoumarin. Thus it is expected that the 
use of long chain hydroxy and non-hydroxy acid groups can fUrther increase the 
antimicrobial potency of the coumarin ester derivatives. 
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Taking in account the observations stated above, all the newly synthesized 
compounds were screened for their in vitro antimicrobial potency against an assortment 
of three Gram-positive bacteria Bacillus subtilis (ATCC 6501), Staphylococcus aureus 
(ATCC-25923), Streptococcus pyogenes (reculured), three Gram-negative bacteria 
Pseudomonas aeruginosa (ATCC-27853), Salmonella typhimurium (recultured), 
Escherichia coli (ATCC-25922) and four strains of fungus Candida albicans (ATCC-
24433), Candida krusei (ATCC-6528), Candida parapsilosis (ATCC-22019) and 
Cryptococcus neoformans (recultured), by the disk diffusion method and measured by 
Halo Zone Test^ °" ^ . The MIC of synthesized compounds against bacterial and fungal 
strains was performed by macro dilution test and the results were recorded visually and 
spectrophotometrically. The screening results for the antibacterial and antifungal 
activity have been summarized in Tables 5.2.2.2 and 5.2.2.3. 
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The investigation of antibacterial screening data revealed that all the tested 
compounds showed moderate to good bacterial inhibition. The data pertaining to 
Tables 5.2.2.2 and 5.2.2.3 reveals that compounds 6-9 have significant effect on the 
antibacterial profile of Gram-positive bacteria. This higher susceptibility of Gram-
positive bacteria may be attributed to the absence of the unique outer peptidoglycon 
membrane, which leaves the bacterial wall permeable to these derivatives. Compounds 
9 showed good inhibition against S. pyogens, S. aureus and E. coli species at 32)ig/ml 
where as compound 8 showed good inhibition against S. aureus at 32 ng/ml 
concentrations. Compounds 8 and 9 showed promising antibacterial activity nearly 
equivalent to that of standard drug (Chloramphenicol) against most of the bacterial 
strains. 
The investigation of antifungal screening data revealed that all the tested 
compounds showed moderate to good fungal inhibition. Compound 8 showed good 
antifungal activity against all strains of fungi. Compound 9 exerted significant 
inhibitory activity nearly equivalent to that of standard drug (Fluconazole) against C. 
parapsilosis at 8 |Jg/ml, against C. neoformans at 16 fig/ml and against C. albicans at 2 
Hg/ml. 
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5.2.3. Experimental 
The sources of all the fatty acids and instrumentation details are the same as 
chapter 1 (pg. 31). 
General procedure for the synthesis of fatty acid derivatives of 7-hydroxy-coumarin 
(7-O-coumarinyl alkenoates, 6-9) 
A solution of FA (5mmol), DCC (5.5mmol), and 7-hydroxy coumarin (5mmol) 
in dichloromethane (50mL) with catalytic amount of DMAP were stirred mechanically 
at room temperature until esterification was complete. The A'iA^-dicyclohexylurea was 
filtered off and the filtrate was washed with water (3x50 mL), 5% acetic acid (3x50 
mL), again with water (3^50 mL) and then dried over anhydrous sodium sulphate. The 
solvent was removed under reduced pressure to give the esters 6-9 (Scheme 5.2.2.1) 
which were chromatographed over a column of silica gel using n-hexane-ethyl acetate 
(94:6, v/v) as eluent. All these novel compounds were characterized from their spectral 
data. 
Spectroscopic data 
7-O-Coumarinyl undec-10-enoate (6) 
White powder; Yield: 91%; Mp 168 °C. 
/i?(KBr): 3080, 2921, 2849, 1729, 1624, 1400, 1269, 1122 cm"'. 
ESI-MS found [M+Na]^ 351.2; C20H24O4 [M+Na]* requires 351.17. 
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The 'H N M R , '^C N M R and COSY data is given in Table 5.2.3.1. 
7-0-Coumarinyl (9Z)-octadec-9-enoate (7) 
Viscous solid; Yield: 89%. 
/i?(KBr): 3120, 2921, 2849, 1708, 1651, 1405, 1270, 1122 cm'. 
ESI-MS found [M+Na]^ 449.3; C27H3g04 [M+Naf requires 449.28. 
The 'H NMR, '^ C NMR and COSY data is given in Table 5.2.3.2. 
7-0-Coumarinyl (9Z,12R)-12-hydroxyoctadec-9-enoate (8) 
Viscous solid; Yield: 85%. 
IR (KBr): 3384, 3080, 2920, 2858, 1732, 1618, 1401, 1267, 1122 cm"'. 
ESI-MS found [M+Na]^ 465.3; C27H38O5 [M+Na]^ requires 465.27. 
The 'H NMR, '^ C NMR and COSY data is given in Table 5.2.3.3. 
7-0-Coumarinyl (12Z,9R)-9-hydroxyoctadec-12-enoate (9) 
Viscous solid; Yield: 87%. 
IR (KBr): 3421, 3002, 2920, 2852, 1736, 1639, 1396, 1270, 1122 cm"', 
ESI-MS found [M+Na]^ 465.3; C27H38O5 [M+Na]^ requires 465.27. 
The ' H NMR, '^ C NMR and COSY data is given in Table 5.2.3.4. 
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Antibacterial studies 
The in-vitro antibacterial activities of 6 to 9 were tested using the bacterial 
cultures of Bacillus subtilis (ATCC 6501), Staphylococcus aureus (ATCC-25923), 
Streptococcus pyogenes (reculured), Pseudomonas aeruginosa (ATCC-27853), 
Salmonella typhimurium (recultured), Escherichia coli (ATCC-25922) and fungal 
cultures of Candida albicans (ATCC-24433), Candida krusei (ATCC-6528), Candida 
parapsilosis (ATCC-22019) and Cryptococcus neoformans (recultured), by the disk 
diffusion method^'''^'. Chloramphenicol (30 [ig) was used as positive control. While the 
disk poured in DMSO was used as negative control. The susceptibility was assessed on 
the basis of diameter of zone of inhibition against Gram-positive and Gram-negative 
strains of bacteria. Inhibition zones were measured and compared with the controls. 
The bacterial zones of inhibition values are given in Table 5.2.2.2. 
The minimum inhibitory concentration (MIC) was assessed by the macro dilution test 
using standard inoculums of 5 X 10^  c.f.u. /ml. Initially the compounds were dissolved 
in DMSO after that serial dilution of the test compounds were set to final 
concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2 and 1 ^g /ml. To each tube was 
added 100 ^1 of 24 h old inoculums. The growth was monitored visually and 
spectrophotometrically. The lowest concentration (highest dilution) required to arrest 
the growth of bacteria was regarded as minimum inhibitory concentration (MIC). The 
minimum inhibitory concentrations are given in Table 5.2.2.3. 
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Antifungal studies 
Antifungal activity was also done by disk diffusion method^ .^ For assaying 
antifungal activity Candida albicans, Candida knisei, Candida parapsilosis, 
Cryptococcus neoformans were used as the test strains. Fluconazole (30 jig) was used 
as positive control. While the disk poured in DMSO was used as negative control. The 
susceptibility was assessed on the basis of diameter of zone of inhibition against 
albicans and non-albicans strains of fungi. Inhibition zones were measured and 
compared with the controls. The fixngal zones of inhibition values are given in Table 
5.2.2.2. 
The minimum inhibitory concentration (MIC) was assessed by the macro 
dilution test using standard inoculums of 1.6 X 10 -6 X 10* c.f.u. /ml. Initially the 
compounds were dissolved in DMSO after that serial dilution of the test compounds 
were set to final concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2 and 1 [jg /ml. To 
each tube was added 100 |J1 of 48-72 h old inoculums. The growth was monitored 
visually and spectrophotometrically. The lowest concentration (highest dilution) 
required to arrest the growth of fungi was regarded as minimum inhibitory 
concentration (MIC). The minimum inhibitory concentrations are given in Table 
5.2.2.3. 
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5.3.1 Synthesis and in vitro Antimicrobial Activity of p-
Sitosterryl Esters of Hydroxy and Non-hydroxy Olefinic 
Fatty Acids* 
Phytosterols are bioactive compounds found in almost all plants as structural 
component of plant membranes. Their function appears to be to control membrane 
fluidity, permeability and signal transduction''*. They are structurally similar and 
functionally analogus to the cholesterol in vertebrate animals. Plant contains more than 
200 different types of phytosterols, the most abundant being P-sitosterol (90%). There 
has been an increasing interest in the use of phytosterols. They reduce the serum low-
density lipoprotein (LDL) cholesterol levels by means of reduction in absorption of 
cholesterol and thus protect against cardiovascular diseases through their 
hypocholesterolemic action'^''^. The |3-sitosterol and lactose P-sitosterol are found to 
have an inhibitory effect on the pathophysiological process in asthama". The P-sitosterol-
3-0-glucopyranoside (Lv), isolated from natural source was found to be a promising 
candidate for b^terial sortase inhibitor'^. The non-glucosidic P-sitosterols are found 
effective against benign prostatic hyperplasia (BPH) and help in increasing the urine flow 
thereby improving the urologic symptoms''. The in vitro studies have suggested that it 
may show anti-cancer activity against colon cancer (HT-29) cells*", prostrate cancer 
(LNCaP) cells*' and breast cancer (MDA-MB-231) cells by inhibition of tumor growth 
and induction of apoptosis in cancerous cells*^. 
•Research paper entitled "DCC/DMAP mediated esterification of hydroxy and non-hydroxy 
olefinic fatty acids with fi-sitosterol: In vitro antimicrobial activity" is published. (Nida N. 
Farshori, Mudasir R. Banday, Zeeshan Zahoor, Abdul Rauf, Chin. Chem. Lett., 2010, 21, 646-
650). 
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P-Sitosterol-3-0-glucopyranoside(Lv) 
(bacterial sortase inhibitor) 
P-Sitosterol has also been found to exert estrogenic effects in mammals^^ and 
clastogenic effect on mitotically dividing chromosomes of bone marrow erythroblasts. 
The genotoxic effects of thermally oxidized derivatives of p-sitosterol have also been 
studied^ "*. It has been suggested to prevent temporary immune weakness that typically 
occurs during recovery from endurance exercise*^. In addition, the purified P-sitosterol 
has applications in biological studies and they have been reported to exert anti-
atherosclerotic^^, anti-inflammatory^' and anti-oxidative^^ activities in animals and have 
been found to play an important role in multi stage treatment of HIV^'. 
Furthermore, the fatty acid esters of phytosterols have water holding property and 
are widely used as ingredients of cosmetics and bath additives^. Due to their 
physiological activity of lowering plasma cholesterol concentrations, the esters of 
phytosterols are being incorporated into a growing spectrum of functional foods, 
including margarine blended with fatty acid sterol esters (FASE) and salad oil dressing 
with added sterol^'. 
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In view to the above mentioned pharmacological applications of phytosterols and 
in continuation of our search of biologically active molecules, the design, synthesis and 
evaluation of antimicrobial potency of hitherto unknown p-sterryl esters fatty acids has 
been carried out. 
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5.3.2. Results and Discussion 
The application of catalysts in organic chemistry for conducting synthetic 
reactions at highly accelerated rates has been an emerging technique. In fact use of 
catalysts has become popular among synthetic organic chemists for improving classical 
organic reactions, shortening reaction time and/or improving yields, as well as for 
promoting new reactions. To explore the probability of getting the pharmacophoric 
important moieties from natural products in higher yields and in shorter reaction time, our 
attention has turned to employ the use of catalyst. 
3P-SitosterryI aikenoates 11-14 were synthesized in quantitative yields by 
condensing long chain fatty acids with P-sitosterryl in dichloromethane using DCC and a 
catalytic amount of DMAP. The reaction was carried out at room temperature (Scheme 
53.2.1). 
205 
Fatty acid alkenoates 
H-,C 
HaC, 
CH, 
DCC/DMAP 
k ^"3 CICH-Cl o 
CH3 ' M 
1-4 10 11-14 
Compound 
U l 
2,12 
R 
^ ^ H . 
-9^ =.^ ^^ ^ 
Compound 
3,13 
4,14 
R 
OH OH 
CH, 
CH, 
Scheme 5.3.2.1. Synthesis of fatty acid analogs of fi-sitosterol (11-14). 
The generality and scope of the synthetic procedure was demonstrated by 
subjecting P-sitosterol with olefinic (terminal and internal) and hydroxy olefinic 
carboxylic acid derivatives. The use of catalyst for the synthesis of fatty alkenoates 
provided higher yield of products. In most of the cases the yield of product was 74-88%. 
1 1 - 1 
The newly compounds were characterized by IR, 'H NMR, ' X NMR, Mass 
spectra. IR absorptions characteristic of ester carbonyl was observed in all the newly 
synthesized compounds. 
IR spectrum of compound 11 revealed characteristic band at 1732 cm~' (ester C-
O stretching). The two olefinic protons, CirH2=CioH and Ce-H were observed at 6H 
5.81 (tdd, IH, ^^.„c„^= 6.7 Hz, J„_^^ =10.1 Hz, J^_^^=16.9 Hz, CH2=C//-), 5.36 (d, 
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\\\,J= 4.8 Hz, Ce-H), 4.98 (dd, IH, J„^_„=\Q.\ Hz, J„^_„^=2.% Hz, //zC=CH), 4.93 
(dd, IH, J;,^_^=16.9 Hz, J„^_„^=2.% Hz, HBIC=C\\-) and correlated with observations 
at 8C 114.23, 122.67, 139.77, 139.27 respectively. A multiplet at 5H 4.61 was observed 
for Csp-H and correlated with observation at 5C 73.75. Besides few other significant 
carbon signals for the fatty acid chain characteristic peak at 6C 174.07 (Ci, ester C=0) 
was recorded. Spectral studies have illustrated that the change in the nature of fatty aids 
at P-C3 has not significantly influenced the pattern of proton and carbon signals of the P-
sitosterol moiety. Similarly other compounds were characterized from their spectral data 
detailed in experimental section. 
Antibacterial studies 
The newly synthesized compounds were further screened for their in vitro 
antibacterial activity against Escherichia coli (K-12), Staphylococcus aureus (ATCC-
25923), Salmonella typhimurium (MTCC-98), Bacillus subtilis (ATCC 6051) bacterial 
strains by disc diffusion method^°'^ ''^ ^. Chloramphenicol (30 ^g) was used as positive 
control. While the disk poured in DMSO was used as negative control. The susceptibility 
was assessed on the basis of diameter of zone of inhibition against various Gram-positive 
and Gram-negative strains of bacteria. Inhibition zones were measured and compared 
with the controls. The bacterial zones of inhibition values are given in Table 53.2.1. 
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Table 5.3.2.1. Antibacterial activity of the newfy synthesized fatty alkenoates (11-14). 
Compounds 
11 
12 
13 
Gram positive 
B. subtilis 
17.8±0.4 
15.6±0.3 
21.9±0.8 
Diameter of 
; bacteria 
iS". aureus 
17.3±0.5 
15.2±0.4 
20.6±0.3 
zone of inhibition (mm). 
Gram negative bacteria 
E. coli 
18.1 ±0.6 
16.5±0.2 
25.2±0.3 
S. typhimurium 
16.3±0.4 
14.6±0.3 
21.7±0.4 
14 20.1±0.2 20.2±0.3 23.9±0.2 n.9±Q.9 
Standard 23.0±0.2 22.0±0.2 27.0±0.2 19.at0.2 
DMSO - - -
Positive control (standard); Chloramphenicol and negative control (DMSO) measured by 
the Halo Zone Test (Unit, mm) 
Minimum inhibitory concentrations (MICs) and minimum bactericidal 
c(Hicentration (MBCs) were also determined for the title compounds by broth dilution 
technique. The lowest concentratimi (highest dilution) required to arre^ the growth of 
bacteria was regarded as MIC. MBC was defined as the lowest drug concentration at 
which 99.9% of the inoculums were killed. The MIC and MBC for die newly syirthesized 
compounds are given in Table S3JL.2. 
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Table 5.3.2.2. MIC and MBC results of newly synthesized fatty alkenoates (11-14). 
Compounds Gram positive bacteria Gram negative bacteria 
B. subtilis S. aureus E. coli S. typhlmurium 
MIC MBC MIC MBC MIC MBC MIC MBC 
11 12.5 25 12.5 12.5 12.5 25 12.5 25 
12 25 25 25 50 12.5 50 25 50 
13 6.25 12.5 12.5 12.5 6.25 12.5 25 6.25 
14 6.25 25 12.5 12.5 6.25 12.5 25 6.25 
Standard 6.25 12.5 6.25 12.5 6.25 12.5 6.25 12.5 
MIC (ng/ml) = minimum inhibitory concentration, i.e. the lowest concentration of the 
compound to inhibit the growth of bacteria completely; MBC (^g/ml) = minimum 
bacterial concentration, i.e., the lowest concentration of the compound for killing the 
bacteria completely. 
Positive control: Chloramphenicol 
The investigation of antibacterial screening data revealed that all the tested 
compounds showed moderate to good bacterial inhibition. Compounds 11 showed good 
inhibition against B. Subtilis, S. aureus, S. typhimurium and E. coli wiiile as compound 12 
was moderately active against S. typhinmrium. In most of the cases compounds 13 and 14 
showed good antibactoial activity nearly equivalent to that of Chloramphenio)!. The 
MBC of few cmnpounds was found to be the same as MIC but in most of the compounds 
it was two or three or four folds higher than the corresponding MIC results 
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Antifungal studies 
In other set of experiments, the compounds 11-14 were screened for their 
antifijngal activity. Antifungal activity was also done by disk diffusion method^ ' . For 
assaying antifungal activity Candida albicans, Aspergillus niger, Penicillium mameffei 
and Heliminthosporum oryazae fungal strains were used. The fungal activity of each 
compound was compared with Greseofulvin which was used as standard drug. Inhibition 
zones were measured and compared with the controls. The fungal zones of inhibition 
values are given in Table 5.3.23. 
Table 5.3.2.3. Antifungal activity of newly synthesized fatty aikenoates (11-14). 
Compounds 
11 
12 
13 
14 
Standard 
DMSO 
Diameter of zone 
CA 
26.1±0.3 
22.2±0.4 
23.1±0.7 
23.6±0.4 
30.0±0.2 
-
AN 
23.1±0.2 
20.6±0.4 
22.3±0.7 
20.8±0.2 
27.0±0.2 
-
of inhibition (mm) 
HO 
18.6±0.4 
21.2±0.2 
19.9±0.6 
19.0±0.3 
24.0±0.3 
-
PM 
17.3±0.5 
16.2±0.3 
15.1±0.9 
15.2±0.2 
20.0±0.5 
-
Positive control (Greseof\iIvin) and negative control (DMSO) measured by the Halo Zone 
Test (Unit, mm). 
Minimum inhibitory concentrations, MICs (the lowest concentration (highest 
dilution) required to arrest the growth of fungus) and minimum fungicidal concentration, 
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MFCs (the lowest drug concentration at which 99.9% of the inoculums was killed) were 
also determined and the results have been tabulated in Table 5.3.2.4. 
Table 5.3.2.4. MIC and MFC results of newly synthesized fatty alkenoates (11-14). 
Compounds CA AN HO PM 
MIC MFC MIC MFC MIC MFC MIC MFC 
11 12.5 25 25 50 25 50 25 100 
12 12.5 25 12.5 25 12.5 25 12.5 50 
13 6.25 25 6.25 25 12.5 25 25 50 
14 12.5 50 25 50 25 50 25 100 
Standard 6.25 12.5 6.25 12.5 6.25 12.5 6.25 12.5 
CA= Candida albicans, AF= Aspergillus niger, HO= Heliminthospomm oryazae, PM= 
Penicillium mameffei. MIC (Mg/ml) = minimum inhibitory concentration, i.e the lowest 
concentration of the compound to inhibit the growth of fungus completely; MFC (ng/ml) 
= minimum fungicidal concentration, i.e., the lowest concentration of the compound for 
killing the flingus completely. 
Positive control Greseofulvin. 
The antifungal screening data showed only moderate activity. Among the 
screened compounds, 11 showed good inhibition against Candida albicans. Compounds 
13 and 14 revealed good results against Candida albicans and Helimirahosporum oryazae 
and moderate activity against Aspergillus niger and Pencillum mameffei. The MFC of all 
the compounds was two or three or four folds higher than the corresponding MIC results. 
The varied divergence in the antimicrobial activity of these compounds validates 
the reason of this study. The importance of such kind of work lies in the possibility that 
the new compounds might be more efficient against bacteria and a thorough study 
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regarding the structure-activity relationship, toxicity and their biological effects would be 
helpful in designing more effective antimicrobial agents for therapeutic use. 
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5.3.3. Experimental 
The sources of all the fatty acids and the instrumentation details are the same as 
Chapter 1 (pg. 31). P-sitosterol were isolated from Ficiis krishnae following the literature 
procedure'^. 
General procedure for the synthesis of fatty acid analogs offi-sitosterol (J 1-14) 
Fatty acid (5mmol), DCC (5.5mmol), and (5mmol) P-sitosterol in 
dichloromethane (20mL) with catalytic amount of 4-dimethylaminopyridine (DMAP) 
were stirred mechanically at room temperature until esterification was complete. A^ .A'-
dicyclohexylurea formed was filtered off. The filtrate was washed with water (3x20 mL), 
5% acetic acid (3x20 mL) again with water (3x20 mL) and dried over anhydrous sodium 
sulphate. Solvent was removed under the reduced pressure to give the ester 11-14 
(Scheme 53.2.1) which were chromatographed over a column of silica gel using n-
hexane-ethyl acetate (96:4 v/v) as eluent. All these newly synthesized compounds were 
characterized from IR, ' H N M R , '^C N M R and mass spectral data. 
Spectroscopic Data 
3p-p-Sitosterrylundec-10'-€noate (11) 
White solid; Rf = 0.76 (»-hexane/ethyl acetate, 3:2 v/v, as developer). Isolated yield: 
88%; Mp 93°C. 
IR (KBr): 2931, 2860, 1736 cm"'. 
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'HNMR (CDCI3): 5 5.80 (tdd, IH, J^ ,^^ = 6.6 Hz, ^_^^ = 10.2 Hz, y^_^^ = 16.4 Hz, 
CH2=C//-), 5.38 (d, IH, J = 4.4 Hz, Ce-//), 4.95 (dd, IH, JH,-H= 10-2 Hz, J„^_/,^ = 2.6 
Hz, 7/zC=CH), 4.91 (dd, IH, y^^_/, = 16.4 Hz, ^^_^^ = 2.8 Hz, /^C-CH-), 4.62 (m, IH, 
Cap-//), 2.31-1.07 (br m, 46H), 1.01 (s, 3H, Co-C/Zj), 0.92 (d, 3H, J = 6.7 Hz, C20-CH3), 
0.86 (dd, 6H, y - 6.4 Hz C25-(C//3)2), 0.84 (d, 3H, J = 6.4 Hz, C29-C//3), 0.68 (s, 3H, C j -
C//3). 
'^CNMR (CDCI3): 6 173.41, 139.77, 139.27, 122.67, 114.23, 73.75, 56.74, 56.17, 50.06, 
42.37, 39.77, 39.59, 38.22, 37.78, 37.06, 36.66, 36.25,35.88, 34.78, 33.89, 31.97, 31.91, 
29.38, 29.30, 29.17, 29.15, 28.97, 28.32, 28.10, 27.88, 25.13, 24.36, 23.90, 22.92, 22.66, 
21.10,19.41,18.79,14.9,11.93. 
ESI-MS found [M+Na]^ 603.83; C40H68O2 [M+Na]^ requires 603.77. 
3p-p-Sitosterryloctadec-9'-(Z)-enoate(12) 
Viscous compound; Rf= 0.56 («-hexane/ethyl acetate, 3:2 v/v, as developer); Isolated 
yield 85%. 
-1 IR (KBr): 2932, 2854, 1732 cm 
'HNMR (CDCI3): 5 5.37 (d, IH, J= 4.6 Hz, Ce-H), 5.35 (m, 2H, C^H=CwH) 4.61 (m, 
IH, C3P-//), 2.31-1.05 {br m, 56H), 1.01 (s, 3H, C10-CH3), 0.91 (d, 3H, J = 6.7 Hz, C20-
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CHi), 0.89 (dist. t, 3H, Cg/Zj), 0.86 (dd, 6H,J= 6.6 Hz Czs-CCZ/sh), 0.84 (d, 3H, J = 
6.4 Hz,C29-C//3), 0.67 (s, 3H, Cn-C/Zj). 
"CNMR (CDCI3): 5 170.42, 139.77, 139.27, 127.67, 124.23, 88.10, 47.26, 44.89, 42.70, 
42.50, 42.37, 39.78, 39.59, 37.22, 37.06, 36.40, 36.15, 36.09, 36.01, 35.88, 35.71, 34.78, 
33.89, 31.97, 31.91, 29.38, 29.30, 29.17, 29.15, 28.97, 28.32, 28.10, 27.88, 25.13, 24.36, 
24.18,24.08,23.83,22.89,22.69,22.63,21.31, 20.18,19.41,18.66,16.62,14.21. 
ESI-MS found [M+Na]* 702.10; C47H82O2 [M+Na]^ requires 702.06. 
3p-p-SUosterryl-12 '-(R)-hydroxyoctadeC'9 '-(Z)-enoate (13) 
Oily compound; Rf= 0.52 (n-hexane/ethyl acetate, 3:2 v/v, as developer); isolated yield: 
78%. 
IR (nujol): 3310, 2926, 2855, 1737 cm"'. 
'HNMR (CDClj): 6 5.40 (m, 2H, C9H=CioH), 5.34 (d, IH, J = 4.6 Hz, C^-H), 4.85 (m, 
IH, OH, D2O exchangeable), 4.61 (m, IH, C3P-/Z), 3.60 (m, IH, drH-OH), 2.30-1.03 
(br m, 54H,), 1.01 (s, 3H, Co-C/Zs), 0.92 (d, 3H, J = 6.4 Hz, C20-CH3), 0.89 (dist. t, 3H, 
C187/3), 0.85 (dd, 6H, J = 6.6 Hz C25-(C//3)2), 0.82 (d, 3H, J = 6.4 Hz, C29-CZ/3), 0.67 (s, 
3H, Cii-CHj). 
"CNMR (CDCI3): 5 170.42, 139.77, 139.27, 127.67, 124.23, 77.10, 68.5, 47.46, 44.39, 
42.20, 42.10, 42.07, 39.75, 39.59, 37.21, 37.06, 36.43, 36.25, 36.19, 36.11, 35.83, 35.72, 
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35.14, 34.75, 33.39, 31.91, 29.38, 29.33, 29.17, 29.15, 28.37, 28.22, 28.10, 27.33, 25.13, 
24.46, 24.18,23.83,22.89,22.69,22.63,21.31,20.18,19.41,18.66,15.98, 13.67. 
ESI-MS found [M+Naf 718.09; C47H82O3 [M+Na]^ requires 718.06. 
3fi-p-Sitosterryl-9 '(R)-hydroxyoctadec-12 '-(Z)-enoate (14) 
Oily compound; Rf= 0.54 (/j-hexane/ethyl acetate, 3:2 v/v, as developer); Isolated yield: 
74%. 
IR (nujol): 3342,2922,2859,1737 cm"'. 
'HNMR (CDCI3): 6 5.40 (m, 2H, CnH=C\2H), 5.33 (d, IH, J = 4.6 Hz, Cf,-H), 4.64 (m, 
IH, OH, D2O exchangeable), 4.57 (m, IH, Csp-T/), 3.60 (m, IH, CgTZ-OH,), 2.31-1.07 
{br m, 54H), 1.01 (s, 3H, Cio-C/Zs), 0.92 (d, 3H, J = 6.5 Hz, C20-C//3), 0.88 (dist. t, 3H, 
C18 //3), 0.85 (dd, 6H, y = 6.6 Hz C25-(C//3)2), 0.81 (d, 3H, J = 6.4 Hz, C29-C//3), 0.67 (s, 
3H,C,3-C//3). 
'^CNMR (CDCI3): 6 170.42, 139.72, 139.19, 127.64, 124.23, 78.33, 67.53, 46.23, 44.77, 
42.71, 42.39, 42.37, 39.76, 39.44, 37.22, 37.16, 36.20, 36.15, 36.00, 35.88, 35.71, 34.71, 
34.34, 33.99, 31.65, 31.11, 29.38, 29.34, 29.30, 29.06, 29.02, 28.81, 28.32, 28.10, 27.32, 
25.33, 24.36,24.76, 23.13, 22.89,22.21,22.13, 21.31, 20.18, 19.41, 16.16, 14.19. 
ESI-MS found [M+Na]^ 718.11; C47Hg203 [M+Na]^ requires 718.06. 
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Antibacterial studies 
The newly synthesized compounds were screened for their in vitro antibacterial 
activity against Escherichia coli (K-12), Staphylococcus aureus (ATCC-25923), 
Salmonella typhimurium (MTCC-98), Bacillus subtilis (ATCC 6051) bacterial strains by 
disc diffusion method ' ' . Chloramphenicol (30 ^g) was used as positive control. 
While the disk poured in DMSO was used as negative control. The susceptibility was 
assessed on the basis of diameter of zone of inhibition against Gram-positive and Gram-
negative strains of bacteria. Inhibition zones were measured and compared with the 
controls. The bacterial zones of inhibition values are given in Table 5.3.2.1. 
Minimum inhibitory concentrations (MICs) were determined by broth dilution 
technique. The lowest concentration (highest dilution) required to arrest the growth of 
bacteria was regarded as minimum inhibitory concentration (MIC). MBC was defined as 
the lowest drug concentration at which 99.9% of the inoculums were killed. The 
minimum inhibitory concentration and minimum bactericidal concentration are given in 
Table 5.3.2.2. 
Antifungal studies 
Antifungal activity was also done by disk diffusion method. For assaying 
antifungal activity Candida albicans, Aspergillus Niger, Penicillium mameffei and 
Heliminthosporum oryazae in DMSO by agar diffusion method^ '^^ '*. The fungal activity 
of each compound was compared with Greseofulvin as standard drug. Inhibition zones 
were measured and compared with the controls. The fimgal zones of inhibition values are 
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given in Table 53.2J. The minimum inhibitory concentrations (MICs) and minimum 
fungicidal concentrations (MFCs) as determined by broth dilution technique are given in 
Table 5.3.2.4. 
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A B S T R A C T 
The long-chain alkenoic acid hydrazides (la-d) on reaction with phenylisocyanate and phenylthiocya-
nate gave their corresponding semicarbazides (2a-d) and thiosemicarbazides (4a-d), vtrhich on further 
refluxing with POCI3 and AcjO yielded corresponding 1.3.4-oxadiazoles (3a-d) and thiadiazoles (Sa-d), 
respectively. 
The structure elucidation of synthesized compounds is based on the elemental analysis and spectral data 
(IR. 'H NMR, "C NMR and MS). The synthesized oxadiazoles and thiadiazoles have been screened for anti-
bacterial and antifungal activities. The investigation of antimicrobial screening revealed that compounds 
3c, 3d. Sc, Sd and compounds 3b, 5b, showed good antibacterial and antifungal activities, respectively. 
© 2010 Published by Elsevier Ltd. 
A wide variety of heterocyclic systems have been explored for 
developing pharmaceutically important molecules. Among them 
the derivatives of oxadiazoles and thiadiazoles have played an 
important role in the medicinal chemistry. These heterocycles have 
been found to possess broad-spectrum antimicrobial activity and 
many other uses.'-^ The therapeutic effects of compounds contain-
ing ^B.^-thiadiazole rings have been studied for a number of 
pathological conditions including inflammation^'', pain,^ "^ and 
hypertension.* Furthermore, the synthesis of thiadiazoles and 
oxadiazoles has attracted wide attention due to the diversity of 
their applications as antibacterial, antimycobacterial'°", anti-
fungal,'^"'^ and antidepressant agents." 
Various biological applications such as antimicrobial'^", anti-
fungal'^ pesticidal," and anticancer activities™ have also been 
reported for seed oils, long-chain alkenoic acids and their 
derivatives. 
The wide range of therapeutic values of alkenoic acids and oxa-
diazoles/thiadiazole ring systems prompted us to synthesize the 
title compounds and screen them for various antimicrobial activi-
ties. The basic idea was to append the long-chain alkenyl/hydrox-
yalkenyl moiety of the long-chain alkenoic acid to the oxadiazole/ 
thiadiazole nucleus so as to combine the beneficial effects in a 
single structure with expected biological activities. 
In this communication we are reporting the synthesis of 1,3,4-
oxadiazoles/thiadiazoles bearing a long alkenyl/hydroxyalkenyl 
Corresponding author. Tel.: +91 09412545345. 
E-mail address; abduloafchem@gmail.com (A. Rauf), 
chain substituent at C-5. To the best of our knowledge the synthe-
sis and antimicrobial activity of these newly synthesized com-
pounds has not been reported so far. 
The long-chain alkenoic acid hydrazides (la-d), used as the 
starting material were prepared from corresponding long-chain 
alkenoic acids by esterification and further treatment with hydra-
zine hydrate.^' Reacting la-d with phenyl isocyanate in dry ben-
zene under reflux and removing excess of solvent under reduced 
pressure gave semicarbazides (2a-d). The treatment of 2a-d with 
POCI3 yielded 2,5-disubstituted-1,3,4-oxadiazoles (3a-d) in good 
yields. The reaction of la-d with phenyl isothiocyanate gave corre-
sponding thiosemicarbazides (4a-d) which on dehydrative cycliza-
tion by AC2O produced 2,5-disubstituted- 1,3,4-thiadiazoles (5a-d) 
in excellent yields. The reaction sequences are outlined in Schemes 
1 and 2. 
The semicarbazide 2a showed IR bands at 3236 cm'' (NH, NH-
NH) and 1667 cm"' (C=0). 'H NMR was more informative, charac-
teristic peaks were observed at d" 13.04 (1H, s, CO-NH-Ar), 9.16 (2H, 
br s, CO-NHNH-CO), 8.17 (2H, d.J = 7.2 Hz, Ar-H-2'76"). 7.60(IH. t, 
J » 7.4 Hz, Ar-H-4") and 7.51 (2H, t, J-7.4 Hz, Ar-H-3"/5"). In '^ C 
NMR peaks at S 168.2 and 165.4 were observed. 
The build up of 3a-d is evident from their spectral data. 
Compound 3a, 5-(Dec-9'-eny))-2-phenylam)ne-l,3,4-oxadia2ole, 
showed IR absorption bands at 3228 cm"', 1504 cm"', 1258 cm"' 
due to stretching vibrations of NH, C=N and C-O-C functions. The 
'H NMR was more informative in assigning the structure. Diagonas-
tic peaks at S 9.07 (1H, s, NH), 7.27 (2H, d.j » 7.6 Hz, Ar-H-2'76"). 7.18 
(IH, t, J - 7.5 Hz, Ar-H-4") and 6.98 (2H, t , ; = 7.3 Hz, Ar-H-3"/5") 
0960-894X/J - see front matter © 2010 Published by Elsevier Ltd. 
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were observed A triplet at <i 2 24 was observed for CH2 protons a to 
oxadiazole ring In "C NMR peaks at d 172 9 and 155 6 were ob-
served for ring carbon atoms The mass spectra showed characteris-
tic molecular ion peak which were in accordance with the molecular 
formula 
5-(Dec-9'-enyl)-2-phenylamine-l,3,4-thiadiazole 5a gave sig-
nificant IR bands at 3221cm ' (NH), 1488 cm ' (C=N), and 
707 cm ^ (C-S-C) 'H NMR peak at 5 12 20 (IH, s, NH), 8 16 (2H, 
d,; = 8 5 Hz, Ar-H-2"/6"), 7 55 (1H, t,; = 7 3 Hz, Ar-H-4"), and 7 44 
(2H, t, J = 7 8 Hz, Ar-H-3"/5") were observed in addition to peaks 
of normal fatty acid chain In "C NMR peaks at S 165 2 and 
153 0 were observed for ring carbon atoms The mass spectra 
showed characteristic molecular ion peak which were in accor-
dance with the molecular formula The newly synthesized com-
pounds have been confirmed by their spectral data^^ 
The characterization data of semicarbazides (2a-d), oxadiazoles 
(3a-d), and thiadiazoles (5a-d) is given in Table 1 
Undec-10-enoic (purity, 985S) and (Z)-octadec-9-enoic (97%) 
acids were purchased from Fluka chemicals (Buck Switzerland) 
(9Z,12R)-12-hydroxyoctadec-9-enoic acid (ricinoleic acid, 98%) 
and (9R,12Z)-9-hydroxyoctadec-12-enoic acid (isoricmoleic acid, 
98%) were isolated from Rianus communis and Wnghtia tmctona 
seed oils, respectively, following Gunstone's partition procedure ^ '' 
Phenyl thiocyanate, phenyl isocyanate, phosphorous trichloride, 
and acetic anhydride were purchased from Merck, Mumbai, India 
Thin layer chromatography (TLC) was done on glass plates 
(20 X 5 cm) with a layer of silica gel G (Merck, Mumbai, India 
0 5 mm thickness) Mixtures of petroleum ether/diethyl ether/ace-
tic acid (70 30 1, v/v) were used as developing solvent The col-
umn chromatography was carried out with silica gel (Merck, 
Mumbai, India, 60-120 mesh) IR spectra were recorded on Shima-
dzu 8201 PC spectrophotometer 'H NMR spectra were recorded 
with a Bruker, DRX 400 spectrometer (400 MHz) in CDCI3, using 
TMS as internal standard Chemical shifts (d) are quoted m ppm 
and coupling constants (/) are given in Hz "C NMR spectra were 
recorded at Bruker DRX 400 spectrometer in CDCI3 with CDCI3 
(.S = 77 00) 
Antibacterial studies The newly prepared compounds were 
screened for their antibacterial activity against Eschenchia coh 
(ATCC-25922), Staphylococcus aureus (ATCC-25923), Pseudomonas 
aeruginosa (ATCC-27853), Streptococcus pyogenes, and Klebsiella 
pneumoniae (Clinical isolate) bacterial strains by disc diffusion 
method ^^^ A standard inoculums (1-2 x lO'' c f u /ml 0 5 McFar-
land standards) were introduced on to the surface of sterile agar 
plates, and a sterile glass spreader was used for even distribution 
of the inoculums The disks measuring 6 mm in diameter were pre-
pared from Whatman no 1 filter paper and sterilized by dry heat at 
140 °C for 1 h The sterile disks previously soaked in a known con-
centration of the test compounds were placed m nutrient agar 
pJL,H-NH, - ^ " ^ ^ R J L , H - N H - 1 L , H - Y ^ 
1a-d ^^-o \ ^ 
- N H - N H j 
O S 
PhNCS II II 
2a-d 
POCL 
N—N 
" • \ 
• 0 " « - ^ > " " - ^ 
1a-d 
R-i^NH-NH—U-NH 
4a-d t^  
N—N 
5a-d 
3a-d 
Scheme 1 Synthesis of 2 5 disubstiCuted 1 3 4-oxadiazoles 3a-d 
Scheme 2 Synthesis of 2 5-disubstituted-1 3 4-thiadiazoles 5a-d 
medium Solvent and growth controls were kept Chloramphenicol 
(30 ng) was used as positive control and the disk poured m DMSO 
was used as negative control The plates were inverted and incu-
bated for 24 h at 37 °C The susceptibility was assessed on the basis 
of diameter of zone of inhibition against Gram-positive and Gram-
negative strains of bacteria Inhibition zones were measured and 
compared with the controls The bacterial zones of inhibition val-
ues are given in Table 2 
Minimum inhibitory concentrations (MlCs) were determined by 
broth dilution technique The nutrient broth, which contained log-
arithmic serially two fold diluted amount of test compound and 
controls were inoculated with approximately 5 x lO'cfu/ml of 
actively dividing bacterial cells The cultures were incubated for 
24 h at 37 °C and the growth was monitored visually and spectro-
photometrically The lowest concentration (highest dilution) 
required to arrest the growth of bacteria was regarded as MIC 
To obtain the minimum bacterial concentration (MBC), 01 ml 
volume was taken from each tube and spread on agar plates The 
number of cfu was counted after 18-24 h of incubation at 
35 "C MBC was defined as the lowest drug concentration at which 
99 9% of the inoculums were killed The minimum inhibitory con-
centration and minimum bactencidal concentration are given in 
Table 3 The PBE (percentual bacteriostatic efficiency, %) was ob-
tained as, 
PBE=100/M1C 
The results have been reported in Table 6 
The investigation of antibacterial screening data revealed that 
all the tested compounds showed moderate to good bacterial inhi-
bition Compounds 3a, 3b, 3c, 3d, 5c, 5d showed good inhibition 
against all Gram-positive and Gram-negative bacterial strains at 
6 25 ng/ml concentrations The compounds 3c, 3d, 5c and 5d were 
found to be almost equally potent as the reference drug, chloram-
phenicol, in case of K pneumoniae The MBC of few compounds was 
found to be the same as MIC but in most of the compounds it was 
two or three folds higher than the corresponding MIC results 
Antifungal studies Antifungal activity was also done by disk dif-
fusion method For assaying antifungal activity Candida albicans, 
/4spei;gillus/umigatus, PeniciKium mameffei, and Tnchop/iyton ment-
agrophytes (recultured) in DMSO by agar diffusion method ^ '*^ ^ 
Sabourauds agar media was prepared by dissolving peptone (1 g), 
D-glucose (4g), and agar (2g) in distilled water (100 ml) and 
adjusting pH to 5 7 Normal saline was used to make a suspension 
of spore of fungal strain for lawning A loopful of particular fungal 
strain was transferred to 3 ml saline to get a suspension of corre-
sponding species Twenty millilitres of agar media was poured into 
each petri dish Excess of suspension was decanted and the plates 
were dried by placing in an incubator at 37 °C for 1 h using an agar 
punch, wells were made and each well was labeled A control was 
also prepared in triplicate and maintained at 37 °C for 3-4 days 
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Table 1 
OlJNctenzation dau of synthesized compounds 2a-d 3a-d and 5a-d 
Compounds R MoJ formuU Mp (-0 Yield (%) 
C 
Analysis (%) found (calculated) 
H N 
2b 
2d 
3d 
6''"2 
OH 
> { K ^ . - ^ C H , 
6 
gCHj 
CH, 
OH 
OH 
•gCHj 
CH, 
OH 
Sd s < ^ _ ^ ^ C H , 
CuHjjOzNs 
CjsHi.OjN, 
C M H 4 , 0 3 N , 
CjsHi.OjNj 
CnHjiONj 
C^HjsONj 
CjsHjsOjNj 
CjsHisOjN, 
CIBHJSSN, 
CjsHjsSN, 
CjsH^OSNs 
CJ5H39OSN3 
103-104 
101-102 
111-113 
113-114 
133-134 
144-146 
133-136 
135-137 
134-135 
138-140 
136-138 
139-141 
80 
79 
77 
72 
92 
90 
87 
87 
95 
91 
85 
83 
6767(6811) 844(856) 1309(1323) 
7195(72 25) 9 86(993) 1002(1011) 
69 23(69 57) 9 50(9 56) 0965(9 73) 
69 33(69 57) 9 20(9 56) 09 65(9 73) 
7206(7221) 811(840) 1390(1403) 
75 23(75 52) 9 74(9 87) 1044(10 56) 
7235(7260) 941(949) 1000(1015) 
7228(7260) 936(949) 0997(1015) 
6830(6853) 778(798) 1307(1331) 
7223(7259) 944(949) 1010(1015) 
69 61(6989) 904(914) 09 78(978) 
6954(69 89) 9 02(914) 09 72(9 78) 
Table 2 
Antibactenal activity of 5-alkenyl/hydroxya)kenyl-2-phenyUmine-1 3 4-oxadiazoles 3a-d and thiadiazoles 5a-d 
Compounds 
3a 
3b 
3c 
3d 
Sa 
Sb 
5c 
Sd 
Standard 
DMSO 
S J^ogcnes 
1 8 0 t 0 5 
156±02 
2 1 2 ± 0 3 
201±02 
135±03 
131±07 
2 2 9 ± 0 8 
2 1 1 ± 0 2 
230±02 
-
Gram-positive bacteria 
5 aureus 
177±06 
153±02 
202±04 
21 1±03 
131±05 
129±03 
216±03 
2 0 8 ± 0 4 
220±02 
-
Diameter of zone of inhibition (mm) 
P aervginosa 
173±08 
193±05 
256102 
194±02 
172±04 
163±06 
2 9 2 1 0 2 
2 5 9 1 0 6 
3 2 0 1 0 3 
-
Cram-
K pneumoniae 
1 6 8 1 0 8 
1 4 9 1 0 3 
197102 
2 0 2 1 0 1 
128102 
121105 
2 2 7 1 0 6 
1 9 9 1 0 9 
190102 
-
•negative bactena 
£ coll 
198106 
1 7 5 1 0 3 
22 8 1 0 J 
2 1 6 1 0 2 
152104 
1 4 8 t a 4 
2 5 5 1 0 5 
2 2 9 1 0 2 
2 7 0 1 0 2 
-
Positive control (standard) chloramphenicol and negative control (DMSO) measured by the Halo Zone Test (Unit mm) 
The fungal activity of each compound was compared with greseo-
fulvin as standard drug Inhibition zones were measured and com-
pared with the controls The funga! zones of inhibition values are 
given in Table 4 The nutrient broth, which obtained logarithmic 
senally two fold diluted amount of test compound and controls 
was inoculated with approximately 1 6 x 10''-6 x 10''cfu/ml 
The cultures were incubated for 48 h at 35 °C and the growth 
was monitored The lowest concentration (highest dilution) re-
quired to arrest the growth of fungus was regarded as minimum 
inhibitory concentration (MIC) 
To obtain the minimum fungicidal concentration (MFC), 0 1 ml 
volume was taken from each tube and spread on agar plates The 
number of c f u was counted after 48 h of incubation at 35 °C 
MFC was defined as the lowest drug concentration at which 
99 9% of the inoculums were killed The minimum inhibitory 
concentration and minimum fungicidal concentration are given 
in Table 5 The ratio MFC/MIC was calculated in order to determine 
if the compound had a fungistatic (MFC/MIC >4) or fungicidal 
(MFC/MIC ^4) activity and the results have been summarized in 
Table 6 
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Table 3 
MIC and MBC results of 5-alkenyl/hydroxyalkenyl-2-phenylamine-l ,3.4-oxadiazoles 3a-<l and thiadiazoles Sa-d: positive control chloramphenicol 
Compounds 
3a 
3b 
3c 
3d 
Sa 
5b 
5c 
5d 
Standard 
S. 
MIC 
12.5 
25.0 
6.25 
6.25 
25.0 
12.5 
6.25 
6.25 
6.25 
Cram-positive 
Pyogenes 
MBC 
50.0 
25.0 
12.5 
25.0 
50.0 
100 
12.5 
25.0 
12.5 
bacteria 
S. 
MIC 
6.25 
12.5 
6.25 
12.5 
12.5 
12.5 
6.25 
6.25 
6.25 
aureus 
MBC 
25.0 
50.0 
12.5 
12.5 
25.0 
25.0 
12.5 
12.5 
12.5 
P. aeruginosa 
MIC 
12.5 
12.5 
6.25 
6.25 
12.5 
12.5 
6.25 
6.25 
6.25 
MBC 
50.0 
50.0 
50.0 
50.0 
25.0 
25.0 
12.5 
25.0 
12.5 
Cram-negative bacteria 
K. Pneumoniae 
MIC 
12.5 
12.5 
6.25 
6.25 
25.0 
25.0 
6.25 
6.25 
6.25 
MBC 
25.0 
50.0 
6.25 
25.0 
50.0 
50.0 
6.25 
6.25 
12.5 
E.coli 
MIC 
12.5 
12.5 
6.25 
6,25 
25.0 
25.0 
6.50 
6.25 
6.25 
MBC 
50 
50 
25 
25 
100 
50 
12.5 
12.5 
12.5 
MIC (ng/ml) - minimum inhibitory concentration, that is, the lowest concentration of the compound to inhibit the growth of bacteria completely; MBC (ng/ml) - minimum 
bacterial concentration, that is. the lowest concentration of the compound for killing the bacteria completely. 
Table 4 
Antifungal activity of 5-Alkenyl/hydroxyaIkenyl-2-phenylamine-1.3,4-oxadiazoIes 
3a-d and thiadiazoles 5a-d: positive control (greseofulvin) and negative control 
(DMSO) measured by the Halo Zone Test (Unit, mm) 
Compounds Diameter of zone of inhibition (mm) 
3a 
3b 
3c 
3d 
5a 
5b 
5c 
5d 
Standard 
DMSO 
CA 
24.2 ±0.4 
26.1 ±0.3 
23.3 ±0.9 
23.2 ±0.2 
19.5 ±0.5 
27.2 ±0.2 
25.1 ±0.7 
24.9 ±1.4 
30.0 ±0.2 
-
AF 
20.8 ±0.3 
23.1 ±0.2 
20.7 ± 0.4 
21.6 ±0.4 
16.5 ±0.4 
23.8 ±1.2 
22.4 ±0.3 
21.8 ±0.2 
27.0 ±0.2 
-
TM 
16.9 ±0.9 
20.2 ±1.2 
17.5 ±0.2 
18.7 ±0.2 
14.1 ±0.3 
20.3 ± 0.7 
18.9 ±0.5 
19.0 ±0.2 
24.0 ±0.3 
-
PM 
15.2 ±1.2 
15.9 ±0.3 
13.9 ±0.3 
16.3 ±0.2 
10.2 ±0.5 
16.1 ±0.2 
15.1 ±0.9 
15.2 ±1.2 
20.0 ±0.5 
-
CA - Candida albicans, AF - AspengiHus/i/migatus, TM - Trichophyton mentagrophytes, 
PM - PcniciHium mamejfei. 
Table 6 
PBE and fungicidal/fungistaric activity (MFC/MIC) of 5-alkenyI/hydroxyalkenyl-2-
phenylamine-1,3,4- oxadiazoles 3a-d and thiadiazoles 5a-d 
Compounds 
SP 
PBE-IOO/MIC 
Bacteria tested 
SA PA KP EC 
MFC/MIC 
Fungi tested 
CA AF TM PM 
3a 
3b 
3c 
3d 
5a 
5b 
Sc 
5d 
Chloramphenicol 
Greseofulvin 
8 
4 
16 
16 
4 
8 
16 
16 
16 
16 
8 
16 
8 
8 
8 
16 
16 
16 
8 
8 
16 
16 
8 
8 
16 
16 
16 
8 
8 
16 
16 
4 
4 
16 
16 
16 
8 
8 
16 
16 
4 
4 
15,4 
16 
16 
2 
4 
4 
2 
2 
2 
2 
2 
-
2 
4 
2 
4 
2 
4 
4 
4 
2 
-
2 
4 
2 
4 
2 
2 
2 
4 
4 
-
2 
2 
4 
8 
4 
4 
2 
2 
4 
-
2 
SP - S. pyogenes, SA - S. aureus. PA - P. aeruginosa, KP - K. Pneumonia, EC - £. Coli, 
CA - C. albicans, AF - A fumigatus, TM - 1 mentagrophyfes, and PM - P. Mamejfei. 
The antifungal screening data showed moderate to good activ-
ity. Among the screened compounds 3b and 5b were found to be 
most active against all test fungal strains. The compound 5b 
showed maximum activity against C albicans, A. fumigatus, and T. 
metagrophyte strains. The compound 3b was active against P. mar-
neffei. The MFC of most of the compounds was two or three folds 
higher than the corresponding MIC results. Most of the synthesized 
Tables 
MIC and MFC of 5-aIkenyl/hydroxyalkenyl-2-phenylamine-1.3,4-oxadiazoIes 3a-d 
and thiadiazoles 5a-d, positive control greseofulvin 
Compounds 
3a 
3b 
3c 
3d 
5a 
5b 
5c 
5d 
Std 
CA 
MIC 
25,0 
6,25 
25,0 
12,5 
25,5 
6.25 
12,5 
25.0 
6.25 
MFC 
50.0 
25.0 
100 
25.0 
50.0 
12.5 
25.0 
50.0 
12.5 
Af 
MIC 
25.0 
6.25 
12.5 
25.0 
25.0 
6.25 
12.5 
25.0 
6.25 
MFC 
100 
12.5 
50.0 
50.0 
100 
25.0 
50.0 
50.0 
12.5 
TM 
MIC 
12.5 
12.5 
12.5 
25.0 
25.0 
6.25 
12.5 
25.0 
6.25 
MFC 
50.0 
25.0 
50.0 
50.0 
50.0 
12.5 
25.0 
100 
12.5 
PM 
MIC 
12.5 
6.25 
12.5 
25.0 
25.0 
6.25 
25.0 
25.0 
6.25 
MFC 
25.0 
25.0 
100 
100 
100 
12.5 
50.0 
100 
12.5 
CA - Candida albicans. AF - Aspergillus fumigatus, TM - Trichophyton mentagrophytes, 
PM-Peniciltium mameffei; Std - standard. MIC (ng/ml)-minimum inhibitory 
concentration, that is, the lowest concentration of the compound to inhibit the 
growth of fungus completely; MFC (ng/ml) - minimum fungicidal. 
compounds showed good fungistatic activity against the fungal 
strain C albicans. 
The present stratagem describes, the synthesis of new 4,5-
disubstituted-l,3,4-oxadiazoles and thiadiazoles using long-chain 
alkenoic acids as the starting material. The described compounds 
have been variously characterized and identified by IR, 'H NMR, 
"C NMR, and mass spectral analysis. The potential antimicrobial 
effects of the synthesized compounds were investigated against 
S, pyogenes, S. aureus, P. aeruginosa, K. pneumoniae and E. coli bacte-
rial strains and C albicans, A fiimigatus, T. mentagrophytes and P. 
mameffei fungal strains. Among the synthesized oxadiazoles/thi-
adiazoles, the compounds with a hydroxyalkenyl chain substituent 
at fifth position of oxa/thiadiazoles were found to increase the 
antibacterial activity in compounds 3c, 3d, 5c and 5d. However 
the position of the hydroxyl group had no significant effect on 
the magnitude of the antibacterial activity. Further, the compounds 
showed parallel activity against Gram-positive and Gram-negative 
bacterial strains. The compounds with an internal double bond in 
the long alkenyl substituent of synthesized oxa/thiadiazoles were 
found to be potent antifungal agents. Contrary to the antibacterial 
studies, the presence of the hydroxyl on the alkenyl side chain 
turns out to be detrimental for the antifungal activity perhaps 
due to pharmacokinetic reasons. 
In conclusion the present study showed that the synthesized 
compounds can be used as template for future development 
through modification and derivatization to design more potent 
and selective antimicrobial agents. 
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28 General procedure for the synthesis of long-chain alkenoic acid hydrande (la-d) 
the hydrazides of lang<hain alkenoic acids (la-d) which are used as the 
starting matenal were prepared by the previously reported methods ^' 
Synthesis of h(alkenoyl/hydroxyalkenoyl)-5-phenylsemicarbazide (2a-d) 
hydrazide (la-d) (l.Ommole) was dissolved in abs ethanol by heating to 
make a clear solution An equal molar amount of phenyl isocyanate was added 
to It and the solution was refluxed for 5 h, cooled to get a precipitate The 
precipitate was filtered, washed with abs ethanol and dned to give analytically 
pure compounds 2a-d The charactenzation data of compounds 2a-d is given 
below 
l-(Undec-10-enoyl]-5-phenylsemicarbazides (2a) white powder yield 80%. mp 
103-104 °C IR {v„„ cm-', KBr) 3236 (NH, NH-NH), 1667 (C=0) 'H NMR 
(400 MHz, CDCI3, S. ppm) 13 04 (1H, s, CO-NH-Ar), 9 16 (2H, br s, CO-NHNH-
CO), 8 17 (2H, d , > 7 2 Hz, Ar-H-2'76"), 7 60 (IH, t, J - 7 4 Hz, Ar-H-4"), 7 51 
(2H, t, J - 7 4 Hz, Ar-H-3'75"), 5 82 (IH, tdd, ; „ . . „ , - 6 8 Hz, J„_„, - 10 0 Hz, 
y«_„,-178Hz, CH2-CH-), 501 (IH, dd, J„,_„-10 0Hz, J « , . „ , . 2 8Hz, 
H2C=CH),4 94(1H,dd,J„, „ .178Hz,J„ , „, - 2 8 Hz, HEC=CH-), 2 45 (2H, t, 
J-74Hz,CH2-CO),2.01(2H,m,CH2=CH-CH2),l 82(2H,m,CHjCHj-CO),l 45-
125(10H,brs,(CH2)5) "CNMR(100MHz,CDCI, d,ppm) 168 2,165 4,139 2, 
133 2,1313,128 9,128 6,114 2,33 8,29 9,296,29 3,29 2 291,290 28 9 
l-/(9Z>Octadec-9-enoyl(-5-phenylsemicarbarides (2b) white powder yield 
79%, mp 101-102 "C IR (v„,;^ cm ', KBr) 3222 (NH, NH-NH) 1665(C=0) 
'H NMR {400MHz, CDCI3, /i. ppm) 13 18 (IH, s, NH), 9 18 (2H, br s, NHNH), 
8 08 (2H, d,J - 7 2 Hz, Ar-H-2'76"), 7 64 (IH, t, J - 7 4 Hz, Ar-H-4'), 7 51 (2H, t 
J - 7.2 Hz, Ar-H-3"/5"), 5 31 (2H, m, CH2-CH=CH-CH2), 2 54 (2H, t, J - 7 8 Hz 
CH2-CO), 2 36 (4H, m, CH2-CH2=CH-CH2), 1 82 (2H, m, CH2-CH2-CO), 1 37-
1 25 (20H, brs, (CH2),i)), 089 (3H, dist t, temiinus CH3) "C NMR (100MHz 
CDa3,a,ppm) 167 4,164 7,139 2,137 3,133 2,131 5,128 8 129 0,319 30 7, 
30 4, 30 1, 29 9, 29 7, 29 6, 29 4, 29 2 'two signals are hidden' 29 1 26 6 22 7 
142 
l-/(9Z,12R>I2-Hydroxy-ocfadec-9-enoj'(/-5-pheny(semicarbozides (2c) off-
white powder, yield 77% mp 111-113°C IR (v„„ cm"', KBr) 3343 (OH) 
3233(NH, NH-NH) 1661 (C=0) 'H NMR(400MHz,CDCI3,.5,ppm) 1323(1H 
s NH), 9 17 (2H, br s, NHNH), 8 12 (2H, d, J - 7 4 Hz, Ar-H-2'76"), 7 65 (IH, t, 
J - 7 4 Hz, Ar-H-4") 7 51 (2H, t, J - 7 2 Hz, Ar-H-375"), 5 37 (2H, m, CH2-
CH=CH-CH2), 4 87 (1H, m, CH-OH), 2 55 (2H, t, J - 7 6 Hz, CH2-CO), 2 36 (4H, 
m, CH2-CH2=CH-CH2), 1 83 (2H, m CH2-CH2-CO), 1 76 (IH, m, CH-OH), 1 44-
1 28 (18H, br s, (CH2)9). 0 88 (3H, dist t, terminus CH3) "C NMR (100 MHz, 
CDCI3, ,\ ppm) 166 2,163 3,138 7,136 3,132 2,128 1,128 0,127 8,70 7,401, 
39 9 39 7, 39 4, 39 2, 31 3, 30 4, 29 4, 29 2, 29 0, 28 8, 261, 22 0,141 
I -(f9R, l2Z)-9-Hydroxy-octadec- I2-enoyl/-S-phenylsemicarbazide (2d) off-white 
powder,yield 72% mp US-IWC lR(v„„ cm \KBr) 3353(OH),3229(NH, 
NH-NH) 1668 {C=0) 'H NMR (400MHz, CDCI3, .5, ppm) 13 03 (IH, s, NH), 
909(2H,brs NHNH),8 16(2H,d,J-7 2 Hz,Ar-H-2"/6"),761 (IH, t , J -74Hz, 
Ar-H-4"), 7 52 (2H, t, J - 7 2 Hz, Ar-H-3"/5"), 5 38 {2H, m, CH2-CH=CH-CH2), 
4 89 (IH, m, CH-OH), 2 55 (2H, t, J - 7 6 H z , CH2-CO), 2 26 (4H, m, CH2-
CH2=CH-CH2), 1 86 (2H, m, CH2-CH2-CO), 1 68 (IH, m, CH-OH), 1 40-1 25 
{18H brs,(CH2)9),0 87(3H,dist t, terminus CH3) "CNMR(100MHz,CDCl3,«, 
ppm) 1676 1632,1384,1376,1312,1287,1283,1255,7056,401,399, 
36 3,24 8,31 3,291,29 0,28 9,28 8,28 5,28 4,251,22 3, 1401 
Synthesis o/5-(alkenyl/hydroxyalkenyl>2-phenylamine 1,3,4-oxadiazoles (3a-d) 
l-alkenoyl-5-phenyl semicarbazides (2a-d) (lOmmole) in POCI3 (6 0 ml) 
were refluxed for 4 h The resulting mixture was then poured into NaOH ice 
water solution, resulting in deposition that was filtered, washed, dned and 
reciystallized from aqueous ethanol and acetone (1 4 ml v/v) to give 
compounds 3a-d The charactenzation data of compounds 3a-d is given 
below 
5-(Dec-9'-enyl>2-phenylamine-l, 3, 4-oxadiazole (3a) white powder, yield 
92%. mp 133-134 °C IR(v„„cm ',KBr) 3228 (NH), 1504 (C=N), 1258(C-0-
C) 'HNMR(400MHz,CDa3,<! ppm) 907 (IH, s, NH), 727 (2H, d,y-76Hz, 
Ar-H-2"/6"), 7 18 (1H, t,J - 7 5 Hz, Ar-H-4"), 6 98 (2H, t,J - 7 3 Hz, Ar-H-3"/5"), 
579(lH,tdd,J„ .cH,-66Hz,J„ „,-101Hz,J„ „, - 16 9Hz,CH2=CH-), 5 00 
(lH,dd,J„, „-101Hz,J„, „,-22Hz,HzC=CH),494(1H,dd,J„, „ - 1 6 9 H z 
IH, H, - 2 2 Hz, HEC=CH-), 2 24 (2H, t, J - 7 5 Hz, CH2 a to nng), 2 00 (2H, m, 
CH2=CH-CH2), 1 58 (2H m, CHj (i to nng), 1 21 (lOH, br s, (CH2)5) "C NMR 
(100MHz,CDCl3,<\ppm) 172 9,155 6,139 4,139 0,128 7,122 2,118 5,1142. 
406, 402 39 8, 394, 33 9, 29 2, 28 9, 25 4 MS (ESI) m/z-322 3 (M+Na)*, 
calcd-322 4 
5-/(8'Z>Heptafadecenyl)-2-phenylamme-I,3,4-oxadiazole (3b) white crystals, 
yield 90%, mp 144-146 X IR (Vm„ cm"', KBr) 3218 (NH), 1505 (C=N), 1242 
(C-O-C) 'H NMR (400MHz, CDCI3. S ppm) 9 39 (IH, s NH), 7 26 (2H, d, 
J - 7 7HZ, Ar-H-2"/6"), 717(1H t, J - 7 5 Hz, Ar-H-4"), 698 (2H, t, J - 7 3 Hz, 
Ar-H-3"/5"), 5 33 (2H, m, CH2-CH^=CH-CH2), 2 23 (2H, t, J - 7 5 Hz, CH2 a to 
nng), 2 01 (4H, m, CH2-CH=CH-CH2), 1 56 (2H, m, CHj p to nng), 1 29 (20H, br 
s,(CH2),o),0 87(3H,dist t terminus CH3) "CNMR{100MHz,CDCl3,/S,ppm) 
172 9, 152 2, 133 5, 1304, 1293. 125 6, 123 2, 1142,406,402, 398, 394, 
386, 384, 33 9, 318, 314, 29 2 284 282, 279, 226 140 MS (ESI) m/ 
z - 420 3 (M+Naj*, calcd - 420 5 
(8Z,U'R)-5-(U -Hydroxy-octadec-8-enyl)-2-phenylamine-h34-oxadi02ole(3c). 
off-whitepowder. yield 87%, mp 133-136-C lR(v„„ cm VKBr) 3358(0H), 
3224(NH), 1518(C=N), 1220{C-O-C) 'H NMR(400MHz,CDCl3,ii,ppm) 931 
(IH, s, NH), 7 62 (2H,d,J- 7 2 Hz, Ar-H-2"/6"), 7 53 (IH, t , J - 70 Hz, Ar-H-4"), 
7 41 {2H, t J - 7 2 Hz, Ar-H-3"/5"), 5 37 (2H, m, CH2-CH=CH-CH2), 4 69 (1H, m, 
CH-OH), 2 38 (2H, t, J - 7 5 Hz, CH2 a to nng), 1 98 (4H, m, CH2-CH - CH-CH2), 
1 78 (IH, m, CH-OH), 1 67 (2H, m, CH2 p to nng), 1 28 (18H, brs, (CHihl 088 
(3H, dist t, terminus CH3) "C NMR (100 MHz, CDCI3, d. ppm) 172 1, 163 2, 
138 7 'one signal hidden" 132 2,128 1,128 0,127 0,70 7,401,39 9,39 7,39 5, 
39 3,31 3,304,29 1,29 0,28 8,28 6,25 1,22 0,13 6 167 2,139 8,139 0,133 5, 
130 0,129 8,127 9,771,38 6,38 4,33 5,317,30 2,299,29 6,29 3,28 7,28 5, 
284,283,22 4,144 MS (ESI) m/z - 436 5 (M+NaP, calcd - 436 59 
(8'R,n'z;-5-(8'-Hydroxy-octadec-jr-eny/>2-phenylamine-I3,4-oradiozole {3d) 
off-white powder, yield 87%, mp 135-137 °C IR (vm„ cm"', KBr) 3353 
(OH), 3217 (NH), 1494 (C=N), 1225 (C-O-C) 'H NMR (400 MHz, CDCI3, 6. 
ppm) 988 (IH, s, NH), 820 (2H, d, J -73HZ, Ar-H-2"/6"), 763 (IH, t, 
J - 7 4 H z Ar-H-4'), 7 54 (2H, t, J -79Hz , Ar-H-3"/5"), 5 34 {2H, m, CH2-
CH=CH-CH2), 4 87 {1H, m, CH-OH), 2 50 (2H, t,/ - 7 5 Hz, CHj a to nng), 1 98 
(4H m, CH2-CH=CH-CH2), 1 77 (IH, m, CH-OH), 1 67 (2H, m, CH2 P to nng), 
128(18H,brs (CH2)9), 0 89 (3H, dist t, terminus CH3) "C NMR{100MHz, 
CDCI3 .S, ppm) d 172 1, 1657, 1391, 1390, 133 0, 1307, 1294, 127 6, 77 3, 
386 364 304 318,29 8,29 6,29 4,29 2,29 0,28 9,28 6,25 9,22 2,14 3 MS 
(ESI) m/z-436 4|M+Nal*,calcd-436 59 
Synthesis of l-(alkenoyl/hydroxyalkenoyl)-5-phenylthiosemicarbazide (4a-d) 1-
alkenoyl-5-phenylthiosemicarbazides (4a-d) were prepared by the reported 
literature method ^' 
Synthesis o/5-(alkeny(/hydroxya/kenyl>2-phenylamine-I,3,4-thiadiazoles (5a-d) 
1 0 mmole of compounds (4a-d) in acetic anhydnde (AC2O) (6 0 ml) was 
refluxed for 5 hrs The resulting mixture was poured into crushed ice (lOOgm) 
with stirnng The product thus obtained was filtered, washed with cold water, 
dned and recrystallized from aqueous ethanol and acetone (1 4 ml v/v) to give 
analytically pure compounds 5a-d The charactenzation data of compounds 
5a-d prepared according to the above procedure is given below 
5-(dec-9'-enyl>2-Phenylamine-I, 3 4-thiadiozole (5a) white powder. Yield 
95% mp 134-135-C lR(v„„cm ', KBr) 3221 (NH), 1488 (C=N), 707 (C-S-
C) 'HNMR(400MHz,CDCl3,<S,PPm) 12 20(1H, s, NH),8 16{2H, d,J-85Hz, 
Ar-H-2 '/6') 7 55 (1H, t, J - 7 3 Hz, Ar-H-4'), 7 44 (2H, t, J - 7 8 Hz, Ar-H-3";5"), 
573(lH,tdd,;„ . „ , - 6 7 H z J „ „,-101Hz,J„ „, - 16 9Hz,CH2=CH-),4 98 
(IH dd;„, „-101Hz, ;„ , „, . 2 1Hz,H2C=CH),485(lH,dd,J„, „ -169Hz, 
J„, H, - 2 1 Hz, H£C=CH-) 2 98 (2H, t , ; - 7 5 Hz, CH2 a to nng), 1 96 (2H, m. 
1938 N N Farshonetal/Bioorg.Med Chem Lett 20(2010) 1933-1938 
CH2=CH-CH2), 1 76 (2H. m. CHj P to ring). 1 25 (lOH br s, (CHjjj) "C NMR 
(100MHz,CDCl3.^,ppm) 165 2.153 0,1391,133 4,1313 1298,1279,1142, 
33 7, 291, 28 9, 288, 28 7, 28 4, 26 0. 25 8 MS (ESI) m/z-338 2 |M+Na|'. 
calcd-338 47 
5-(8'ZXheptadec-S'-enyl)-2-Phenylamme-l,3,4-thiadiazole (5b) white powder. 
Yield 91X,inpl38-140°C IR(v„a«.cm ', KBr) 3219 (NH) 1468 (C=N), 701 
(C-S-C) 'H NMR (400MHz, CDCI3, .5, ppm) 12 10 (IH, s, NH) 814 (2H, d, 
J - 8 5 Hz, Ar-H-2'76"), 7 55 (1H, t. J • 7 4 Hz, Ar-H-4"), 7 45 (2H, t, J - 7 8 Hz, 
Ar-H-3'75"), 5 30 (2H, m, CH2-CH=CH-CH2), 2 98 (2H, t, 7 - 7 7 Hz CH2 a to 
ring), 2 36 (4H, m, CH2-CH2=CH-CH2). 1 76 (2H m, CH2 P to nng), 1 28 (20H, br 
s,(CH2),o),0 80(3H,dist t, terminus CH3) "CNMR(I0OMHz CDCI3, .S ppm) 
165 4,158 0'one signal hidden, 139 1,137 2 1332,1313 128 8,128 6,319, 
299. 29 7. 29 5 'two signals are hidden'. 29 4 'two signals are hidden', 29 3. 
291.28 7.264.22 7.14 2 MS (ESI) m/z-436 3 [M+Na]*. calcd-436 6 
S-KffZ,))'/!> 11'-)iydroxy-heptadec-S'-eny/;-2-Pheny(aminc-1,3 4-thiadiazo/e (Sc) 
white powder. Yield 85%, mp 136-138-C IR (,v„,, cm ', KBr) 3310 (OH), 
3219(NH), 1467(C=N),695(C-S-C) 'H NMR(400MHz.CDCl3 i>.ppm) 1237 
(IH. s, NH). 8 23 (2H. d.J- 8 5 Hz, Ar-H-2 76"), 7 62 (IH, t J - 7 4 Hz, Ar-H-4''), 
7 52 (2H, t,J - 7 8 Hz, Ar-H-3"/5"), 5 37 (2H, m, CH2-CH=CH-CH2), 3 59 (IH, s, 
CH-OH), 3 00 (2H, t, J - 7 5 Hz, CH2 a to ring), 2 38 (4H. m, CH2-CH2=CH-CH2). 
1 83 (2H m, CHj p to nng), 1 71 (IH, m CH-OH). 1 26 (18H br s. (CHj),), 087 
(3H, dist t terminus CH3) "C NMR (100MHz. CDCI3. .S. ppm) 1709. 165 0. 
133 3 131 1.130 7. 130 2, 128 8, 128 5, 73 9, 34 1, 31 5, 29 8, 29 7. 29 5. 29 3, 
291,28 9 27 1,25 2,231 22 5.213 14 6 MS (ESI) m/z-452 4 IM+Na]*, 
calcd - 452 6 
5-l(8fR.ll Z)-H'-hydroxy-heptttdec-lV-enyll-2-PlKnylamne-l,3,4-tht<iduaok (Sd) 
off-white powder. Yield S3%. mp 139-141 -C IR (v„„ cm ', KBr) 3322 (OH), 
3236(NH) 1461 (C=N) 699 (C-S-C) 'H NMR(400 MHZ.CDCI3, <S, ppm) 1217 
(IH s,NH),8 31(2H,d,J-8 4Hz Ar-H-2'/6') 743 (IH. t.J-74Hz. Ar-H-4'), 
7 25 (2H t,y- 74 Hz, Ar-H-3'/5"), 5 36 (2H, m. CH2-CH=CH-CH2), 3 57(IH, s. 
CH-OH), 2 81 (2H, t.J - 7 5 Hz, CH2 a to ring), 2 23 {4H, m. CH2-CH2=CH-CH2), 
2 04(2H, m CHj P to ring), 1 71 (IH, m CH-OH), 1 33 (18H br s.(CH2)9), 0 90 
(3H. dist t. terminus CH3) "C NMR (100MHz, CDCI3, d. ppm) 168 9, 163 1 
137 6 133 2,131 2 128 7,128 3,125 5,70 56,40 1, 399. 36 3, 24 8,31 3. 29 1 
290 ,289 ,288 ,285 ,284 251,223,1401 MS (ESI) m/z-452 5 |M+Nal* 
calcd-452 6 
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A B S T R A C T 
In the present study we synthesized, characterized and checked the antimicrobial activity of fatty acid 
analogs of cholesterol. The synthesized compounds were characterized using IR, 'H NMR, '^ C NMR and 
mass spectral data and tested for their antimicrobial activity by disk diffusion assay with slight modi-
fications against Gram-positive, Gram-negative strains of bacteria as well as fungal strains. Minimum 
inhibitory concentration (IV1IC) of all the synthesized compounds was also determined. Compounds 7-14 
showed inhibitory action against both the groups of bacteria and four strains of fungus. In vitro anti-
microbial activity of the test compounds show that the compounds 10 and 13 are excellent antibacterial 
agents, where as compounds 13 and 14 are the excellent antifungal agents among the eight synthesized 
compounds. 
© 2010 Elsevier Masson SAS. All rights reserved. 
1. Introduction 
Morbidity and mortality because of enteric bacterial infection 
are the major health problems. Every year millions of people are 
being killed by some Gram-positive and Gram-negative strains of 
bacteria. These bacteria mostly lead to food poisoning, rheumatic, 
salmonellosis and diarrhea [1 ]. In addition drug resistance in food 
poisoning, rheumatic, salmonellosis and diarrhea is being devel-
oped against the commonly used antimicrobial agents which are 
being extensively used for the treatment of above diseases. These 
diverse parasitic bacteria have significant effect on the human 
mucosa. These micro organisms may cause great damage to host 
tissue and severe infections [2]. 
More than 90% of the cases of vaginitis are of candidiasis, tricho-
moniasis and bacterial vaginosis [3]. Almost 75% women encompass 
fungal vulvovaginitis at least on one occasion or more in their lives 
and nearly 40-50% women encompass second incident of vulvova-
ginal candidiasis in their life. In view of the above, the design and 
synthesis of newer antimicrobials will always remain an area of 
immense significance. 
Corresponding author, Tel.: +91 9412545345. 
£-moil address: abduloafchemPgmail com (A. Rauf). 
Many seed oils, fatty acids (FA) and their derivatives are known 
for their antimicrobial (4,5], antifiingal [6], and pesticidal [7] activi-
ties. A number of investigations have demonstrated that a variety of 
modified FA are promising molecules in cancer prevention and have 
potential in the treatment of cancers [8-10]. FA-ester analogs have 
received very little attention despite the fact that such molecules 
have been found to be associated with diverse biological activities 
such as antioxidant 111), antifeedant |12], anti-inflammatory [13], 
antiparasitic [14], antimicrobial (15] and neuroprotective [16]. Some 
fatty esters have been also found very effective for treatment of 
dermatitis [17], cardiovascular, hepatic and renal disorders (18 ]. Thus 
FA-esters may lead to a new route to potential pharmaceutical 
molecules. 
In the earlier studies it has been reported that direct use of 
N,N-Dicyclohexylcarbodiimide (DCC) promotes esterification of 
primary and secondary alcohols under very mild conditions while 
tertiary alcohols result in poor yields [19]. A number of methods 
[20] reported for esterification of fatty acids either requires acidic 
or basic conditions or application of the heat. Literature reveals 
that some fatty acids have been esterified with cholesterol 
[21-23|. 
The purpose of this study was to find the novel bioactivity of 
various cholesteryl esters. It was discussed that cholesterol deriva-
tives could have antimicrobial activity [24]. In view of the significance 
of long-chain FA as potential pharmacophores; we report here the 
synthesis and spectral studies of new cholesterol analogs containing 
0223-5234/$ - see front matter © 2010 Elsevier Masson SAS. All rights reserved. 
doi:10.1016/j.ejmech.2009.12.052 
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CU and C18 FA along with their in vitro evaluation against a panel of 
Gram-positive, Gram-negative strains of bacteria and some strains of 
fungus FA incorporated at the C3 a-hydroxy group of cholesterol 
are undec-10-enoic 10,11-dibromo-undecanoic, 10,11-epoxy-
undecanoic, (9Z)-octadec-9-enoic (9Z,12R)-12-hydroxyoctadec-
9-enoic (ricmolic) and (9R,12Z)-9-hydroxyoctadec-12-enoic 
(isoricinolic) acids (Scheme 1) 
2. Chemistry 
Undec-10-enoic (purity 98%) and (92)-octadec-9-enoic (97%) 
acids were purchased from Fiuka Chemicals (Bucks, Switzerland) 
(9Z,12R)-12-Hydroxyoctadec-9-enoic (ricinolic, 98%) acid and 
(9R,12Z)-9-hydroxyoctadec-12-enoic (isoricinolic, 98%) acid were 
isolated from Rianus communis and Wnghtia anctona seed oils 
Compound R 
1,7,9 
i ^ ^ ^ / ^ H j 
2,8,10 Br' Y \ J-^"^ Br 
3,11 
4,12 
I^CH, 
O 
5,13 OH 
6,14 
OH 
'3 "6 
Scheme 1 Synthesis of fatty acid analogs of cholesteiol 
MR Banday et al / European Journal 0/Medicinal Chemistry 45 (2010) 1459-1464 1461 
respectively following Gunstone's partition procedure |25] 
Cholesterol was purchased from S-d fine-chem (Mumbai, India) 3-
3-Hydroxy-5a,6p-dibromocholesterol (26), 10,11-dibromo-unde-
canoic acid |27], and 10,11-epoxy-undecanoic acid [28| were 
synthesized following the literature methods 
A solution of FA, DCC and cholesterol/dibromocholesterol in 
dichloromethane with catalytic amount of 4-dimethylaminopyr-
idine (DMAP) were stirred mechanically at room temperature until 
estenfication was complete Products were purified by column 
chromatography and identified using different spectral techniques 
3. Pharmacology 
31 Antibacterial studies 
The m vitro antibacterial activities of 7-14 were tested using the 
bactenal cultures of Streptococcus mutans UA159 (MTCC#497), 
Pseudomonas aeruginosa (ATCC-27853),Staphylococcus aureus (ATCC-
25923), S pyogenes (reculured). Salmonella typhimunum (recultured), 
Escherichia cob (ATCC-25922) and fungal cultures of Candida albicans 
(ATCC-24433), Candida krusei (ATCC-6528), Candida parapsilosis 
(ATCC-22019), Cryptococcus neoformans (recultured), by the disk 
diffusion method [2930] A standard inoculums (1-2 x 10^  c f u /mL 
05 McFarland standards) was introduced on to the surface of sterile 
agar plates, using a sterile glass spreader for even distribution of the 
inoculums Discs measuring 6 mm in diameter, sterilized by dry heat 
at 140 °C for 1 h, were prepared from Whatman No 1 filter paper The 
sterile discs previously soaked in a known concentration of the test 
compounds were placed in nutrient agar medium Solvent and 
growth controls were kept Chloramphenicol (30 ng/mL) was used as 
positive control While the disk poured in DMSO was used as negative 
control The plates were inverted and incubated for 24 h at 37 °C The 
susceptibility was assessed on the basis of diameter of zone of inhi-
bition against Gram-positive and Gram-negative strains of bactena 
Inhibition zones were measured and compared with the controls The 
bactenal zones of inhibition values are given in Table 1 
The minimum inhibitory concentration (MIC) was assessed by 
the macro dilution test using standard inoculums of 5 x 10^ c f u / 
mL Initially the compounds were dissolved in DMSO after that 
serial dilution of the test compounds were set to final concentra-
tions of 512, 256,128. 64, 32,16, 8, 4, 2 and 1 ng/mL To each tube 
was added 100 nL of 24 h old inoculums The growth was moni-
tored visually and spectrophotometrically The lowest concentra-
tion (highest dilution) required to arrest the growth of bacteria was 
regarded as minimum inhibitory concentration (MIC) The 
minimum inhibitory concentrations are given in Table 2 
The investigation of antibacterial screening data revealed that 
all the tested compounds showed moderate to good bacterial 
inhibition Compounds 13, 11,10 and 7 showed good inhibition 
against S mutans. S pyogenes, S aureus and £ coh species at 32 ng/ 
mL concentrations Compounds 13, 11, 10 and 7 showed good 
antibacterial activity nearly equivalent to that of Chloramphenicol 
3 2 Antifimgal studies 
Antifungal activity was also done by disk diffusion method For 
assaying antifungal activity C albicans, C krusei, C parapsilosis, C 
neoformans were inoculated in Sabouraud Dextrose broth medium 
(Hi-Media Mumbai) and incubated for 48-72 h at 35 "C, and 
subsequently a suspension of about 16 x 10''-6 x 10'* c f u /mL was 
introduced on to the surface of sterile agar plates, and a sterile glass 
spreader was used for even distribution of the inoculum The discs 
measuring 6 mm in diameter were prepared from Whatman No 1 
filter paper and sterilized by dry heat at 140 °C for 1 h The sterile 
discs previously soaked in a known concentration of the test 
compounds were placed in Sabouraud Dextrose Agar (SDA) plates 
Solvent and growth controls were kept Fluconazole (30 ng/mL) was 
used as positive control While the disk poured in DMSO was used as 
negative control The plates were inverted and incubated for 48-72 h 
at 35 °C The susceptibility was assessed on the basis of diameter of 
zone of inhibition against albicans and non-albicans strains of fungi 
Inhibition zones were measured and compared with the controls 
The fungal zones of inhibition values are given in Table 3 
The minimum inhibitory concentration (MIC) was assessed by 
the macro dilution test using standard inoculums of 16 x 10''-
6 X Iff* c f u /mL Initially the compounds were dissolved in DMSO 
after that serial dilution of the test compounds were set to final 
concentrations of 512, 256,128, 64, 32,16, 8, 4, 2 and 1 ng/mL To 
each tube was added 100 nL of 48-72 h old inoculums The growth 
was monitored visually and spectrophotometrically The lowest 
concentration (highest dilution) required to arrest the growth of 
fungi was regarded as minimum inhibitory concentration (MIC) 
The minimum inhibitory concentrations are given in Table 4 
The investigation of antifungal screening data revealed that all 
the tested compounds showed moderate to good fungal inhibition 
Compounds 14 and 13 showed good antifungal activity (almost 
equivalent to Fluconazole) against all strains of fungi Compounds 11 
and 8 exhibited antifungal activity nearly equivalent to that of Flu-
conazole against C parapsilosis at 8 ngjml and compounds 11 and 8 
showed good antifungal activity against C albicans at 1 ^g/mL 
4. Results and discussion 
FA and their derivatives are reported as antimicrobial agents 
[5 6J It has been suggested that FA may increase antimicrobial 
activity of certain organic moieties [17] The present study is based 
nblel 
Antibacterial activity of fatty acid analogs of cholesterol 
Compounds 
7 
8 
9 
10 
11 
W 
13 
14 
Chloramp 
DMSO 
Diameter of zone of inhibition (mm) 
Gram-positive bactena 
S mucans 
20 5 ± 0 2 
2 0 3 ± 0 2 
21 5 ± 0 5 
23 1 ± 0 ^ 
2 1 9 ± 0 5 
• 1 8 9 ± 0 4 
2 2 8 ± 0 5 
1 7 3 ± 0 5 
2 6 8 ± 0 5 
-
S Pyogenes 
1 9 2 ± 0 3 
1 8 8 ^ : 0 3 
2 0 2 ± 0 5 
23 3 ± 0 7 
2 0 5 ± 0 3 
1 7 2 ± 0 8 
2 2 6 ± 0 5 
1 6 8 ± 0 3 
2 2 4 ± 0 4 
-
S aureus 
1 9 8 ± 0 3 
1 9 5 ± 0 5 
201 ± 0 2 
2 2 5 ± 0 4 
2 1 9 ± 0 5 
1 7 8 ± 0 8 
22 1 ± 0 3 
171 ± 0 4 
21 ± 0 5 
-
Cram negative bactena 
P aeruginosa 
1 6 2 ± 0 2 
151 ± 0 5 
171 ± 0 5 
171 ± 0 3 
1 8 5 ± 0 4 
1 4 3 * 0 2 
1 6 5 ± 0 4 
8 8 ± 0 I 
171 ± 0 2 
-
S typhimunum 
1 6 4 ± 0 2 
161 ± 0 3 
1 6 2 ± 0 2 
2 1 3 ± 0 5 
1 7 2 ± 0 5 
1 5 1 ± 0 5 
211 ± 0 4 
1 4 8 ± 0 2 
2 5 2 ± 0 8 
-
£co/i 
1 6 5 ± 0 2 
1 6 4 ± 0 2 
1 9 8 ± 0 5 
2 0 5 ± 0 4 
1 9 9 ± 0 5 
1 6 1 ± 0 5 
2 0 4 ± 0 2 
9 6 ± 0 2 
200 ± 0 J 
-
Positive control Chloramphenicol and negative control (DMSO) measured by the Halo Zone Test (Unit mm) 
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Table 2 Table 2 
Minimum inhibitory concentration (MIC) fatty acid analogs of cholesterol, positive 
control Chloramphenicol. 
Table 4 
Minimum inhibition concentration (MIC) of fatty acid analogs of cholesterol, posi-
tive control Fluconazole 
Strains Compounds 
MIC Cng/ml) 
7 8 9 10 11 12 13 14 Chloramphenicol 
S. mucans 32 
S. pyogenes 32 
S. aureus 64 
P. aeruginosa 32 
32 32 32 32 64 32 64 32 
32 64 32 32 64 32 128 32 
64 64 32 32 64 32 64 32 
128 512 64 64 128 128 128 32 
S. typhtmunum 128 128 128 64 64 128 32 128 32 
Ecoli 128 128 128 32 32 128 32 512 32 
on the synthesis and antimicrobial activities of cholesterol deriva-
tives derived from different FA. Six FA—undec-10-enoic 
(1), 10,11-dibromo-undecanoic (2), 10,11-epoxy-undecanoic (3), 
(9Z)-octadec-9-enoic (4), (9Z,12R)-12-hydroxyoctadec-9-enoic (5) 
and (9R,12Z)-9-hydroxyoctadec-12-enoic (6) acids were esterified 
with the C3P-hydroxy group of cholesterol with the help of DCC in 
the presence of a catalytic amount of DMAP to produce 7,8,11-14 in 
quantitative yields (Scheme 1). Similarly compounds 1 and 2 on 
reacting with 3-3-Hydroxy-5a,6P-dibromocholesterol afforded 
ester 9 and 10 respectively. The products 7-14 were purified on 
a silica gel column with n-hexane/ethyl acetate as eluent. The 
purity of the compounds was checked by TLC. The signals of the FA 
and cholesterol moieties in the 'H and '^ C NMR spectra of 
compounds 7-14 were successfully assigned. The high-resolution 
mass (electroionization) spectral studies have further confirmed 
their structures. A detailed spectral description for compound 7 is 
discussed below. 
IR spectrum of compound 7 revealed characteristic band at 
1732 cm"' (ester C-0 stretching). The two olefinic protons, 
CivH2=C,o'H and Cs-H were observed at 5H 5.81 (tdd, IH, 
JH-9/CH, = 6 7Hz,J„_„, = 101Hz,J„.„, = 16 9 Hz, CH2=CH-), 
5.36 (d, IH, J = 4.8 Hz, Ce-H), 4.98 (dd, IH, J„,_H = 10 1 Hz, 
JH,-HE = 2.8 Hz, H2C=CH), 4.93 (dd, IH, J„ , .H = 1 6 9HZ, 
JHC-HZ = 2 8 Hz, H£C=CH-) and correlated with observations at 5c 
114.23,122.67,139.77,139.27 respectively. A multiplet at 6H 4.61 was 
observed for C3K-H and correlated with observation at 6c 73.75. 
Besides few other significant carbon signals for the fatty acid chain 
characteristic peak at c^ 174.07 (Cr, ester C=0) was recorded. 
Spectral studies have illustrated that the change in the nature of FA 
at P-C3 has not significantly influenced the pattern of proton and 
carbon signals of the cholesterol moiety. Similarly other compounds 
were characterized from their spectral data. 
Table 3 
Antifungal activity of fatty acid analogs of cholesterol: Positive control (Fluconazole), 
and negative control (DMSO) measured by the Halo Zone Test (Unit, mm). 
Compounds 
7 
8 
9 
10 
11 
12 
13 
14 
Fluconazole 
DMSO 
Diameter of 
CA 
18.3 ± 0.2 
19.5 ± 0.2 
15.5 ± 0.5 
17.8 ±0.2 
19.6 ± 1.4 
18.7 ±0 .5 
20.3 ± 1.2 
22.5 ± 0.5 
20.0 ± 0.5 
-
zone of inhibition (mm) 
CK 
16.1 ±0.2 
17.5 ±0 .4 
13.4 ±1.2 
15.5 ± 0.3 
17.8 ±0.2 
16.8 ± 03 
18.7 ± 0.4 
20.7 ± 0.4 
20.0 ± 0.5 
-
CP 
15.1 ± 0.2 
16.8 ±0 .2 
12.8 ± 0.2 
14.4 ± 0.4 
16.9 ± 0.3 
15.7 ± 0.3 
17,8 ± 0.4 
19.8 ± 0 4 
18.0 ± 0.5 
-
CN 
12.1 ± 0.2 
15.9 ±0 .4 
12.7 ± 0.5 
13.8 ± 1.2 
15.8 ±1.2 
15.1 ± 0.2 
16.9 ± 0.2 
19.1 ± 0.5 
19.0 ± 0.5 
-
Strains 
C. albicans 
C. Itrusei 
C parapsilosis 
C. neoformans 
Compounds 
MIC(ng/ml) 
7 8 9 
2 1 16 
256 128 256 
32 8 256 
128 32 128 
10 
4 
512 
64 
64 
11 
1 
128 
8 
32 
12 
2 
256 
16 
32 
13 
1 
64 
8 
8 
14 
1 
64 
8 
8 
Fluconazole 
1.0 
64.0 
8.0 
8.0 
CA; Candida albicans, CK; Candida krusei, CP; Candida parapsilosis. CN; Cryptococcus 
neoformans 
5. Conclusion 
Here we have reported the application of DCC coupling chem-
istry procedure to synthesize the fatty acid analogs of cholesterol. 
The structures of compounds were extensively characterized. The 
preliminary biological testing revealed that compounds 14 and 13 
showed good antifungal activity (almost equivalent to Fluconazole) 
against all strains of fungi. Compounds 13,11,10 and 7 showed good 
antibacterial activity nearly equivalent to that of Chloramphenicol. 
The varied divergence in the antimicrobial activity of these 
compounds validates the reason of this study. The importance of 
such kind of work lies in the possibility that the new compounds 
might be efficient antimicrobials. A detailed study regarding the 
structure-activity relationship, toxicity and other biological effects 
of such analogs would be helpful in designing more effective 
antimicrobial agents for therapeutic use. 
6. Experimental protocol 
6.1. Physical and spectroscopic measurements 
Thin layer chromatography was done on glass plates (20 x 5 cm) 
with a layer of silica gel G (Merck, Mumbai, India, 0.5 mm thickness). 
Mixture of petroleum ether-ethyl acetate-acetic acid (50:50:1 v/v) 
were used as developing solvents. Column chromatography was 
carried out on silica gel (Merck, Mumbai, India, 60-120 mesh). 'H 
NMR was recorded with Bruker DRX 400 spectrometer at 400 MHz 
and "C NMR was recorded at 100 MHz in CDCI3. Chemical shifts [6) 
are quoted in ppm. Melting points were taken in open capillary and 
are uncorrected. 
6.2. Synthesis of fatty acid analogs of cholesterol 
A solution of FA (5 mmol), DCC (5.5 mmol) and cholesterol/ 
dibromocholesterol (5 mmol) in dichloromethane (50 mL) with 
catalytic amount of 4-dimethylaminopyridine (DMAP) were stirred 
mechanically at room temperature until esterification was 
complete. The N.N -dicyclohexylurea was filtered off and the filtrate 
was washed with water (3 x 50 mL), 5% acetic acid (3 x 50 mL) again 
with water (3 x 50 mL) and then dried over anhydrous sodium 
sulphate. The solvent was removed under reduced pressure to give 
the ester 7-14 (Scheme 1) which were chromatographed over 
a column of silica gel using n-hexane-ethyl acetate (94:6 v/v) as 
eluent. All these novel compounds were characterized from their 
spectral data. 
6.2.1 Sff-Cholesteryl-undec-lff-enoate (7) 
White amorphous compound; R/= 0.83 (n-hexane/ethyl acetate, 
1:1 v/v, as developer), isolated yield, 92%. m.p, 86 °C. IR (KBr, c m ' ) : 
2927, 2851, 1732, 1466; 'H NMR (CDCI3, 6n): 5.81 (tdd, IH, 
JH-SKIH, = 67Hz, JH H, = 10.1 Hz, ]„ „, = 16.9 Hz. CH2=CH-), 
536 (d, IH, J = 4.8 Hz, Ce-H), 4.98 (dd, IH, JH,-H = 10 1 HZ, 
M R. Banday et al / EuropeanJoumol 0/Medicinal Chemistry 45 (20W) 1459-1464 1463 
yHz-H, = 2 8 H z , HzC=CH-) , 4 93 (dd. IH, J H , - H = 1 6 9 H Z , 
JH,-HI = 2 8 HZ. H £ C = C H - ) , 4 6 1 (m, IH, CjP-H). 2 3 5 1 - 1 0 7 (far m, 
44H). 101 (s, 3H, C,o-CH3), 0 90 (d, 3H,J = 6 5 Hz. C20-CH3), 0 86 (dd. 
6H.7 = 6 6 Hz C25-(CH3)2), 0 67 (s, 3H, Cn-CHj ) " C NMR (CDCI3. k) 
173 41.139 77.139 27.122 67 114 2 3 , 7 3 7 5 . 5 6 74.5617. 50 0 6 . 4 2 37. 
3778 . 39 59. 38 22. 3706 , 36 66, 3 6 2 5 3 5 88 . 34 78. 33 89 . 3197. 
3191 . 2 9 3 8 . 2 9 3 0 . 2917. 2 9 1 5 , 28 97, 28 32, 2 8 1 0 , 2 7 8 8 , 2 5 1 3 
2 4 3 6 , 23 90, 22 92, 22 66, 2110, 1941 , 18 79, 1 1 9 3 , ESl-MS found 
[M + Na]+ 5 7 4 4 1 , C38H6402 [M + Na]* requires 575 35 
622 3P-Cholesteryl-W.n'-dibromo-undecanoate (8) 
Off-white solid. Rf = 0 77 (n-hexane/ethyl acetate, 1 1 v/v, as 
developer), isolated yield, 94X m p, 84 °C IR (KBr cm ') 2940. 
2853.1732.1464. ' H NMR (CDCI3. «H) 5 36(d. 1 H , / = 4 8 Hz, Ce-H), 
461 (m, IH, C3P-H), 416 (m, IH, Cio-H), 3 85 (dd, 2H,i = 10 0 Hz, 
j = 2 4 Hz. C„ -H2). 2 31 -107 (6r m. 44H), 104 (s, 3H, C10-CH3). 0 94 
(d. 3H.y = 6 6 Hz. C20-CH3). 0 85 (dd, 6H,7 = 6 6 Hz C25-(CH3)2), 0 67 
(s, 3H, C,3-CH3) "C NMR (CDCI3, <5c) 173 37,139 75,122 68 73 77, 
56 73, 5616, 53 20, 50 05, 42 36, 39 77, 39 58, 38 22, 37 05, 36 66, 
3643, 3624, 3605, 35 87, 34 76, 3197, 3105, 29 25, 29 21, 2911, 
28 80, 28 31. 28 09, 2788, 26 78. 25 09, 24 36, 23 89 22 92, 22 65, 
2109,1941,18 78,1193 , ESl-MS found [M + Na]* 733 78/735 76/ 
73769, C38H6402Br2 [M + Nal+ requires 733 35/735 35/73735 
623 5a.60-Dibromo-3p-cholesteryl-undec-lO'-enoate (9) 
White amorphous compound, Rf-0 78 (n-hexane/ethyl acetate, 
1 1 v/v, as developer), isolated yield. 90* m p, 82 °C IR (KBr, cm"') 
2932, 2850, 1738, 1466. ' H NMR (CDCI3, <5H) 5 73 (tdd, IH 
JH-9<H, = 6 7 H Z , JH-HZ = 10 1 Hz, ;„_„, = 16 9Hz, CH2=CH-), 
495 (dd, 1H,;H,_H = 10 1 HZ,JHZ-HE = 2 8 HZ, HZC=CH) , 488 (dd, 
1H,;H,-H = 1 6 9 H Z , ; H J », = 2 8Hz.H£C=CH-),475(m,lH,C3P-
H), 3 63 (t, IH, ; = 4 8 Hz, Cg-H), 2 23-1 07 (br m, 44H,), 1 01 (s 3H, 
C10-CH3), 082 (t, 3H, J = 6 6 Hz, C20-CH3), 0 79 (dd, 6H,i = 6 4 Hz 
C25-(CH3)2). 063 (s. 3H. C,3-CH3) "C NMR (CDCI3. 5c) 173 27, 
139 25, 11423, 8819, 7179, 56 20, 5610, 5517, 4721 42 72, 4198, 
4190, 3961. 39 54. 3724, 36 54. 3616. 3581, 3461, 33 86, 3103 
3084, 2935, 2926, 2912, 28 94, 28 22, 28 07, 26 27, 25 04, 24 09, 
23 84. 22 89. 22 63. 2132, 20 21, 18 71, 12 25 ESl-MS found 
[M + NaJ+ 733 75/735 79/73776, C38H6302Br2 [M + N a r requires 
733J5/735J5/73735 
624 Sa.ep.lO'.U'-Tetrabromo-SP-cholesteryl-undecanoate (10) 
Off-white solid, Rf = 0 74 (n-hexane/ethyl acetate 1 1 v/v as 
developer), isolated yield. 74* mp , 88 °C IR (KBr cm ') 2945, 
2886.1732.1465, ' H NMR(CDCI3. (5H) 4 82 (m. 1H, C3P-H), 416 (m, 
IH,Cw-H), 3 84(dd, 2H,; =10 0 Hz,/ = 2 4 Hz, Ci, -H2), 3 63 (t. 1H, 
; = 4 8 Hz, Cs-H), 2 58-1 07 (br m. 44H,), 1 00 (s, 3H, Co-CHs), 0 90 
(d, 3H,J = 6 6 Hz, C20-CH3). 0 85 (dd. 6H, J = 6 6 Hz C25-(CH3)2). 
064 (s, 3H, C13-CH3) "C NMR (CDCI3, 5c) 17318, 7179, 5619 
5614, 56 09, 47 26, 44 89, 42 70, 42 50, 39 67, 39 60 39 53, 39 48 
37 22, 36 52, 36 40, 3615, 36 09, 36 01, 35 79, 35 71, 34 71, 34 56 
3164, 3101, 30 83, 29 23, 2917, 28 77, 28 05, 26 95, 26 75, 24 99, 
23 83, 22 63. 2141,18 70,11 91 , ESl-MS found [M + Na]+ 89131/ 
893 67/895 81/89773/899 91, C38H6302Br4 (M + Nal+ requires 
891 35/893 35/895 35/89735/899 35 
6,25 S^-Cholesteryl-lff.W-epoxyundecnoate (11) 
White solid R/= 0 74 (n-hexane/ethyl acetate, 1 1 v/v, as devel-
oper), isolated yield, 72% mp, 94 "C IR (KBr cm"') 2932, 2854 
1732,1464,1174, ' H NMR (CDC3I, <5H) 5 36 (d, IH.i = 4 4 Hz, Ce-H) 
461 (m, IH, C3P-H). 2 90 (m. IH. Cw-H). 2 75 (dd 2H,7 = 101 Hz 
y = 2 6 Hz, Cu -H2), 2 31 -1 05 (br m, 44H), 1 01 (s 3H, C10-CH3), 0 95 
(d. 3H,; = 6 4 Hz, C20-CH3). 0 85 (dd. 6H.7 = 6 6 Hz C25-(CH3)2) 0 67 
(s. 3H, C13-CH3) "C NMR (CDCI3. 6c) 173 18,139 75,122 68, 73 77, 
56 73, 5616, 53 20, 50 05, 42 36, 39 77, 39 58, 38 22, 37 05, 36 66 
36 43, 36 24, 3605, 35 87, 34 76, 3197, 3105, 29 25, 29 21, 2911, 
28 80, 28 31, 28 09, 27 88, 26 78, 25 09, 24 36, 23 89, 22 92. 22 65, 
2109,19 41,18 78,11 9 1 , ESI-MS found JM + Na]+ 571 74, C38H64O3 
IM + Nal+ requires 591 57 
62 6 3|3-Cholestery(octadec-9'-fZ>enoQte (12) 
Viscous pale-yellow oil, R/= 0 70 (n-hexane/ethyl acetate, 1 1 v/v, 
as developer), isolated yield 80% IR(KBr, cm"') 2930,2852,1737, 
1463, ' H NMR(CDCl3. 6H) 5 36(d.IH.J = 4 8 Hz.Ce-H), 533 (m,2H. 
C9.H=Cio'H). 4 62 (m. 1 H. C3P-H). 2 31 -107 (br m, 53H.). 101 (s. 3H, 
C10-CH3). 0 90 (d. 3H. j = 6 5 Hz. C20-CH3). 0 88(dist t, 3H. Cis H3), 
085 (dd. 6H.J = 6 6 Hz C25-(CH3)2), 067 (s, 3H, C13-CH3) "C NMR 
(CDCI3 &c) 170 42,139 77,139 27,127 67,124 23, 8810,47 26.44 89. 
42 70. 42 50, 42 37, 39 78, 39 59, 3722, 3706, 3640, 3615, 3609, 
3601, 35 88, 35 71, 3478, 33 89, 3197, 3191, 29 38, 2930, 2917, 
2915, 2897, 2832. 2810, 2788, 2513, 24 36, 2408, 23 83, 2289, 
22 69 22 63 2131,2018,1941,18 66,1421 ESl-MS found IM + Na)* 
674 03, C45H78O2 (M + Na]-^  requires 673 42 
62 7 3(J-Cho(estery/-I2'-(Rj-hydroxyoctadec-9'-(Z;-enoate (13; 
Viscous colorless oil, R; = 0 67 (n-hexane/ethyl acetate. 1 1 v/v, 
as developer), isolated yield, 75% IR (nujol, cm ' ) 3452, 2935, 
2863,1737,1463, ' H NMR(CDCl3, «H) 5 41 (m,2H.C9H=Ci(yH).5 36 
(d, lH, i = 4 6 Hz, Cs-H), 4 87 (m, IH, OH, D2O exchangeable), 461 
(m, 1H, C3P-H), 3 61 (m, 1H, C,2 H-OH), 2 31 -104 (br m, 51H,), 101 
(s, 3H, C,o-CH3). 0 94 (d, 3H, J = 6 5 Hz, C20-CH3), 0 89 (dist t, 3H, 
C,8 H3) 0 85 (dd, 6H, j = 6 6 Hz C25-(CH3)2), 0 67 (s, 3H, C13-CH3) 
"C NMR (CDCI3, 6c) 17042, 139 77, 139 27, 12767, 12423, 7710, 
68 5, 4746, 44 39, 42 20, 4210, 42 07, 39 75, 39 59, 3721, 3706, 
36 43, 36 25, 3619, 3611, 35 83, 35 72, 34 75, 33 39, 3191, 29 38, 
29 33, 2917, 2915, 28 37, 28 22, 2810, 2733, 2513, 2446, 2418, 
23 83, 22 89, 22 69, 22 63, 21 31, 2018,19 41,18 66,13 67, ESl-MS 
found [M + Nal+ 690 07, C45H78O3 (M + Nal+ requires 689 42 
628 3(3-C/iolesteryl-9'-(R>hydroxyoctadec-12 -(Z;-enoate (14) 
Viscous colorless oil, R/= 0 8 (n-hexane/ethyl acetate. 1 1 v/v. as 
developer), isolated yield. 98% lR(nujol,cm"') 3449.2922.2859, 
1737, 1466, ' H NMR (CDCI3, 6») 5 40 (m, 2H, Ci, H=Ci2H), 5 33 
(d, 1H,J = 4 8 Hz, Ce-H), 4 6 4 (m, IH, OH, D2O exchangeable), 4 57 
(m, IH C3P-H), 3 60 (m, IH, C9 H-OH,), 2 31-107 (br m, 51H,), 101 
(s, 3H, C10-CH3), 0 92 (d, 3H, J = 6 5 Hz, C20-CH3), 0 88 (dist t. 3H. 
C,8 H3). 0 85 (dd. 6H. J = 6 6 Hz C25-(CH3)2). 0 67 (s. 3H. C^-CHs) 
"C NMR (CDCI3. 6c) 170 42. 139 72,13919,127 64,124 23, 78 33, 
67 53, 46 23, 44 77, 42 71, 42 39, 42 37, 39 76. 39 44. 37 22. 3716, 
36 20, 3615 36 00, 35 88, 35 71, 34 34, 33 99, 3165, 3111, 29 38, 
29 34, 29 30 29 06, 29 02, 28 81, 28 32, 2810, 27 32, 25 33, 24 36, 
24 76, 2313, 22 89, 22 21, 2213, 21 31, 2018, 19 41,1419 , ESl-MS 
found [M + Nal+ 69009, C,5H7803 (M + N a r requires 689 42 
6 3 Pharmacology 
Antibaaerial activity and antifungal activity of the synthesized 
compounds was completed by disk diffusion method and measured 
by Halo Zone Test [29 30) The MIC of synthesized compounds 
against bacterial and fungal strains was performed by macro dilution 
test and results were observed visually and spectrophotometncally 
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Abstract 
A new senes of fatty alkenoates were synthesized using an appropnate synthetic route involving DCC and DMAP as catalysts 
Compounds were charactenzed by their spectral data All the synthesized compounds were evaluated for their in vitro antimicrobial 
activity. The minimum inhibitory concentration (MIC), minimum bactenal concentration (MBC) and minimum fungicidal 
concentration (MFC) were determined for test compounds as well as for reference standards Among the compounds tested, 
compounds having hydroxy group at the fatty acid chain showed the most potent antibacterial as well as antifungal activities. 
© 2010 Abdul Rauf. Published by Elsevier B V on behalf of Chinese Chemical Society All rights reserved 
Keywords Fatty acids, p-Sitosterol, DCC, DMAP, IR, NMR, Mass, Antimicrobial activity 
The negative health trends call for a new interest in infectious disease in the medical and public health communities 
and renewed strategies on treatment and prevention Solutions outlined by the Centre for Disease Control and 
Prevention (CDC) include: prevention, (such as vaccination); improved monitoring; and the development of new 
treatments. Last solution would encompass the development of new antimicrobials by which these infectious diseases 
can be defeated [1 ]. Many seed oils, fatty acids and their derivatives are known for their antimicrobial [2], antifungal 
[3] and pesticidal [4] activities. A number of investigations have demonstrated that a variety of modified fatty acids are 
promising molecules in cancer prevention and have potential in the treatment of cancers [5,6]. Fatty alkenoates have 
received very little attention despite the fact that such molecules have been found to be associated with diverse 
biological activities such as antioxidant [7], antifeedant [8], anti-inflammatory [9], antiparasitic [10], antimicrobial 
[11] and neuroprotective [12]. Some fatty esters have been also found very effective for treatment of dermatitis [13], 
cardiovascular, hepatic and renal disorders [14]. Thus fatty alkenoates may lead to a new route to potential 
pharmaceutical molecules. 
A number of methods [15] reported for esterification of fatty acids require either acidic or basic conditions or 
application of the heat. A^,A^-Dicyclohexylcarbodiimide (DCC) is used as a dehydrating/activating agent in organic 
synthesis [16] and is extensively used for building the peptide and amide linkages [17]. Literature reveals that long-
chain fatty acids have not been estenfied with p-sitosterol in the presence of DCC. 
* Corresponding author 
E-mail address abduJoafchem@groa)J com (A Rauf) 
1001-8417/$-see front matter © 2010 Abdul Rauf Published by Elsevier B V on behalf of Chinese Chemical Society All nghts reserved 
doi 10 1016/jcclet2010 01 003 
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The purpose of this study was to find the novel bioactivity of p-sitosteryl esters. It was discussed that P-sitosterol 
derivatives could have antimicrobial activity [18,19]. In view of the significance of long-chain fatty acids as potential 
pharmacophores, we report here the synthesis and spectral studies of new P-sitosterol analogs containing C11 and C18 
fatty acids along with their in vitro evaluation against a panel of Gram-positive, Gram-negative strains of bacteria and 
some strains of fungus. 
1. Experimental 
Undec-10-enioc (purity 98%) and (9Z)-octadec-9-enoic (97%) acids were purchased from Fluka Chemicals 
(Buchs, Switzerland). (9Z,/2/?)-12-Hydroxyoctadec-9-enoic (ricinoleic) and (9/?,/2Z)-9-hydroxyoctadec-12-enoic 
(isoricinoleic) acids were isolated from the natural sources, i.e. from Ricinus communis and Wrightia tinctoria seed 
oils respectively. The concentrate of pure hydroxy acids was obtained by Gunstone's partitioning [20] of freshly 
prepared acids and further purified by column chromatography. p-Sitosterol was isolated from Ficus krishnae 
following the literature procedure [21]. 
Fatty acid (5 mmol), DCC (5.5 mmol), and 3-sitosterol (5 mmol) in dichloromethane (20 mL) with catalytic 
amount of 4-dimethylaminopyridine (DMAP) were stirred mechanically at room temperature until esterification was 
complete. N,N-dicyclohexylurea formed was filtered off. The filtrate was washed with water (3 x 20 mL), 5% acetic 
acid (3 X 20 mL) again with water (3 x 20 mL) and dried over anhydrous sodium sulphate. Solvent was removed 
under the reduced pressure to give the ester 6-9 (Scheme 1) which were chromatographed over a column of silica gel 
using n-hexane-ethyl acetate (96:4, v/v) as an eluent. All these newly synthesized compounds were characterized by 
IR, 'H NMR, '^C NMR and mass spectral data [22]. 
The newly synthesized compounds were screened for their in vitro antibacterial activity against selected bacterial 
strains by disk diffusion method [23J. Chloramphenicol (30 jxg) was used as positive control. While the disk poured in 
DMSO was used as negative control. The susceptibility was assessed on the basis of diameter of zone of inhibition 
against Gram-positive and Gram-negative strains of bacteria. Inhibition zones were measured and compared with the 
controls. The bacterial zones of inhibition values are given in Table 1. MICs and MBCs were determined by broth 
dilution technique and the results are given in Table 2. 
Antifungal activity was also done by disk diffusion method. For assaying antifungal activity was measured by agar 
diffusion method [24]. The fungal activity of each compound was compared with greseofulvin as a standard drug. The 
fungal zones of inhibition values are given in Table 3. The minimum inhibitory concentration (MIC) and minimum 
fungicidal concentration (MFC) are given in Table 4. 
2. Results and discussion 
The use of catalysts has become popular among synthetic organic chemists for improving classical organic 
reactions, shortening reaction time and/or improving yields, as well as promoting new reactions. To explore the 
probability of getting the pharmacophoric important moiety from natural products in higher yields and in shorter 
ConipoiiiKl 
1,6 
2,7 
"f^^ 
CH, 
Compound 
3,8 
4,9 
'ih^-
OH OH ^ 
CH2 
Scheme I. Synthesis of fatty acid esters of p-sitosterol using DCC/DMAP as a catalyst. 
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Table 1 
Antibactenal activity of the newly synthesized fatty alkenoates 
Compounds Diameter of zone of inhibition (mm) 
Gram-positive bactena Gram-negative bactena 
B subtilis S aureus E coll S typhimunum 
6 
7 
8 
9 
Standard 
DMSO 
! 7 8 ± 0 4 
15 6 ± 0 3 
2 1 9 ± 0 8 
20 1 ± 0 2 
23 0 ± 0 2 
I 7 3 ± 0 5 
1 5 2 ± 0 4 
20 6 ± 0 3 
20 2 ± 0 3 
22 0 ± 0 2 
18 1 ± 0 6 
165 ± 0 2 
25 2 ± 0 3 
23 9 ± 0 2 
27 0 ± 0 2 
1 6 3 ± 0 4 
1 4 6 ± 0 3 
2 1 7 ± 0 4 
1 8 9 ± 0 9 
I 9 0 ± 0 2 
Positive control (standard), chloramphenicol and negative control (DMSO) measured by the Halo Zone Test (unit, mm) 
Table 2 
MIC and MBC results of newly synthesized fatty alkenoates positive control chloramphenicol 
Compounds 
6 
7 
8 
9 
Standard 
Gram-positive 
B subtilis 
MIC 
125 
25 
6 25 
6 25 
6 25 
bactena 
MBC 
25 
25 
125 
25 
125 
S aureus 
MIC 
125 
25 
125 
125 
6 25 
MBC 
125 
50 
125 
125 
125 
Gram-negative 
E coll 
MIC 
125 
125 
6 25 
6 25 
6 25 
bactena 
MBC 
25 
50 
125 
125 
125 
S typhimunum 
MIC 
125 
25 
25 
25 
6 25 
MBC 
25 
50 
6 25 
6 25 
125 
MIC ((jLg/mL), minimum inhibitory concentration, i e the lowest concentration of the compound to inhibit the growth of bactena completely, MBC 
((ig/mL), minimum bactenal concentration, i e the lowest concentration of the compound for killing the bacterial completely 
Table 3 
Antifungal activity of newly synthesized fatty alkenoates 
Compounds Diameter of zone of inhibition (mm) 
CA AN HO PM 
6 
7 
8 
9 
Standard 
DMSO 
26 I ± 0 3 
22 2 ± 0 4 
23 1 ± 0 7 
23 6 ± 0 4 
3 0 0 ± 0 2 
23 1 ± 0 2 
20 6 ± 0 4 
22 3 ± 0 7 
20 8 ± 0 2 
27 0 ± 0 2 
1 8 6 ± 0 4 
21 2 ± 0 2 
I 9 9 ± 0 6 
1 9 0 ± 0 3 
24 0 ± 0 3 
17 3 ± 0 5 
162 ± 0 3 
151 ± 0 9 
1 5 2 ± 0 2 
20 0 ± 0 5 
Table 4 
MIC and MFC results of newly synthesized fatty alkenoates positive control greseofulvm 
Compounds 
6 
7 
8 
9 
Standard 
CA 
MIC 
12 5 
125 
6 25 
125 
6 25 
MFC 
25 
25 
25 
50 
125 
AN 
MIC 
25 
125 
6 25 
25 
6 25 
MFC 
50 
25 
25 
50 
125 
HO 
MIC 
25 
125 
125 
25 
6 25 
MFC 
50 
25 
25 
50 
125 
PM 
MIC 
25 
125 
25 
25 
6 25 
MFC 
100 
50 
50 
100 
125 
CA, Candida albicans, AF, Aspergillus niger, HO, Heliminthosporum oryazae, PM Penicillium mameffei MIC ((jLg/mL), minimum inhibitory 
concentration, i e the lowest concentration of the compound to inhibit the growth of fungus completely, MFC ((j,g/mL), minimum fungicidal 
concentration, i e the lowest concentration of the compound for killing the fungus completely 
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reaction time, our attention has turned to employ the use of catalysts. The use of catalysts for the synthesis of fatty 
alkenoates provided higher yield of products. In most of the cases the yield of product was 74-88%. At first the 
esterification of ^-sitosterol with undec-10-enoic acid was chosen as a model to optimize the conditions for the 
preparation of compounds 6-9. In order to determine the optimum conditions for the synthesis fatty alkenoates, 
variations in molar ratios of reagents and the catalysts were investigated. After some experimentation, we found a set 
of conditions that generally provide products in good yield and thus optimum conditions for molar ratio of fatty acids, 
P-sitosterol, DCC and DMAP were set up. The generality and scope of the synthetic procedures were demonstrated by 
subjecting P-sitosterol with olefinic (terminal and internal) and hydroxy olefinic carboxylic acids. IR absorptions 
characteristic of ester (1732-1737 cm~') were observed in all the newly synthesized compounds. 
In the ' H N M R spectra of compound 6, the olefinic protons were observed at 5H 5.80 (tdd, IH, Jff_<^(-H = 6 6 Hz, 
JH-HZ = 10.2Hz, JH-HE = 164Hz, CH2=CH-), 5.38 (d, IH, 7 = 4.4 Hz, Cg-H), 4.95 (dd, IH, JHZ-H^= 10.2HZ, 
JHZ-HE = 2.6Hz, H z C ^ H ) , 4.91 (dd, IH, JHI:-H = 164Hz, JHE-HZ = 2 8Hz, //gC^^CH-) and correlated with 
observations at 5c 114.23, 122.67, 139.77, 139.27 respectively. A multiplet at SH 4.62 was observed for C3/3-H and 
correlated with observation at 5c 73.75. Besides few other significant carbon signals for the fatty acid chain 
characteristic peak at 5c 174.41 (C)/, ester C=0) were recorded. Spectral studies have illustrated that the change in the 
nature of fatty acids at p-C^ has not significantly influenced the pattern of proton and carbon signals of the 3-sitosterol 
moiety. 
The investigation of antibacterial screening data revealed that all the tested compounds showed moderate to good 
bacterial inhibition. In most of the cases compounds 8 and 9 showed good antibacterial activity nearly equivalent to 
that of chloramphenicol. The MBC of few compounds was found to be the same as MIC but in most of the compounds 
it was two or three folds higher than the corresponding MIC results. The antifungal screening data showed only 
moderate activity. Among the screened compounds, 6 showed good inhibition against Candida albicans. Compounds 
8 and 9 revealed good results against C. albicans and Heliminthospomm oryazae and moderate activity against 
Aspergillus niger and Penicillium marneffei. The MFC of all the compounds was two or three folds higher than the 
corresponding MIC results. 
The varied divergence in the antimicrobial activity of these compounds validates the reason of this study. The 
importance of such kind of work lies in the possibility that the new compounds might be more efficient against bacteria 
and a thorough study regarding the structure-activity relationship, toxicity and their biological effects would be 
helpful in designing more effective antimicrobial agents for therapeutic use. 
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Abstract A new series of 7-0-coumarinyl alkenoates were synthesized from 
7-hydroxyl-coumarin and fatty acids using DCC and DMAP as catalyst. The syn-
thesized compounds were characterized on the basis of their spectral data. All the 
target compounds were evaluated for their in vitro antimicrobial activity against 
Bacillus subtilis. Staphylococcus aureus, Streptococcus pyogene, Pseudomonas 
aeruginosa. Salmonella typhimurium, Escherichia coli and fungal cultures of 
Candida albicans, Candida krusei, Candida parapsilosis and Cryptococcus neo-
formans. The minimum inhibitory concentration (MIC) was determined for the 
test compounds as well as for reference standards. Among the tested compounds, 
T-O-coumarinyl (9Z, 12/?)-12-hydroxyoctadec-9-enoate and 7-0-coumarinyl 
(12Z, 9/?)-9-hydroxyoctadec-12-enoate showed the most potent antifungal as well as 
antibacterial activities. 
Keywords 7-Hydroxy-coumarin • Fatty acids DCC DMAP 
Antimicrobial activity 
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Introduction 
Morbidity and mortality because of enteric bacterial infection are the major health 
problems in some areas like Indian subcontinent, portions of South America and 
tropical fraction of Africa (Qadri et ai, 2005; Devasia et ai, 2006). Every year 
millions of people are being killed by some or the other Gram-positive and Gram-
negative strains of bacteria. These bacteria mostly lead to food poisoning, 
rheumatic, salmonellosis and diarrhoea (Khan et ai, 2008). In addition, drug 
resistance is being developed by these bacteria against the commonly used 
antimicrobial agents which are being extensively used for the treatment of above 
diseases. Furthermore, the pharmacological drugs available are either too expensive 
or have undesirable side effects or contraindications (Berger, 1985). Many 
traditional plant treatments for the antimicrobial infections exist, and there lies a 
hidden wealth of potentially useful natural products for the control of microbial 
diseases (Gray and Flatt, 1997). Natural plant drugs are frequently considered to be 
less toxic and free from side effects than synthetic ones (Morin, 1987). Among the 
most significant classes of natural compounds, an important position is occupied by 
oxygen-containing heterocyclic compounds. 7-Hydroxy coumarin (7-HC) is a 
benzopyrone in nature, which is a major human metabolite and plays a role as 
dietary antioxidant in the human diet (fruits and vegetables). 7-HC has been 
reported to have antitumor (Kofinas et al., 1998), aldose reductase inhibitor (Okada 
et al., 1995) and xanthine oxidase inhibitor (Mills and Bone 2000) activities. The 
parent compound coumarin has been reported to reduce blood glucose levels 
(Maries and Famsworth, 1996). A number of natural and synthetic coumarin (2-oxo-
2//-chromene) derivatives have been reported to exert antimicrobial (Czerpack and 
Skolska, 1982; Jund et ai, 1971), antifungal (El-Ansary et al, 1992; Reddy and 
Somayojulu, 1981), antiamoebic (Iqbal etal., 2009) and tuberculostatic (Abd Allah, 
2000) activities. Moreover, the antibiotic novobiocin belongs to the hydroxy 
coumarin series. Coumarin may be a prodrug and 7-HC is the pharmacologically 
active agent (Ritschel et ai, 1981). Many seed oils, fatty acids (FA) and their 
derivatives are known for their antimicrobial (Rauf and Parveen, 2005; Kabara 
et ai, 1972), antifungal (Ahmed et ai, 1985) and pesticidal (Khan et al., 1983) 
activities. A number of investigations have demonstrated that a variety of modified 
FA are promising molecules in cancer prevention and have potential in the 
treatment of cancers (Mujeebur-Rahman et ai, 2005; Nagao et al, 1991; Lie Ken 
lie et ai, 1990). FA-ester analogs have received very little attention despite the fact 
that such molecules have been found to be associated with diverse biological 
activities such as antioxidant (Viklund et ai, 2003), antifeedant (Mallavadhani 
et al., 2003), anti-inflammatory (Feng et al., 2009), antiparasitic (Grunberg et al., 
1973), antimicrobial (Mod et al., 1975) and neuroprotective (Takahashi et al., 
2003). Some fatty esters have been found to be very effective for the treatment of 
dermatitis (Csoka et al., 2(X)7) cardiovascular, hepatic and renal disorders 
(Greelings et al., 2003). Thus, FA-esters may lead to a new route to potential 
pharmaceutical molecules. Literature reveals that long-chain fatty acids have not 
been esterified with 7-HC in presence of DCC and DMAP. 
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Compound 
1,6 
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40H ^ 
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Scheme 1 Synthetic route for the target compounds 
The purpose of this study is to find the novel bioactivity of 7-HC esters. As 
discussed, the coumarin derivatives possess antimicrobial activity and in view of the 
significance of long-chain FA as potential pharmacophores; we herein report the 
synthesis and spectral studies of new coumarin derivatives containing CI 1 and CI8 
FA chain. These derivatives were further tested for their in vitro antimicrobial 
activity against a panel of Gram-positive, Gram-negative strains of bacteria and 
selected strains of fungus. FA incorporated at the C7 hydroxy group of coumarin are 
undec-10-enioc, (9Z)-octadec-9-enoic, (9Z, 12/?)-12-hydroxyoctadec-9-enoic (ricin-
oleic) and (9/?, 12Z)-9-hydroxyoctadec-12-enoic (isoricinoleic) acids (Scheme 1). 
Results and discussion 
Chemistry 
FA and their derivatives have been reported as antimicrobial agents. It is expected 
that the incorporation of the hydroxyl and non-hydroxyl FA chain may increase the 
antimicrobial activity of certain organic moieties. This study is based on the 
synthesis, characterization and evaluation of antimicrobial activities of 7-HC 
derivatives derived from different FA. 7-Hydroxy coumarin reacts with fatty acid in 
the presence of DCC and 4-dimethyl aminopyridine (DMAP) in dichloromethane by 
stirring at room temperature. The completion of the reaction was checked by thin 
layer chromatography (TLC). The reaction time varied from 2 to 3 h. The purity of 
the compounds was checked by TLC and the compounds under the study were 
characterized by the spectral data. In general, the IR spectra showed ester peak at 
1729 cm"' and CH2 (methylene) peak at 2921 and 2849 cm"'. In the 'H-NMR 
spectra, the signals of the respective protons of the prepared derivatives were 
verified on the basis of their chemical shifts, multiplicities and coupling constants. 
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The spectra of all the compounds showed peaks at d 6.39-7.69 ppm corresponding 
to the protons of 7-hydroxy coumarin. The '^C-NMR spectra of all the compounds 
were also in good agreement. Characteristic molecular ion peaks [M + Na] was 
observed for all the compounds under study. A detailed spectral description for 
compound 6 is discussed below. 
IR spectrum of compound 6 revealed characteristic band at 1729 cm~' (ester C-
O stretching). In the ' H - N M R the olefinic protons, Cn'H2=Cio'H were observed at 
^H 5.81 (tdd, IH, yio'-9' = 6.8, J\^-HZ = 16.8, JW-HC = 10.4, CH2=CH-), 4.99 
(dd, IH, 7^,-10' = 16.8, JH,-H, =3.2, //zC=CH), 4.93 (dd, IH, JH.-I^ = 10.4, 
Jht-Hi = 3.2, //£C=CH-) and were correlated with observations in the ''C-NMR 
which gave signals at ^C 139.18 and 114.24, respectively. Besides these a 
characteristic carbon signal for the fatty acid chain at dC 171.68 (Ci-, ester C=0) 
was recorded. Similarly other compounds were characterized from their spectral 
data. Spectral studies have illustrated that the change in the nature of FA at C7 has 
not significantly influenced the pattern of proton and carbon signals of the 7-HC 
moiety. 
Pharmacology 
A variety of acylated 7-hydroxycoumarins were investigated in the early 1970s for 
antibiotic and antifungal activities (Jund et al., 1971). Acyl groups in the study 
included acetyl, propanoyl and butanoyl. These compounds were found to possess 
activity against a number of fungal strains (MIC approximately 125 |ig/ml) and 
Gram-negative bacteria (MIC sub 500 |ig/ml). It was observed that the ester 
derivatives of 7-hydroxycoumarins increased the antimicrobial activity of 
7-hydroxycoumarin. Thus, it is expected that the use of long-chain hydroxyl and 
non-hydroxyl fatty acid groups can further increase the antimicrobial potency of the 
coumarin ester derivatives. 
The determination of MIC of synthesized compounds against bacterial and fungal 
strains was performed by macro dilution test and the results were recorded visually 
and spectrophotometrically. The investigation of antibacterial screening data 
(Table 5) revealed that all the tested compounds showed moderate to good 
bacterial inhibition. Compound 9 showed good inhibition against S. pyogens, S. 
aureus and E. coli species at 32 |xg/ml where as compound 8 showed good 
inhibition against S. aureus at 32 (ig/ml concentrations. Compounds 8 and 9 showed 
good antibacterial activity nearly equivalent to that of standard drug (Chloram-
phenicol) against most of the bacterial strains. 
The investigation of antifungal screening data revealed that all the tested 
compounds showed moderate to good fungal inhibition. Compound 8 showed good 
antifungal activity against all strains of fungi. Compound 9 exhibited antifungal 
activities nearly equivalent to that of standard drug (Fluconazole) against C. 
parapsilosis at 8 |ig/ml, against C. neoformans at 16 ng/ml and C. albicans at 2 ng/ml. 
One of the reasons for activity difference may be based on the several unique 
characteristics of Gram-negative bacteria such as the structure of the outer 
membrane. The outer leaflet of the membrane comprises a complex lipopolysac-
charide whose lipid portion acts as an endotoxin. This outer membrane protects the 
unnaiQisis 
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bacteria from several antibiotics, dyes and detergents which would normally 
damage the inner membrane or cell wall (peptidoglycan). The outer membrane 
provides these bacteria with resistance to lysozyme and penicillin. That is why most 
of the times Gram-negative bacteria have higher MIC values as compared to Gram-
positive bacteria. In case of antifungal activity, Candida albicans are generally 
susceptible for most of the antifungals while non-albicans like Candida krusei, 
Candida parapsilosis, Cryptococcus neoformans are resistant to most of the 
antifungal drugs. Furthermore, the compounds having a hydroxyl group in the 
alkenyl side chain showed greater activity. 
Experimental 
Chemicals and instruments 
Undec-10-enioc (purity 98%) and (9Z)-octadec-9-enoic (97%) acids were purchased 
from Fluka Chemicals (Bucks, Switzerland). (9Z, 12/?)-12-Hydroxyoctadec-9-enoic 
(ricinoleic, 98%) acid and (9/?, I2Z)-9-hydroxyoctadec-12-enoic (isoricinoleic, 
98%) acid were isolated from Ricinus communis and Wrightia tinctoria seed oils, 
respectively, following Gunstone's (1954) partition procedure. 7-Hydroxy-coumarin 
was purchased from S-d fine-chem. (Mumbai, India). Thin layer chromatography 
was done on glass plates (20 x 5 cm) with a layer of silica gel G (Merck, Mumbai, 
India, 0.5-mm thickness). Mixture of petroleum ether-ethyl acetate-acetic acid 
(50:50:1, v/v) were used as developing solvents. Column chromatography 
was carried out on silica gel (Merck, Mumbai, India, 60-120 mesh). 'H NMR 
was recorded with Bruker DRX 400 spectrometer at 400 MHz and '^ C NMR was 
recorded at 100 MHz in CDCI3. Chemical shifts (S) are quoted in ppm. Melting 
points were taken in open capillary and are uncorrected. 
Chemistry: synthesis of fatty acid derivatives of 7-hydroxy-coumarin 
A solution of FA (5 mmol), DCC (5.5 mmol) and 7-hydroxy-coumarin (5 mmol) in 
dichloromethane (50 ml) with catalytic amount of DMAP were stirred mechanically 
at room temperature until esterification was complete. The A',A'-dicyclohexylurea 
was filtered off and the filtrate was washed with water (3 x 50 ml), 5% acetic acid 
(3 X 50 ml) again with water (3 x 50 ml) and then dried over anhydrous sodium 
sulphate. The solvent was removed under reduced pressure to give the esters 6-9 
(Scheme 1) which were chromatographed over a column of silica gel using 
n-hexane-ethyl acetate (94:6, v/v) as eluent. All these novel compounds were 
characterized from their spectral data. 'H, '^C NMR and COSY spectra of 
synthesized compounds shown in Tables 1, 2, 3, 4. 
7-O-Coumarinyl undec-10-enoate (6) 
White powder; Yield: 91%; mp: 168°C; Rf: 0.59; IR (KBr): 3080 (C=C aromatic 
ring). 2921 (C-H asymm.), 2849 (C-H symm.), 1729 (C=0 ester), 1624 (C=0 
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Table 2 
H number 
4 
5 
8 
6 
3 
9'-10' 
2' 
8', 11' 
3' 
4'-7', 12'-
18' 
'H-NMR, " 
-17' 
^(ppi 
7 70 
7 49 
709 
7 03 
6 37 
5 35 
2 59 
2 03 
175 
141-
0 87 
C-NMR and COSY data of (7) 
m) 
1 26 
Integration 
IH 
IH 
IH 
IH 
IH 
2H 
2H 
4H 
2H 
10 X 
3H 
2H 
Multiplicity 
d 
d 
s 
d 
d 
m 
t 
m 
q 
br s 
dist t 
in CDCI3 
^(Hz) 
96 
84 
84 
96 
76 
116 
COSY 
H-3 
H-6 
H-5 
H-4 
H-3' 
H-9'-10' 
H-2' 
Cnu 
4 
5 
8 
6 
3 
10' 
9' 
2' 
9' 
11' 
3'-7' 
18' 
10 
9 
7 
2 
1' 
mber 
, 12'-17' 
5 (ppm) 
142 91 
127 76-
115 76 
118 34" 
116 44'' 
130 07" 
129 84" 
34 17" 
31 79° 
3140" 
29 64-22 57 
14 03 
127 75" 
153 15" 
154 48" 
160 31 
17147 
" Assignment!! may be reversed 
coumarin carbonyl), 1400 (C-0), 1269 (C=C), 1122 (C-H aromatic ring) cm"'. 
ESI-MS found [M + Na]+ 351.2; C20H24O4 [M + Na]+ requires 351.17. 
7-0-Coumarinyl (9Z)-octadec-9-enoate (7) 
Viscous solid; Yield: 89%; Rf: 0.57; IR (KBr): 3120 (C=C aromatic ring), 2921 (C-
H asymm.), 2849 (C-H symm.), 1728 (C=0 ester), 1651 (C=0 coumarin carbonyl), 
1405 (C-O), 1270 (C=C), 1122 (C-H aromatic ring) cm"' . ESI-MS found 
[M -t- Na]+ 449.3; C27H38O4 [M -t- Na]+ requires 449.28. 
7-0-Coumarinyl (9Z, 12R)-l2-hydroxyoctadec-9-enoate (8) 
Viscous solid; Yield: 85%; Rf: 0.52; IR (KBr): 3384 (0-H), 3080 (C=C aromatic 
ring), 2920 (C-H asymm.), 2858 (C-H symm.), 1732 (C=0 ester), 1618 (C=0 
coumarin carbonyl), 1401 (C-O), 1267 (C=C), 1122 (C-H aromatic ring) cm~'. 
ESI-MS found [M + Na]+ 465.3; C27H,805 [M + Na]+ requires 465.27. 
7-0-Coumarinyl (I2Z,9R)-9-hydroxyoctadec-12-enoate (9) 
Viscous solid; Yield: 87%; Rf: 0.53; IR (KBr): 3421 (0-H), 3002 (C=C aromatic 
ring), 2920 (C-H asymm.), 2852 (C-H symm.), 1736 (C=0 ester), 1639 (C=0 
iinaa:Q!Si3 
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Table 3 ' H - N M R , ' ^ C - N M R and COSY data of (8) in CDCI-, 
H number 6 (ppm) Integration Multiplicity J (Hz) COSY C number 5 (ppm) 
4 
5 
8 
6 
3 
9' 
10' 
12' 
2' 
II' 
8' 
3' 
OH 
4'-7', 
18' 
761 
7 40 
7 03 
6 97 
631 
5 33 
5 48 
3 55 
251 
2 14 
197 
168 
155 
13'-17' 1 43-
121 
0 80 
IH 
IH 
IH 
IH 
IH 
IH 
IH 
IH 
2H 
2H 
2H 
2H 
IH 
9 X 2H 
3H 
d 
d 
s 
d 
d 
m 
m 
q 
t 
t 
qd 
q 
br m 
br s 
dist t 
96 
84 
84 
J = 96 
84 
76 
72 
76 
112 
H-3 
H-6 
H-5 
H-4 
H-lC, H-8' 
H-ir, H-9' 
H-ll' 
H-3' 
H-12', H-10' 
H-9' 
H-2' 
4 
5 
8 
6 
3 
9' 
10' 
12' 
2' 
11' 
8' 
3'-7', 
18' 
142 97 
125 18'' 
115 99" 
11849" 
116 60" 
128 57" 
133 31" 
71 57 
35 32° 
36 81" 
34 31" 
13'-17' 31 84-
24 69 
1411 
10 
9 
7 
2 
1' 
125 28" 
153 29" 
154 66' 
160 50 
17165 
Assignments may be reversed 
coumarin carbonyl), 1396 (C-O), 1270 (C=C), 1122 (C-H aromatic ring) cm" 
ESI-MS found [M + Na]+ 465.3; C27H38O5 [M + Na]+ requires 465.27. 
Pharmacology 
Antibactenal studies 
The minimum inhibitory concentration (MIC) was assessed by the macro dilution 
test using standard inoculums of 5 x 10^  c.f.u./ml. Initially, the compounds were 
dissolved in DMSO after that serial dilution of the test compounds were set to final 
concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2 and 1 |ig/ml. To each tube was 
added 100 nl of 24-h old inoculums. The growth was monitored visually and 
spectrophotometrically. The lowest concentration (highest dilution) required to 
arrest the growth of bacteria was regarded as minimum inhibitory concentration 
(MIC). The minimum inhibitory concentrations are given in Table 5. 
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Table 4 ' 
H number 
4 
5 
8 
6 
3 
12'-13' 
9' 
2' 
11', 14' 
3' 
OH 
4'-8', 10', 
\5'-\r 
18' 
H-lvTMR, '•'C-NMR and COSY data of (9) 
S (ppm) 
7 73 
7 55 
7 02 
6 98 
6 30 
5 27 
344 
2 52 
2 02 
167 
155 
1 40-1 02 
0 80 
Integration 
IH 
IH 
IH 
IH 
IH 
IH 
IH 
2H 
2 X 2H 
2H 
IH 
9 X 2H 
3H 
Multiplicity 
d 
d 
s 
d 
d 
m 
q 
t 
m 
q 
br m 
br s 
dist t 
in CDC1-, 
y(Hz) 
9 6 
88 
84 
96 
84 
7 6 
120 
COSY 
H-3 
H-6 
H-5 
H-4 
H-11', 
H-14' 
H-3' 
H-12'-13' 
H-2 
C number 
4 
5 
8 
6 
3 
12' 
13' 
9' 
2' 
14' 
3'-7', 
15'-
\r 
10' 
18' 
8' 
9 
7 
2 
1' 
11', 
-17' 
S (ppm) 
143 37 
128 90" 
110 19" 
11661" 
115 75" 
129 99" 
129 61" 
70 53 
33 88" 
34 18° 
30 95-22 50 
22 50 
37 39" 
14 11 
39 83° 
153 23° 
15451" 
160 24 
17152 
' Assignments, may be reversed 
Antifungal studies 
The minimum inhibitory concentration (MIC) was assessed by the macro dilution 
test using standard inoculums of 1.6 x 10''-6 x 10"* c.f.u./ml. Initially, the 
compounds were dissolved in DMSO after that serial dilution of the test compounds 
were set to final concentrations of 512, 256, 128, 64, 32, 16, 8, 4, 2 and 1 ng/ml. To 
each tube was added 100 \il of 48-72-h-old inoculums. The growth was monitored 
visually and spectrophotometncally. The lowest concentration (highest dilution) 
required to arrest the growth of fungi was regarded as minimum inhibitory 
concentration (MIC). The minimum inhibitory concentrations are given in Table 5. 
Conclusion 
It is conceivable that these derivatives showing antimicrobial activity can be further 
modified to exhibit better potency than the standard drugs. Compound 9 showed 
good antibacterial activity nearly equivalent to that of chloramphenicol. The varied 
divergence in the antimicrobial activity of these compounds validates the reason of 
l;ll;IH!MIHdil 
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Table 5 Minimum 
Strams 
Gram positive 
B subtihs 
S Pyogenes 
S aureus 
Gram negative 
P aeruginosa 
S typhimurium 
E coll 
Fungi 
C albicans 
C krusei 
C parapsilosis 
C neoformans 
inhibition concentration (MIC) fatty acid 
Compounds 
6 7 
MIC (ng/ml) 
64 
64 
128 
128 
64 
128 
4 
256 
32 
16 
64 
128 
128 
128 
128 
128 
8 
512 
64 
32 
8 
64 
64 
32 
128 
64 
64 
4 
256 
16 
16 
9 
64 
32 
32 
128 
64 
32 
2 
256 
16 
8 
analogs of 7 
Chloram 
32 
32 
32 
64 
32 
32 
NT 
NT 
NT 
NT 
-hydroxy coumarin 
Fluconazol DMSO 
NT 
NT 
NT 
NT 
NT 
NT 
1 0 
640 
80 
80 
NT not tested, Chloram chloramphenicol 
this Study. Compounds 8 and 9 showed good antifungal activity against all strains of 
fungi. The importance of such kind of work lies in the possibility that the new 
compounds might be more efficient against bacteria for which a thorough study 
regarding the structure-activity relationship, toxicity and in their biological effects 
would be helpful in designing more effective antimicrobial agents. 
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